<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/260874-modified-lysine-mimetic-compounds by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:13:11 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 260874:MODIFIED LYSINE-MIMETIC COMPOUNDS</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">MODIFIED LYSINE-MIMETIC COMPOUNDS</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>MODIFIED LYSINE-MIMETIC COMPOUNDS<br>
Field<br>
The present teachings relate to lysine mimetic compounds having pharmacological<br>
activity, such as antiarrhythmic activity, and desirable bioavailability properties. The<br>
present teachings further relate to pharmaceutical compositions comprising such<br>
compounds and methods of using and making such compounds and compositions.<br>
Background<br>
There is increasing recognition that intercellular communication is essential for<br>
cellular homeostasis, proliferation and differentiation. Such communication is<br>
believed to be facilitated by gap junctions. These structures are thought to be a<br>
route for coupling cells and permitting "cross-talk." (See generally, Sperelakis N.,<br>
eds., Cell Interactions and Gap Junctions, CRC Press, Inc. (1989)). The cross-talk<br>
between gap junctions is referred to as "gap junctional intercellular communication"<br>
(GJIC).<br>
Generally, gap junctions are specialized regions of the cell membrane that contain<br>
clusters of hundreds to thousands of densely packed channels that directly connect<br>
the cytoplasm of two adjacent cells. The gap junction channels are composed of<br>
two hemichannels, or connexons, provided by each of two neighboring cells.  [Each<br>
connexon, in turn, is made up of six proteins called connexins.<br>
In the heart, conduction of electrical impulses takes place through gap junctions.<br>
Abnormal GiJIC has been linked to a variety of disease states, including heart<br>
disease.  For example, it has been shown that mice heterozygous for the Cx43<br>
gene, which codes for a specific ventricular connexin, develop spontaneous<br>
ventricular arrhythmias and suffer from sudden cardiac death.  (Guerrero et al., J.<br>
Clin. Invest, 99, 1991-1998 (1997)). Reduced expression of Cx43 in heterozygous<br>
mice is directly linked to an increased incidence of ventricular arrhythmias during<br>
ischemia. (Lerner et at., Circulation, 101, 547-552 (2000)). Several other studies<br>
have shown reduced expression or altered distribution of Cx43 in chronically<br>
ischemic, hibernating, or hypertrophied hearts. (Kaprelian et al., Circulation, 97,<br><br>
651-660 (1998); Peters et al., Circulation, 88, 864-875 (1993); Saffitz et a!.,<br>
Cardiovasc. Res., 42, 309-317 (1999)).<br>
Several peptides that influence GJIC have been identified, including antiarrhythmic<br>
peptides AAP (Aonuma et al., Chem. Pharm. Bull. (Tokyo), 28, 3332-3339 (1980)),<br>
AAP10 (Dhein et al., Naunyn Schmiedebergs Arch Pharmacol., 350, 174-184<br>
(1994); Muller et al., Eur. J. Pharmacol., 327, 65-72 (1997)), and HP5 (disclosed in<br>
U.S. Patent No. 4,775,743). However, these peptides exhibit undesirable<br>
characteristics, including low stability, short half-life, and a lack of oral<br>
bioavailability.<br>
Summary<br>
Broadly, the present teachings relate to lysine mimetic compounds having useful<br>
pharmacological activity, such as antiarrhythmic activity, and desirable<br>
bioavailability properties. The present teachings provide compounds represented<br>
generally by Formula I:<br><br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof,<br>
wherein Y is OX, OR2, NXR2, or NR2R3; k is 0, 1, or 2; X is H or a lysine mimetic; X1<br>
is OR3, NR2R3, or a lysine mimetic; R1 is H, an optionally substituted C1-10 alkyl; an<br>
optionally substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, or an amino<br>
acid side chain; and R2 and R3 are defined as described herein.<br>
Particular examples of compounds according to the present teachings include 4-<br>
amino-pyrrolidine-2-carboxylic acid (4-aminoproline, 4Amp) analogs having<br>
Formula II or Formula III:<br><br><br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof,<br>
wherein A, B, E, k, R1, R4, R5, Y', Z and Z' are defined herein.<br>
Brief Description of the Figures<br>
Figure 1 shows the results of a test to study the effect of the compounds on<br>
metabolic stress induced atrial conduction slowing and in an in vitro model as<br>
described in Haugan et al., J. Cardiovasc. Electrophysiol., 16, 537-545 (2005).<br>
Detailed Description<br>
In one aspect, the present teachings provide compounds represented by Formula I:<br><br>
and pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof;<br>
wherein:<br>
Y is selected from OX, OR2, NXR2, and NR2R3;<br>
k is 0, 1, or 2;<br>
X is H or a lysine mimetic;<br>
X' is selected from OR3, NR2R3, and a lysine mimetic;<br>
R1 is selected from H, an optionally substituted C1-10 alkyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, and an amino acid side<br>
chain;<br><br>
R2 and R3 each independently is selected from H, an optionally substituted<br>
C1-10alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C7-20<br>
aralkyl, an optionally substituted C6-20 aryl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R6,<br>
C(O)OR6, C(O)NR6R7, S(O)2R6, and S(O)2NR6R7;<br>
alternatively, R2 and R3 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N and S and optionally substituted<br>
with 1-5 Q groups;<br>
R6 and R7 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10 alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R8,<br>
C(0)0R6, and C(O)NR8R9;<br>
alternatively, R6 and R7 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1 -4 ring<br>
heteroatoms independently selected from O, N and S and optionally substituted<br>
with 1-5 Q groups;<br>
R8 and R9 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10 alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, and an optionally substituted 5-20 membered heteroaryl;<br>
Q, at each occurrence, independently is selected from an optionally<br>
substituted C1-10 alkyl, an optionally substituted C2-10 alkenyl, an optionally<br>
substituted C2-10 alkynyl, an optionally substituted C3-20 cycloalkyl, an optionally,<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, an optionally substituted<br>
3-20 membered cycloheteroalkyl, an optionally substituted 5-20 membered<br>
heteroaryl, F, Cl, Br, I, CN, CF3, OCF3, NO2, OR8, SR8, S+R82, S(O)R8, S(O)2R8,<br>
S(O)2OH, S{O)2NR8R9, NR8S(O)2R9, C(O)R8, C(O)OR6, C(O)NR8R9, OC(O)R8,<br>
NR8R9, NR8C(O)R9, NR8C(O)OR9, NR8C(O)NR8R9, and N+R83;<br>
provided:<br>
a)	when Y is OX or NXR2 and X is H, X' is a lysine mimetic;<br>
b)	when Y is OR2 or NR2R3, X' is a lysine mimetic; and<br><br>
c)        the compound is not 1-(2-aminopropanoyl)-4-benzamidopyrrolidine-<br>
2-carboxylic acid or 1-(2-aminopropanoyl)-4-benzamidopiperidine-2-carboxylic acid.<br>
Some embodiments of the present teachings include those compounds and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
Y is OX or NXR2, X' is OR3 or NR2R3, and X is a lysime mimetic, wherein the lysine<br>
mimetic is selected from:<br><br>
wherein:<br>
Z' is selected from H, (CH2)m-C6-20 aryl, (CH2)m-5-20 membered heteroaryl,<br>
C(O)(CH2)m-C6-20 aryl, C(O)(CH2)rn-5-20 membered heteroaryl, (CH2)mC(O)-C6-20<br>
aryl, (CH2)mC(O)-5-20 membered heteroaryl. S(O)2(CH2)m-C6-20 aryl, and<br>
S(O)2(CH2)m-5-20 membered heteroaryl, wherein each of the C6-2O aryl and 5-20<br>
membered heteroaryl is optionally substituted with 1-5 Q groups;<br><br>
R5 is H or an optionally substituted C1-10 alkyl;<br>
m is 0. 1, or 2; and<br>
Q, R2 and R3 are defined as described above.<br>
In other embodiments, Y is OR2. NR2R3, OX or NXR2, X is H, and X' is a lysine<br>
mimetic, wherein the lysine mimetic is selected from:<br><br>
wherein:<br>
71 is selected from H, (CH2)m-C6-20 aryl, (CH2)m-5-20 membered heteroaryl,<br>
C(O)(CH2)m-C6-20 aryl, C(O)(CH2)m-5-20 membered heteroaryl, (CH2)mC(O)-C6-20<br>
aryl, (CH2)mC(O)-5-20 membered heteroaryl, S(O)2(CH2)m-C6-20 aryl, and<br>
S(O)2(CH2)m-5-20 membered heteroaryl, wherein each of the C6-20 aryl and 5-20<br>
membered heteroaryl is optionally substituted with 1-5 Q groups;<br>
R5 is H or an optionally substituted C1-10 alkyl;<br>
m is 0, 1, or 2;<br><br>
E is selected from C(O)OR6, C(O)NR6R7, and a carboxylic acid bioisostere;<br>
and<br>
Q, R2, R3, R6 and R7 are defined as described above.<br>
In some examples of these embodiments, E is C(O)OH. In other examples, E is<br>
C(O)NR6R7 (e.g., C(O)NHR7 or C(O)NH2).<br>
In any of the compounds of the present teachings, Z' can be C(0)(CH2)m-C6-20 aryl<br>
optionally substituted with 1 -5 Q groups and m can be 0.  For example, Z' can be<br>
benzoyl.<br>
In some embodiments of the compounds of the present teachings, R1 is H. In other<br>
embodiments, R1 is an amino acid side chain.  Examples of suitable amino acid<br>
side chains for R1 can include, but are not limited to, the side chains of valine,<br>
norvaline, leucine, norleucine, isoleucine, methionine, alanine, phenylalanine,<br>
tyrosine, tryptophan, serine, threonine, cysteine, lysine, argenine, histidine, aspartic<br>
acid, glutamic acid, asparagine, glutamine, ornithine, 2,4-diaminobutyric acid, and<br>
2,6-diaminopimelic acid.<br>
In some embodiments, k is 0; in others, k is 1.<br>
Particular compounds of the present teachings have structures represented by<br>
Formulae l(a) - l(p) below, wherein X1 is OR3 (e.g., OH) or NR2R3 (e.g.,NH2), Y is<br>
OR2 (e.g., OH) or NR2R3 (e.g., NH2), E is C(O)OR6 or C(O)NR6R7, and R1, R2, R3,<br>
R5, R6, R7 and Z' are defined as described herein:<br><br><br><br><br><br><br>
Certain compounds of the present teachings have structures represented by<br>
Formulae I(q) - l(x) below, wherein R1, R2, E and each R5 and Z' (each of which can<br>
be the same or different) are defined as described herein:<br><br><br><br><br><br><br>
In some embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
X' is OR3 or NR2R3 (e.g., OH or NH2), Y is NXR2, X is<br><br>
and Z', k, R1, R2, R3 and R5 are defined as described above. In some examples of<br>
these compounds, Z' is C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q<br>
groups, and m is 0 (e.g., Z' can be benzoyl).  In some compounds, R1 is H.  In<br>
others, R1 is an amino acid side chain, wherein the amino acid is selected from<br>
valine, leucine, isoleucine, methionine, alanine, phenylalanine, tyrosine, tryptophan,<br>
serine, threonine, cysteine, lysine, argenine, histidine, aspartic acid, glutamic acid,<br>
asparagine and glutamfne.  In some compounds, k is 0; in others, k is 1. Specific<br>
examples of compounds according to these embodiments of the present teachings<br>
include, but are not limited to, 3-[(4-benzoylamino-pyrrolidine-2-carbonyl)-amino]-<br>
propionic acid, {[4-(4-nitro-benzoylamino)-pyrrolidine-2-carbonyl]-amino}-acetic<br>
acid, {[4-(4-methoxy-benzoylamino)-pyrrolidine-2-carbonyl]-amino}-acetic acid, 2-<br>
[(4-benzoylamino-pyrro!idine-2-carbonyl)-amino]-succinamic acid, 2-[(4-<br>
benzoylarnino-pyrrolidine-2-carbonyl)-amino]-3-phenyl-propionic acid, 2-[(4-<br>
benzoylamino-pyrrolidine-2-carbonyl)-amino]-4-methyJ-pentanoic acid, 6-amino-2-<br>
(4-benzamidopyrrolidine-2-carboxamido)hexanoic acid, [(4-benzoylamino-<br>
pyrrolidine-2-carbonyl)-amino]-acetic acid, {[4-benzoylamino-piperidine-2-carbonyi]-<br>
amino}-acetic acid, {[4-benzoylamino-piperidins-2-carbonyl]-amino}-propIonic acid,<br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br><br>
In certain embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
X' is OR3 or NR2R3 (e.g., OH or NH2), Y is NXR2, X is<br><br>
and Z', k, R1, R2, R3 and R5 are defined as described above. In some examples of<br>
these compounds, Z' is C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q<br>
groups, and m is 0 (e.g., Z' can be benzoyl). In some compounds, R1 is H. In<br>
others, R1 is an amino acid side chain, wherein the arnino acid is selected from<br>
valine, leucine, isoleucine, methionine, alanine, phenylalanine, tyrosine, tryptophan,<br>
serine, threonine, cysteine, lysine, argenine, histidine, aspartic acid, glutamic acid,<br>
asparagine and glutamine. In some compounds, k is 0; in others, k is 1. Specific<br>
examples of compounds according to these embodiments of the present teachings<br>
include, but are not limited to, 3-amino-5-benzoylamino-benzoylamino)-acetic acid,<br>
(3-iamino-5-(4-methoxy-benzoylamino)-benzoylamino)-acetic acid, (3-amino-5-(4-<br>
methyl-benzoylamino)-benzoylamino)-acetic acid, (3,5-diamino-benzoylamino)-<br>
acetic acid, and pharmaceutically acceptable salts, esters, hydrates, and prodrugs<br>
thereof.<br>
In some embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
X' is OR3 or NR2R3 (e.g., OH or NH2). Y is NXR2, X is<br><br>
and Z', k, R1, R2 and R3 are defined as described above. In some examples of<br>
these compounds, Z' is C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q<br>
groups, and m is 0 (e.g., Z' can be benzoyl).  In some compounds, R1 is H.  In<br>
others, R1 is an amino acid side chain, wherein the amino acid is selected from<br><br>
valine, leucine, isoleucine, methionine, alanine, phenylalanine, tyrosine, tryptophan,<br>
serine, threonine, cysteine, lysine, argenine, histidine, aspartic acid, glutamic acid,<br>
asparagine and glutamine.  In some compounds, k is 0; in others, k is 1. Specific<br>
examples of compounds according to these embodiments of the present teachings<br>
include, but are not limited to, [(1-benzoyl-imidazolidine-2-carbonyl)-amino]acetic<br>
acid, {[1-(4-nitro-benzoyl)-imidazolidine-2-carbonyl]-amino}acetic acid, and<br>
pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br>
In certain embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
X1 is OR3 or NR2R3 (e.g., OH or NH2), Y is NXR2, X is<br><br>
and 71, k, R1, R2, R3 and R5 are defined as described above.  In some examples of<br>
these compounds, Z' is C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q<br>
groups, and m is 0 (e.g., Z' can be benzoyl). In some compounds, R1 is H.  In<br>
others, R1 is an amino acid side chain, wherein the amino acid is selected from<br>
valine, leucine, isoleucine, methionine, alanine, phenylalanine, tyrosine, tryptophan,<br>
serine, threonine, cysteine, lysine, argenine, histidine, aspartic acid, glutamic acid,<br>
asparagine and glutamine.  In some compounds, k is 0; in others, k is 1.  Specific<br>
examples of compounds according to these embodiments of the present teachings<br>
include, but are not limited to, [2-amino-3-(4-benzoylamino-phenyl)-<br>
propionylamino]-acetic acid, 2-{2-amino-3-[4-(4-<br>
methoxybenzamido)phenyl]propanamido}acetic acid, 2-{2-amino-3-[4-(4-<br>
nitrobenzamido)phenyl]propanamido}acetic acid, 2-{2-amino-3-[4-(4-<br>
methylbenzamido)phenyl]propanamido}acetic acid, and pharmaceutically<br>
acceptable salts, esters, hydrates, and prodrugs thereof.<br>
In some embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
X' is OR3 or NR2R3 (e.g., OH or NH2), Y is NXR2, X is<br><br><br>
and Z', k, R1, Ra and R3 are defined as described above.  In some examples of-<br>
these compounds, Z' is C(O)(CH2)m-C6-20 ary! optionally substituted with 1-5 Q<br>
groups, and m is 0 (e.g., Z' can be benzoyl).  In some compounds, R1 is H. In<br>
others, R1 is an amino acid side chain, wherein the amino acid is selected from<br>
valine, leucine, isoleucine, methionine, alanine, phenylatanine, tyrosine, tryptophan,<br>
serine. threonine, cysteine, lysine, argenine, histidine, aspartic acid, glutamic acid,<br>
asparagine and glutamine.  In some compounds, k is 0; in others, k is 1. Specific<br>
examples of compounds according to these embodiments of the present teachings<br>
include, but are not limited to, [(4-amino~1-benzoyl-piperidine-4-carbonyl)-amino]-<br>
acetic acid and pharmaceutically acceptable salts, esters, hydrates, and prodrugs<br>
thereof.<br>
In certain embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
Y is OR2 or NR2R3, X' is<br><br>
and Z', k, E, R', R2, R3 and R5 are defined as described above, provided the<br>
compound is not 1-(2-aminopropanoyl)-4-benzamidopiperidine-2-carboxylic acid. In<br>
some examples of these embodiments, Y is OH or NH2. In some compounds, E is<br>
C(O)OR6 (e.g., C(O)OH) or C(O)NR6R7 (e.g., C(O)NHR7 or C(O)NH2). In some<br>
compounds, Z1 is C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups,<br>
and m is 0 (e.g., Z' is benzoyl).   In some compounds, R1 is H: In others, R1 is an<br><br>
amino acid side chain, wherein the amino acid is selected from valine, leucine,<br>
isoleucine, methionine, alanine, phenylalanine, tyrosine, tryptophan, serine,<br>
threonine, cysteine, lysine, argenine, histidine, aspartic acid, glutamic acid,<br>
asparagine and glutamine (provided the compound is not 1-(2-aminopropanoyl)-4-<br>
benzamidopiperidine-2-carboxylic acid).  In some compounds, k is o; in others, k is<br>
1. Specific examples of compounds according to these embodiments of the<br>
present teachings include, but are not limited to, 1-(2-amino-4-carboxy-butyryl)-4-<br>
benzoylamino-piperidine-2-carboxylic acid, 1-(2-amino-4-methyl-pentanoyl)-4-<br>
benzoylamino-piperidine-2-carboxylic acid, 4-benzoyIamino-1-(2,6-diamino-<br>
hexanoyl)-piperidine-2-carboxylic acid, 1 -(2-amino-acetyl)-4-benzoyIamino-<br>
piperidine-2-carboxylic acid, 1 -(3-amino-propionyI)-4-benzoylamino-piperidine-2-<br>
carboxylic acid, 1-[2-amino-3-(1H-indol-3-yl)-propionyl]-4-benzoyIamino-piperidine-<br>
2-carboxylic acid, 1-(2-amino-3-phenyl-propionyl)-4-benzoylamino-piperidine-2-<br>
carboxylic acid, 4-benzoylamino-1-(2-hydroxy-acetyl)-piperidine-2-carboxylic acid,<br>
and pharmaceuticaily acceptable salts, esters, hydrates, and prodrugs thereof.<br>
In some embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
Y is OR2 or NR2R3. X' is<br><br>
and Z', k, E, R1, R2 and R3 are defined as described above.  In some examples of<br>
these embodiments, Y is OH or NH2. In some compounds, E is C(O)OR6 (e.g.,<br>
C(O)OH) or C(O)NR6R7 (e.g., C(O)NHR7 or C(O)NH2). In some compounds, Z' is<br>
C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups, and m is o (e.g., Z' is<br>
benzoyl).   In some compounds, R1 is H.  In others, R1 is an amino acid side chain,<br>
wherein the amino acid is selected from valine, leucine, isoleucine, methionine,<br>
alanine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, lysine,<br>
argenine, histidine, aspartic acid, glutamic acid, asparagine and glutamine. In<br>
some compounds, k is 0; in others, k is 1. Specific examples of compounds<br>
according to these embodiments of the present teachings include, but are not<br>
limited to, 1-(2-amino-4-carboxy-butyroyl)-3-benzoyl-imidazolidine-2-carboxylic<br><br>
acid, 1-benzoyl-3-(2-hydroxy-acetyl)-imidazolidine-2-carboxylic acid amide, 1-<br>
benzoyl-3-(2-hydroxy-acetyl)-imidazolidine-2-carboxylic acid, and pharmaceutically<br>
acceptable salts, esters, hydrates, and prodrugs thereof.<br>
In certain embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
Y is OR2 or NR2R3, X' is<br><br>
and Z' k, E, R1, R2, R3 and R5 are defined as described above.  In some examples<br>
of these embodiments, Y is OH or NH2.  In some compounds, E is C(O)OR6 (e.g.,<br>
C(O)OH) or C(O)NR6R7 (e.g., C(O)NHR7 or C(O)NH2).  In some compounds, Z- is<br>
C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups, and m is 0 (e.g., Z'.is<br>
benzoyl).   In some compounds, R1 is H.  In others, R1 is an amino acid side chain,<br>
wherein the arnino acid is selected from valine, leucine, isoleucine, methionine,<br>
alanine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, lysine,<br>
argenine, histidine, aspartic acid, glutamic acid, asparagine and glutamine.  In<br>
some compounds, k is 0; in others, k is 1. Specific examples of compounds<br>
according to these embodiments of the present teachings include, but are not<br>
limited to, 3-benzoylamino-5-(2-hydroxy-acetylamido)-benzoic acid, 3-(2-<br>
aminoacetamido)-5-benzarnidobenzoic acid, 3-(2-aminoacetamido)-5-(4-<br>
methylbenzamido)benzoic acid, 3-(2-amino-3-carbamoyl-propionylamino)-5-<br>
benzoylamino-benzoic acid, and pharmaceutically acceptable salts, esters,<br>
hydrates, and prodrugs thereof.<br>
In certain embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceuticafiy acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
Y is OR2 or NR2R3, X' is<br><br><br>
and Z' k, E, R1, R2, R3 and R5 are defined as described above. In some examples<br>
of these embodiments, Y is OH or NH2.  In some compounds, E is C(O)OR6 (e.g.,<br>
C(O)OH) or C(O)NR6R7 (e.g., C(O)NHR7 or C(O)NH2). In some compounds, Z' is<br>
C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups, and m is 0 (e.g., 2" is<br>
benzoyl).   In some compounds, R1 is H. In others, R1 is an amino acid side chain,<br>
wherein the arnino acid is selected from valine, leucine, isoleucine, methionine,<br>
alanine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, lysine,<br>
argenine, histidine, aspartic acid, glutamic acid, asparagine and glutamine. In<br>
some compounds, k is 0; in others, k is 1. Specific examples of compounds<br>
according to these embodiments of the present teachings include, but are not<br>
limited to, 3-(4-benzoylamino-phenyl)-2-(2-hydroxy-acetylarnido)-propionic acid, N-<br>
{4-[2-carbamoyl-2-(2-hydroxy-acetylamido)-ethyl]-phenyl}-benzamide, and<br>
pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br>
In some embodiments, the present teachings provide compounds of Formula I and<br>
pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof, wherein<br>
Y is OR2 or NR2R3. X' is<br><br>
and Z', k, E, R1, R2 and R3 are defined as described above.  In some examples of<br>
these embodiments, Y is OH or NH2.  In some compounds, E is C(O)OR6 (e.g.;<br>
C(O)OH) or C(O)NR6R7 (e.g., C(O)NHR7 or C(O)NH2). In some compounds, Z' is<br>
C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups, and m is 0 (e.g., Z' is<br>
benzoyl).   In some compounds, R1 is H.  In others, R1 is an amino acid side chain,<br>
wherein the amino acid is selected from valine, leucine, isoleucine, methionine,<br>
alanine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, lysine,<br><br>
argenine, histidine, aspartic acid, glutamic acid, asparagine and glutamine. In<br>
some compounds, k is 0; in others, k is 1. Specific examples of compounds<br>
according to these embodiments of the present teachings include, but are not<br>
limited to, 4-benzoylamino-1-(2-hydroxy-acetylamido}-cycIohexanecarboxylic acid,<br>
4-(2-aminoacetarnido)-1-benzoylpiperidine-4-carboxylic acid, and pharmaceutically<br>
acceptable salts, esters, hydrates, and prodrugs thereof.<br>
The present teachings include all stereoisomers of the compounds described<br>
herein.  For example, the stereochemistry of dipeptide embodiments of the present<br>
teachings can be 2R4R, 2R4S, 2S4S, or 2S4R.<br>
In another aspect, the present teachings provide compounds having the Formula II:<br><br>
and pharmaceutically acceptable salts, esters, hydrates and prodrugs thereof,<br>
wherein:<br>
A is (CH2)k-Y';<br>
k is 0, 1, or 2;<br>
Y' is OR2 or NR2R3;<br>
R1 is selected from H, an optionally substituted C1-10 alkyl, an optionally<br>
substituted C6-2O aryl, an optionally substituted C7-20 aralkyl, and an amino acid side<br>
chain;<br>
alternatively, A and R1 together with the carbon atom to which they are<br>
bound form a 5-20 mernbered heteroaryl containing 1-4 ring heteroatoms<br>
independently selected from N, O, and S and optionally substituted with 1-5 Q<br>
groups;<br>
B is selected from NR5, NR5(CH2)nC(O), NR5(CH2)nS(O)2, and an amide<br>
bioisostere;<br>
n is 0, 1, or 2;<br><br>
Z is selected from H. (CH2)m-C6-20 aryl optionally substituted with 1-5 Q<br>
groups, and (CH2)m-5-20 membered heteroaryl optionally substituted with 1-5 Q<br>
groups;<br>
m is 0, 1, or 2;<br>
E is selected from C(O)OR8, C(O)NR6R7, a carboxylic acid bioisostere and<br>
an amide bioisostere;<br>
Q, at each occurrence, independently is selected from an optionally<br>
substituted C1-10 alkyl, an optionally substituted C2.10 alkenyl, an optionally<br>
substituted C2-10 alkynyl, an optionally substituted C3-20 cycloalkyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, an optionally substituted<br>
3-20 membered cycloheteroalkyl, an optionally substituted 5-20 membered<br>
heteroaryl, F, Cl, Br, I, CN, CF3, OCF3, NO2, OR8, SR8, S+R82. S(O)R9, S(O)2R8,<br>
S(O)2OH, S(O)2NR8R9, NR8S(O)2R9, C(O)R8, C(O)OR8, C(O)NR8R9, OC(O)R8,<br>
NR8R9, NR8C(O)R9, NR8C(O)OR9, NR8C(O)NR8R9, and N+R83;<br>
R2 and R3 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C7-20<br>
aralkyl, an optionally substituted C6-20 aryl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R6,<br>
C(O)OR6, C(O)NR6R7. S(O)2R6, and S(O)2NR6R7;<br>
alternatively, R2 and R3 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N and S atoms and optionally<br>
substituted with 1-5 Q groups;<br>
R5 is H or an optionally substituted C1-10 alkyl;<br>
R6 and R7 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10 alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R8,<br>
C(O)OR8, and C(O)NR8R9;<br>
alternatively, R6 and R7 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N and S and optionally substituted<br>
with 1-5 Q groups; and<br><br>
R8 and R9 each independently is selected from H, an optionally substituted<br>
C1-10alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10 alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, and an optionally substituted 5-20 membered heteroaryl,<br>
provided that the compound is not 1-(2-aminopropanoyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid.<br>
In some embodiments, A is (CH2)k-Y' and Y' is NR2R3.  Examples of these<br>
embodiments include compounds wherein R2 is H and R3 is selected from H (i.e., Y'<br>
is NH2), an optionally substituted C1-10 alkyl, C(O)R6, and C(O)OR6. In some<br>
examples, A is (CH2)K-Y', Y' is NR2R3, R2 is H, R3 is C(O)R6 and R6 is H or an<br>
optionally substituted C1-10 alkyl. In other examples, A is (CH2)k-Y', Y' is NR2R3and<br>
R2 and R3 each independently is an optionally substituted C1-10 alkyl. In other<br>
embodiments, Y' is OR2 and R2 is H or a C1-10 alkyl.  In any of these examples, k<br>
can be 0, 1 or 2.<br>
In certain embodiments, A and R1 together with the carbon atom to which they are<br>
bound form a 5-20 membered heterocycle containing 1-4 ring heteroatoms<br>
independently selected from N, O, and S and optionally substituted with 1-5 Q<br>
groups. Examples of heterocycle groups can include, but are not limited to,<br>
piperidine, piperazine, morpholine, thiomorpholine, pyrrolidine, oxazolidine,<br>
thiazolidine, imidazolidine, pyrrole, imidazole, pyrazole, triazole, tetrazole, furan,<br>
thiofuran, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, pyridine,<br>
pyridazine, pyrimidine, pyrazine, indole, benzofuran, and benzothiophene, each of<br>
which optionally can be substituted. Exemplary compounds of these embodiments<br>
include, but are not limited to, 4-benzamido-1-(1H-imidazole-2-carbonyl)pyrrolidine-<br>
2-carboxylic acid, 4-benzamido-1-(1 H-pyrazole-5-carbonyl)pyrrolidine-2-carboxylic<br>
acid, and 4-berizamido~1-(1H-imidazole-5-carbonyl)pyrrolidine-2-carboxylic acid.<br>
In some embodiments, B is NR5(CH2)nC(O), n is 0 (i.e., B is NR5C(O)), and Z is a<br>
C6-20 aryl optionally substituted with 1-5 Q groups or a 5-20 membered heteroaryl<br>
optionally substituted with 1-5 Q groups.  Examples of these embodiments include<br>
compounds wherein R5 is H (i.e., B is NHC(O)). In some compounds, Z is a phenyl<br>
optionally substituted with 1-5 Q groups, such as, for example, F, Cl, Br, I, C1-10<br><br>
alkyl, CF3, OCF3, NO2, O-C1-10 alkyl, OH, NH2. NH(C1-10 alkyl), N(C1-10 alkyl)2, or<br>
NHC(O)C1-10 alkyl. In certain embodiments B-Z is NHC(Q)-phenyl. In some<br>
embodiments, Z is (CH2)m-5-20 membered heteroaryl optionally substituted with 1-5<br>
Q groups. In certain embodiments, m is 0. Exemplary compounds of these<br>
embodiments include, but are not limited to, 1-(2-aminoacetyl)-4-<br>
(picolinamidc)pyrrolidine-2-carboxylic acid, 1 -(2-aminoacetyl)-4-<br>
(nicotinamido)pyrrolidine-2-carboxylic acid, 1-(2-aminoacetyl)-4-<br>
(isonicotinamido)pyrrolidine-2-carboxylic acid, 1-(2-aminoacetyl)-4-(pyrimidine-5-<br>
carboxamido)pyrrolidine-2-carboxylic acid, 1 -(2-aminoacetyl)-4-(2-<br>
fluorobenzamido)pyrrolidine-2-carboxylic acid, 1-(2-aminoacetyl)-4-(3-<br>
fluorobenzamido)pyrrolidine-2-carboxylic acid, 1-(2-aminoacetyl)-4-(4-<br>
fluorobenzamido)pyrrolidine-2-carboxylic acid, 1 -(2-aminoacetyl)-4-(2-<br>
methylbenzamido)pyrrolidine-2-carboxylic acid, 1 -(2-aminoacetyl)-4-(3-<br>
methylbenzamido)pyrrolidine-2-carboxylic acid, 1 -(2-aminoacetyl)-4-(4-<br>
methylbenzamido)pyrrolidine-2-carboxylic acid 1 -(2-aminoacetyI)-4-(4-<br>
methoxybenzamido)pyrrolidine-2-carboxylic acid, 1-(2-aminoacetyl)-4-(3-<br>
methoxybenzamido)pynrolidine-2-carboxylic acid, 1-(2-aminoacetyl)-4-(4-<br>
hydroxybenzarnido)pyrrolidine-2-carboxylic acid, and 1-(2-aminoacetyl)-4-(3-<br>
hydroxybenzamido)pyrrolidine-2-carboxylic acid.<br>
In some embodiments, B is NR5(CH2)nC(O), n is 0 (i.e., B is NR5C(O)) and Z is<br>
(CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups or (CH2)m-5-20 membered<br>
heteroaryl optionally substituted with 1-5 Q groups, wherein m is 1 or 2. A non-<br>
limiting example of these embodiments is 1-(2-aminoacetyJ)-4-(2-<br>
phenylacetamido)pyrrolidine-2-carboxylic acid.  In other embodiments, B is<br>
NR5(CH2)nC(O) wherein n is 1 or 2. A non-limiting example of these embodiments<br>
is l-(2-aminoacetyl)-4-(2-oxo-2-phenylethylamino)pyrrolidine-2-carboxylic acid).<br>
In other embodiments, B is NR5, R6 is H, Z is (CH2)m-C6-20 aryl optionally substituted<br>
with 1-5 Q groups or (CH2)m-5-20 membered heteroaryl optionally substituted with<br>
1-5 Q groups, and m is 0 (e.g., 1-(2-arninoacety!)-4-(phenylamino)pyrroJidine-2-<br>
carboxylic acid) or 1 (e.g., 1-(2-aminoacetyl)-4-(benzylamino)pyrrolidine-2-<br>
carboxylic acid), in still other embodiments, B is NR5(CH2)nS(O)2, n is 0 (i.e., B is<br>
NR5S(O)2) and Z is (CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups or<br>
(CH2)m-5-20 membered heteroaryl optionally substituted with 1-5 Q groups. One<br><br>
non-limiting example of these embodiments is 1-(2-aminoacetyl)-4-<br>
(phenylsulfonamido) pyrrolidine-2-carboxylic acid).<br>
In still other embodiments, B is an amide bioisostere, such as, for example,<br>
imidazole, oxazole, thiazole, pyrazole, triazole, oxadiazole, thiadiazole, or tetrazole,<br>
each of which optionally can be substituted. Exemplary compounds of these<br>
embodiments include, but are not limited to, 1-(2-aminoacetyl)-4-(4-phenyloxazol-2-<br>
yl)pyrrolidine-2-carboxylic acid, 1-(2-aminoacetyl)-4-(5-phenyloxazol-2-<br>
yl)pyrrolidine-2-carboxylic acid, 1-(2-aminoacetyl)-4-{5-phenyl-1H-imidazol-2-<br>
yl)pyrrolidine-2-carboxylic acid, and 1-(2-aminoacetyl)-4-(4-phenyl-1H-imidazol-2-<br>
yl)pyrrolidine-2-carboxylic acid.<br>
In some embodiments, E is C(O)OR6.  Examples include compounds wherein E is<br>
C(O)OH.  In other embodiments, E is C(O)NR6R7.  In some compounds, E is<br>
C(O)NH2.  In other compounds, E is C(O)NR6R7, R6 is H, and R7 is selected from an<br>
optionally substituted C1-10alkyl, an optionally substituted C3-20 cycloalkyl, an<br>
optionally substituted C6-20 aryl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, and an optionally substituted 5-20 membered heteroaryl.<br>
In other embodiments, E is a carboxylic acid bioisostere such as, for example,<br>
imidazole, oxazole, thiazole, pyrazole, triazole, oxadiazole, thiadiazole, or tetrazole,<br>
each of which optionally can be substituted. Exemplary compounds of these<br>
embodiments include, but are not limited to, N-[1-(2-aminoacetyl)-5-(1H-tetrazol-5-<br>
yl)pyrrolidin-3-yl]benzamide, N-[1 -(2-aminoacetyl)-5-(1 H-imidazol-2-yl)pyrrolidin-3-<br>
yl]benzamide, N-[1-(2-aminoacetyl)-5-(5-methyl-1H-imidazol-2-yl)pyrrolidin-3-<br>
yl]benzamide, N-[1-(2-aminoacetyl)-5-(5-isopropyl-1H-imidazol-2-yl)pyrrolidin-3-<br>
yl[benzamide, N-[1-(2-aminoacetyl)-5-(oxazol-2-yl)pyrrolidin-3-yl]benzamide, N-(1-<br>
(2-aminoacetyl)-5-(5-isopropyloxazol-2-yl)pyrrolidin-3-yl]benzamide, N-[1 -(2-   .<br>
aminoacetyl)-5-(5-methyloxazol-2-yl)pyrrolidin-3-yl]benzamide, N-[1-(2-<br>
aminoacetyl)-5-(4-methyloxazol-2-yl)pyrrolidin-3-yl]benzamide, N-[1-(2-<br>
aminoacetyl)-5-(1H-pyrazol-5-yl)pyrrolidin-3-yl]benzamide, N-[1-(2-aminoacetyl)-5-<br>
(3-isopropyl-1H-pyrazo!-5-yl)pyrrolidin-3-yl]benzamide, N-[1-(2-aminoacetyl)-5-(3-<br>
methyl-1 H-pyrazol-5-yl)pyrrolidin-3-yl]benzamide, N-[1-(2-aminoacetyl)-5-(1 H-1,2,4-<br>
triazol-5-yl)pyrrolidin-3-yl]benzamide, N-[1-(2-aminoacetyl)-5-(3-methyl-1H-1,2,4-<br>
triazol-5-yl)pyrrolidin-3-yl]benzamide, N-[1-(2-aminoacetyl)-5-(3-isopropyl-1H-1,2,4-<br><br>
triazol-5-yl)pyrrolidin-3-yl]benzarnide, N-[1-(2-aminoacetyl)-5-(1,3,4-oxadiazol-2-<br>
yf)pyrrolidin-3-yl]benzamide, and N-[1-(2-aminoacetyl)-5-(5-methyl-1,3,4-oxadiazol-<br>
2-yl)pyrrolidin-3-yl]benzamide.<br>
In some embodiments, when A is (CH2)k-Y', Y' is NH2, k is 0, E is C(O)OH, B is<br>
NHC(O), and Z is phenyl, then R1 is not methyl. In other embodiments, when A is<br>
(CH2)K-Y', Y' is NH2, k is 0, R1 is methyl, E is C(O)OH, and Z' is phenyl, then the<br>
phenyl is substituted with at least one Q group. In still other embodiments, when A<br>
is (CH2)K-Y', Y' is NH2, k is 0, R1 is methyl, B is NHC(O), and Z is phenyl. then E is<br>
not C(O)OH.  In other embodiments, when A is (CH2)k-Y', Y' is NH2, R1 is methyl, E<br>
is C(O)OH, B is NHC(O), and Z' is phenyl, then k is 1 or 2.  In yet other<br>
embodiments, when A is (CH2)k-T, k is 0, R1 is methyl, E is C(O)OH, B is NHC(O),<br>
and Z' is phenyl, then Y' is not NH2.<br>
Compounds according to the present teachings include those having the following<br>
structures:<br><br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br>
In another aspect, the present teachings provide compounds having the Formula III:<br><br><br>
and pharmaceuticalty acceptable salts, esters, hydrates, and prodrugs thereof,<br>
wherein:<br>
Y' is OR2 or NR2R3;<br>
k is 0, 1, or 2;<br>
Z' is selected from H, (CH2)m-C6-20 aryl, (CH2)m-5-20 membered heteroaryl,<br>
C(O)(CH2)m-C6-20 aryl, C(O)(CH2)m-5-20 membered heteroaryl, (CH2)mC(O)-C6-20<br>
aryl, (CH2)mC(O)-5-20 membered heteroaryl, S(O)2(CH2)m-C6-20 aryl, and<br>
S(O)2(CH2)m-5-20 membered heteroaryl, wherein each of the C6-20 aryl and 5-20<br>
membered heteroaryl is optionally substituted with 1-5 Q groups;<br>
m is 0, I, or 2;<br>
Q, at each occurrence, independently is selected from an optionally<br>
substituted C1-10 alkyl, an optionally substituted C2-10 alkenyl, an optionally<br>
substituted C2-10 alkynyl, an optionally substituted C3-20 cycloalkyl, an optionally'<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, an optionally substituted<br>
3-20 membered cycloheteroalkyl, an optionally substituted 5-20 membered<br>
heteroaryl, F, Cl, Br, I, CN, CF3, OCF3, NO2, OR8, SR8, S+R62, S(O)R8, S(O)2R8,<br>
S(O)2OH, S(O)2NR8R9, NR8S(O)2R9, C(O)R8, C(O)OR8, C(O)NR8R9, OC(O)R8,<br>
NR8R9, NR8C(O)R9, NR8C(O)OR9, NR8C(O)NR8R9, and N+R83;<br>
R1 is selected from H, an optionally substituted d.10 alkyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, and an amino acid side<br>
chain;<br>
R2 and R3 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C7-20<br>
aralkyl, an optionally substituted C6-20 aryl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R6,<br>
C(O)OR6, C(O)NR6R7, S(O)2R6, and S(O)2NR6R7;<br><br>
alternatively, R2 and R3 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N or S and optionally substituted with<br>
1-5 Q groups;<br>
R4 is OR6 or NR6R7;<br>
R5 is H or an optionally substituted C1-10alkyl;<br>
R5 and R7 each independently is selected from H, an optionally substituted<br>
C1-10alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-1O alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R8,<br>
C(O)OR8, and C(O)NR8R9;<br>
alternatively, R6 and R7 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N or S and optionally substituted with<br>
1-5 Q groups; and<br>
R8 and R9 each independently is selected from H, an optionally .<br>
substituted d-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally<br>
substituted C2-10 alkenyl, an optionally substituted C2-10 alkynyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, an optionally substituted<br>
3-20 membered cycloheteroalkyl, and an optionally substituted 5-20 membered<br>
heteroaryl;<br>
provided that the compound is not 1-(2-aminopropanoyl)-4-<br>
berizamidopyrrolidine-2-carboxylic acid.<br>
In some embodiments k is 0; in others, k is 1.<br>
In some embodiments, Y' is NR2R3 and R2 is H (i.e., Y1 is NHR3) and R3 is selected<br>
from H (i.e., Y' is NH2), an optionally substituted d-10 alkyl, C(O)R6, or C(O)OR6. In<br>
some embodiments, Y' is NR2R3, R2 is H, R3 is C(O)R6 and R6 is H (i.e., R3 is<br>
C(O)H) or an optionally substituted d-10 alkyl (e.g., R3 is C(O)CH3). In other<br>
embodiments, Y' is NR2R3; and R2 and R3 each independently is an optionally<br>
substituted C1-10 alkyl.  In still other embodiments, Y' is OR2 and Rz is H (i.e., Y is<br>
OH) or an optionally substituted C1-10 alkyl.<br><br>
In certain embodiments, R1 is H. In other embodiments, R1 is an amino acid side<br>
chain and the amino acid is selected from valine, leucine, isoleucine, methionin.e,<br>
alanine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, lysine,<br>
argenine, histidine, aspartic acid, glutamic acid, asparagine and glutamine,<br>
provided that the compound is not 1-(2-aminopropanoyl)-4-benzamidopyrrolidine-2-<br>
carboxylic acid.<br>
Other embodiments of the present teachings include compounds wherein R4 is-OR5<br>
(e.g., OH). Alternatively, R4 can be NR6R7, wherein R6 is H and R7 is selected from<br>
H (i.e., R4 is NH2), an optionally substituted C1-10 alkyl, an optionally substituted C3-20<br>
cycloalkyl, an optionally substituted C6-20 aryl, an optionally substituted 3-20<br>
membered cycloheteroalkyl, or an optionally substituted 5-20 membered heteroaryl.<br>
In still other alternatives, R6 and R7 together with the nitrogen atom to which they<br>
are bound form a 3-20 membered heterocycle selected from piperidine, piperazine,<br>
morpholine, thiomorpholine, pyrrolidine, oxazolidine, thiazolidine, and imidazolidine,<br>
each of which optionally can be substituted with 1-5 Q groups.<br>
In some embodiments, Z' is C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q<br>
groups and m is 0 (i.e., Z is C(0)-C6-20 aryl optionally substituted with 1-5 Q<br>
groups). Exemplary compounds of these embodiments include those wherein Z' is<br>
benzoyl.  In other examples, Z is benzoyl substituted with 1-5 Q groups, such as,<br>
for example, F, Cl, Br, I, C1-1O alkyl. CF3, OCF3, NO2, O-C1-10 alkyl, OH, NH2, NH(C1-<br>
10 alkyl), N(C1-10 alkyl)2, and NHC(O)C1-10 alkyl.<br>
In some embodiments, when Y' is NH2, k is 0, R4 is OH, R5 is H, and Z' is benzoyl,<br>
then R1 is not methyl. In other embodiments, when Y' is NH2, k is 0, R1 is methyl,<br>
R4 is OH, R5 is H, and Z' is benzoyl, then the benzoyi is substituted with at least one<br>
Q group. In still other embodiments, when Y' is NH2, k is 0, R1 is methyl, R5 is H,<br>
and Z is benzoyl, then R4 is not OH. In other embodiments, when Y' is NH2, R1 is<br>
methyl, R4 is OH, R5 is H, and Z1 is benzoyl, then k is 1 or 2. In yet other<br>
embodiments, when k is 0, R1 is methyl, R4 is OH, R5 is H, and Z' is benzoyl, then<br>
Y' is not NH2.<br><br>
Compounds according to the present teachings include those having the following<br>
structures:<br><br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br>
Examples of suitable prodrugs of any of the compounds of the present teachings<br>
include, but are not limited to, oxazolidinone or imidazolidinone prodrugs.<br>
In another aspect, the present teachings provide pharmaceutical compositions<br>
comprising a compound according to the present teachings and a pharmaceutically<br>
acceptable carrier.<br>
In still another aspect, the present teachings provide methods of preventing or<br>
treating a pathological condition comprising administering to a subject in need '<br>
thereof (e.g., a human being) a therapeuticaily effective amount of a compound or<br>
pharmaceutical composition according to the present teachings. Examples of<br>
pathological conditions that can be treated or prevented using compounds of the<br>
present teachings include, but are not limited to, cardiovascular disease (e.g., atrial<br>
fibrillation, atrial flutter, ventricular tachycardia or ventricular fibrillation);<br>
osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue;<br>
bladder incontinence; impaired hearing, such as due to diseases of the cochlea;<br>
endothelial lesions; diabetes including diabetic retinopathy and diabetic neuropathy;<br><br>
CMS related conditions; ischemia (e.g. ischemia of the central nervous system,<br>
spinal cord, brain or brain stem); dental tissue disorders including periodontal<br>
disease; kidney diseases; haematologic manifestations (e.g., anaemia, leukopenia,<br>
thrombocytopenia, and pancytopenia) especially following treatment with cytostatic<br>
compounds or irradiation therapy; wounds such as superficial wounds and deep<br>
wounds resulting from trauma; erectile dysfunction; urinary bladder incontinence;<br>
neuropathic pain; subchronic and chronic inflammation; cancer; failure of bone<br>
marrow and stem cell transplantation; conditions which arise during transplantation<br>
of cells and tissues or during medical procedures such as surgery; conditions<br>
caused by an excess of reactive oxygen species, free radicals or nitric oxide;<br>
diseases or disorders of pregnancy (e.g., preeclampsia and preterm labor); and<br>
stroke.<br>
The compounds and pharmaceutical compositions according to the present<br>
teachings can be formulated for parenteral or oral administration.<br>
A.	Definitions<br>
Unless specified otherwise, the following definitions are provided for specific terms,<br>
which are used in the following written description.<br>
Throughout the description and claims the three-letter code for natural amino acids<br>
is used as well as generally accepted three letter codes for other a-amino acids,<br>
such as sarcosine (Sar). Where the L or D form has not been specified, it is to'be<br>
understood that the amino acid in question can be either the L or D form. A mixture<br>
of equimolar amounts of D and L compounds is termed racemic and is designated<br>
by the prefix DL, e.g., DL-leucine. It can alternatively be designated by the prefix<br>
rac- (e.g. rac-leucine) or by the prefix [+/-]. The present teachings include all<br>
possible stereoisomers of the compounds of Formulae I, II and III as well as of the<br>
specific compounds shown herein.<br>
The term "peptide" herein designates a chain of two or more molecules that are<br>
linked by means of a peptide bond.   Peptides can contain one or more naturally<br>
occurring amino acids, one or more unnatural amino acids, one or more molecules<br>
that are not amino acids but are capable of forming peptide bonds, or mixtures,<br>
thereof.<br><br>
The term "amino acid" refers to a molecule having the general formula<br>
NHR-CHR'-COOH (wherein R is H and R' is an amino acid side chain, or R and R'<br>
together with the carbon and nitrogen to which they are bonded form a ring, e.g.,<br>
proline) which is capable of forming a peptide bond with one or more other<br>
molecules having the same general formula. The term embraces both L and D<br>
amino acids.<br>
A "naturally occurring amino acid" refers to one of the following 20 amino acids: Ala<br>
(A), Cys (C), Ser (S), Thr (T), Asp (D), Glu (E), Asn (N), Gln (Q), His (H). Arg (R),<br>
Lys (K), lle (I), Leu (L). Met (M), Val (V), Phe (F), Tyr (Y), Trp (W), Gly (G), and Pro<br>
(P). Normally these are L-amino acids, but the present teachings also allow for the<br>
use of D-amino acids.<br>
As used herein, the term "lysine mimetic" refers to an unnatural amino acid<br>
comprising a C5-6 aliphatic or aromatic ring and at least two basic amine<br>
functionalities (i.e., at least one basic amine functionality in addition to the N-<br>
terminal amine).  In some cases, the lysine mimetic has the formula<br>
NHR-CHR'-COOH, wherein R and R' together with the carbon and nitrogen to <br>
which they are bonded form a 5-6 membered ring, wherein the ring either (a)<br>
contains at least one additional ring nitrogen, e.g., imidazolidine-2-carboxylic acid<br>
(lca), or (b) bears an amine substituent, e.g., amino-pyrrolidine-2-carboxylic acid<br>
(4Amp) or amino-piperidine-2-carboxylic acid (4Ampi). In other cases, the lysine<br>
mimetic has the formula NHR-CHR'-COOH wherein R is H and R' is a side chain<br>
comprising a C5-6 aliphatic or aromatic ring, wherein (a) the ring either contains at<br>
least one ring nitrogen or bears an amine substituent, and (b) the ring is separated<br>
from the amino acid backbone methylene by 1 or 2 atoms. A non-limiting example<br>
of such a lysine mimetic is amino-phenylalanine (4AmF), wherein 1 atom separates<br>
the ring from the backbone. Lysine mimetics can also have the formula<br>
NHR-CR'R"-COOH wherein R is H and R' and R" together form a C5-6 aliphatic or<br>
aromatic ring, wherein the ring either contains at least one ring nitrogen or bears an<br>
amine substituent. One non-limiting example of this type of lysine mimetic is 4-<br>
amino-piperidine-4-carboxylic acid (Pip). Also included within the definition of<br>
"lysine mimetic" are unnatural - and Y-amino acids comprising a C5-6 aliphatic or<br>
aromatic ring and at least two basic amine functionalities as described above, such<br><br>
as 3,5-diamino-benzoic acid (Damba). Other lysine mimetics are 4-aminoproline<br>
analogs wherein the proline ring nitrogen is not present (e.g., 3-<br>
aminocyclopentanecarboxylic acid) or is located in another position in the proline<br>
ring (e.g., 3-aminopyrrolidine-1-carboxylic acid or 3-aminopyrrolidine-1-<br>
carboxamide). In any of the lysine mimetics, the basic amine functionalities can be<br>
a primary arnino group (e.g. 4AmF, Damba, 4Ampi, and 4Amp) or a secondary<br>
amino group (e.g. Pip and lca). Examples of lysine mimetics having aliphatic cyclic<br>
amine groups and aryl amines include Damba, 4Amp, 4Ampi, lea, Pip, and 4AmF,<br>
having the following structures:<br><br>
The term "halogen" refers to F, Cl, Br, and I.<br>
The term "alkyl," as used herein either alone or as part of another group, refers to a<br>
substituted or unsubstituted aliphatic hydrocarbon chain, e.g., having from 1 to 10<br>
carbon atoms, that can be straight-chain or branched. Examples of alkyl groups<br>
include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-<br>
butyl, isobutyl, s-butyl, t-butyl), pentyl groups (e.g., n-pentyl, isopentyl, neopentyl)<br><br>
and the like. Specifically included within the definition of "alkyl" are those aliphatic<br>
hydrocarbon chains that are optionally substituted.<br>
The term "alkenyl," as used herein either alone or as part of another group, refers to<br>
a substituted or unsubstituted aliphatic hydrocarbon chain, e.g., having from 2. to 10<br>
carbon atoms, that can be straight-chain or branched and contains one or more<br>
carbon-carbon double bonds. The one or more double bonds can be internal (such<br>
as in 2-butene) or terminal (such as in 1-butene). Preferably alkenyl moieties<br>
contain one or two double bonds. The term "alkenyl" includes both E and Z isomers<br>
of each of the one or more double bonds. Specifically included within the definition<br>
of "alkenyl" are those aliphatic hydrocarbon chains that are optionally substituted.<br>
Examples of alkenyl moieties include vinyl, allyl, and butenyl (e.g., 1-butene and 2-<br>
butene).<br>
The term "alkynyl," as used herein either alone or as part of another group, refers to<br>
a substituted or unsubstituted aliphatic hydrocarbon chain, e.g., having from 2 to 10<br>
carbon atoms, that can be straight-chain or branched and contains one or more<br>
triple carbon-carbon bonds. The one or more triple carbon-carbon bonds can be<br>
internal (such as in 2-butyne) or terminal (such as in 1-butyne).  Specifically<br>
included within the definition of "alkynyl" are those aliphatic hydrocarbon chains that<br>
are optionally substituted. Examples of alkynyl groups include ethynyl, propynyl,<br>
butynyl, pentynyl, and the like.<br>
As used herein either alone or as part of another group, the term "cycloalkyl" refers<br>
to substituted or unsubstituted non-aromatic carbocyclic groups, e.g., having from 3<br>
to 20 ring carbon atoms and optionally containing one or more (e.g., 1, 2 or 3)<br>
double or triple bonds, including cyclized alkyl, alkenyl, and alkynyl groups.<br>
Cycloalkyl groups can be monocyclic (e.g., cyclohexyl) or poly-cyclic (e.g. fused,<br>
bridged, or spiro ring systems), wherein the carbon atoms are located inside or<br>
outside of the ring system. Any suitable ring position of the cycloalkyl moiety can<br>
be covalently linked to the defined chemical structure. Examples of cycloalkyl<br>
groups include cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl,<br>
cyclohexylmethyl, cyclohexylethyl, cycloheptyl, cyclopentenyl, cyclohexenyl,<br>
cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl,<br>
spiro[4.5]decanyl groups, hornologs, isomers, and the like. Also included in the<br><br>
definition of cycloalkyl groups are moieties that have one or more aromatic rings<br>
fused (i.e., having a bond in common with) to the cycloalkyl ring, for example,<br>
benzo derivatives of cyclopentane (indanyl), cyclohexane (tetrahydronaphthyl), and<br>
the like. Specifically included within the definition of "cycloalkyl" are those<br>
carbocycles that are optionally substituted.<br>
The term "aryl," as used herein either aldne or as part of another group, refers to<br>
substituted or unsubstituted aromatic monocyclic or polycyclic hydrocarbons such<br>
as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, and the like. In<br>
some embodiments, aryl groups have from 6 to about 20 carbon atoms. Any<br>
suitable ring position of the aryl moiety can be covalently linked to the defined<br>
chemical structure (e.g., 1-naphthyl, 2-naphthyl, etc.). Specifically included within<br>
the definition of "aryl" are those aromatic hydrocarbons that are optionally<br>
substituted.<br>
The term "aralkyl" refers to an aryl moiety, as defined herein, bonded to an alkyl<br>
moiety, as defined herein. Aralkyl groups are covalenfly linked to the defined<br>
chemical structure through their alkyl groups. Aralkyl groups optionally can be<br>
substituted on the aryl moiety, the alkyl moiety, or both.<br>
As used herein either alone or as part of another group, "cycloheteroalkyl" refers to<br>
a substituted or unsubstituted non-aromatic cycloalkyl group, e.g., having from 3 to<br>
20 ring atoms, that contains 1-4 ring heteroatoms independently selected from<br>
oxygen (O), nitrogen (N) and sulfur (S), and optionally contains one or more (e.g..<br>
1, 2 or 3) double or triple bonds. The cycloheteroalkyl group can be attached to the<br>
defined chemical structure at any heteroatom or carbon atom that results in a stable<br>
structure. One or more N or S atoms in a cycloheteroalkyl ring can be oxidized<br>
(e.g., N-hydroxypiperidine, morpholine N-oxide, thiomorpholine S-oxide,<br>
thiomorpholine S,S-dioxide). Examples of cycloheteroalkyl groups include<br>
morpholine, thiomorpholine, pyran, imidazolidine, imidazoline, oxazolidine,<br>
pyrazolidine, pyrazoline, pyrrolidine, pyrroline, tetrahydrofuran, tetrahydrothiophene,<br>
piperidine, piperazine, and the like. Also included in the definition of<br>
cycloheteroalkyl are moieties that have one or more aromatic rings fused (i.e., have<br>
a bond in common with) to the cycloheteroalkyl ring, for example, benzimidazoline,<br>
chromane, chromene, indolinetetrahydroquinoline, and the like. Cycloheteroalkyl<br><br>
groups can also contain one or more oxo groups, such as phthalimide, piperidone,<br>
oxazolidinone, pyrimidine-2,4(1H,3H)-dione&gt; pyridin-2(1H)-one, and the like.<br>
Specifically included within the definition of "cycloheteroalkyl" are those ring<br>
systems that are optionally substituted on any heteroatom and/or carbon atom that<br>
results in a stable structure.<br>
As used herein either alone or as part of another group, "heteroaryl" refers to<br>
monocyclic or polycyclic aromatic ring systems having from 5 to 20 ring atoms and<br>
containing 1-4 ring heteroatoms independently selected from O, N and S.<br>
Generally, heteroaryl rings do not contain O-O, S-S, or S-O bonds. Heteroaryl<br>
groups include monocyclic heteroaryl rings fused to a phenyl ring. The heteroaryl<br>
group can be attached to the defined chemical structure at any heteroatom or<br>
carbon atom that results in a stable structure. One or more N or S atoms in a<br>
heleroaryl ring can be oxidized (e.g., N-hydroxypyridine, pyridine N-oxide,<br>
thiophene S-oxide, thiophene S,S-dioxide). Examples of heteroaryl groups include,<br>
for example, pyrrole, furan, thiophene, pyridine, pyrimidine, pyridazine, pyrazine,<br>
triazole, pyrazole, imidazole, isothiazole, thiazole, thiadiazole, isoxazole, oxazole,<br>
oxadiazole, indole, isoindole, benzofuran, benzothiophene, quinoline, 2-<br>
methylquinoline, isoquinoline, quinoxaline, quinazoline, benzotriazole,<br>
benztetrazole, indazole, benzimidazole, benzothiazole, benzisothiazole,<br>
benzisoxazole, benzoxadiazole, benzoxazole, cinnoline, 1H-indazole, 2H-indazole,<br>
indolizine, isobenzofuran, naphthyridine, phthalazine, pteridine, purine,<br>
oxazolopyridine, thiazolopyridine, imidazopyridine, furopyridine, thienopyridine,<br>
pyridopyrimidine, pyridopyrazine, pyridopyridazine, thienothiazole, thienoxazole,<br>
and thienoimidazole. Specifically included within the definition of "heteroaryl" are<br>
those aromatic ring systems that are optionally substituted on any heteroatom<br>
and/or carbon atom that results in a stable structure.<br>
The term "heterocycle" means a heteroaryl or cycloheteroalkyl as defined herein.<br>
As used herein, "carboxylic acid bioisostere" means a substituent or group that has<br>
chemical or physical properties similar to that of a carboxylic acid moiety and that<br>
produces broadly similar biological properties to that of a carboxylic acid moiety.<br>
See, generally, R. B. Silverman, The Organic Chemistry of Drug Design and Drug<br>
Action (Academic Press, 1992).   Examples of carboxylic acid bioisosteres include,<br><br>
but are not limited to, amides, sulfonamides, sulfonic acids, phosphonamidic acids,<br>
alkyl phosphonates, N-cyanoacetamtdes, 3-hydroxy-4H-pyran-4-one, imidazoles,<br>
oxazoles, thiazoles, pyrazoles, triazoles, oxadiazoles, thiadiazoles, or tetrazoles,<br>
each of which optionally can be substituted (e.g., by C1-10 alkyl, OH, etc.).<br>
As used herein, "amide bioisostere" means a substituent or group that has chemical<br>
or physical properties similar to that of an amide moiety and that produces broadly<br>
similar biological properties to that of an amide moiety. See, generally, R. B.<br>
Silverman, The Organic Chemistry of Drug Design and Drug Action (Academic<br>
Press, 1992).   Examples of amide bioisosteres include, but are not limited to,<br>
carboxylic acids, sulfonamides, sulfonic acids, phosphonamidic acids, alkyl<br>
phosphonates, N-cyanoacetamides, 3-hydroxy-4H-pyran-4-one, imidazoles,<br>
oxazoles, thiazoles, pyrazoles, triazoles, oxadiazoles, thiadiazoles, or tetrazoles,<br>
any of which optionally can be substituted (e.g., by C1-10 alkyl, OH, etc.).<br>
The phrase "hydrophobic group" refers to an optionally substituted aromatic carbon<br>
ring, preferably a 6- to 12-membered aromatic carbon ring. The hydrophobic group<br>
can be optionally substituted as discussed below. Illustrative hydrophobic groups<br>
include benzyl, phenyl, and napthyl.<br>
The term "optionally substituted" as used herein means one or more hydrogen<br>
atoms (e.g., 1, 2, 3, 4, 5, or 6 hydrogen atoms) of the group can each be replaced<br>
with a substituent atom or group commonly used in pharmaceutical chemistry.<br>
Each substituent can be the same or different.  Examples of suitable substituents<br>
include, but are not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl,<br>
cycloheteroalkyl, heteroaryl, OR6 (e.g., hydroxyl. alkoxy (e.g., methoxy, ethoxy, and<br>
propoxy), aryloxy, heteroaryloxy, aralkyloxy, ether, ester, carbamate, etc.),<br>
hydroxyalkyl, alkoxycarbonyl, alkoxyalkoxy, perhaloalkyl, perfluoroalkyl (e.g., CF3,<br>
CF2CF3), perfluoroalkoxy (e.g., OCF3, OCF2CF3), alkoxyalkyl, SR6 (e.g., thiol,<br>
alkylthio, arylthio, heteroarylthio, aralkylthio, etc.), S+R62, S(O)R6, SO2R6, NR6R7<br>
(e.g., primary amine (i.e., NH2), secondary amine, tertiary amine, amide,<br>
carbamate, urea, etc.), hydrazide, halide, nitrile, nitro, sulfide, sulfoxide, sulfone,<br>
sulfonamide, thiol, carboxy, aldehyde, keto, carboxylic acid, ester, amide, imine,<br>
and imide, including seleno and thio derivatives thereof, wherein each of the    <br>
substituents can be optionally further substituted. Preferably, 1-3 optional<br><br>
substituents can be present, wherein the substituents are Q groups as defined<br>
herein.  In embodiments in which a functional group with an aromatic carbon ring is<br>
substituted, such substitutions will typically number less than about 10 substitutions,<br>
more preferably about 1 to 5, with about 1 or 2 substitutions being preferred.<br>
The carbon numbers used in the definitions herein (e.g., C1-10 alkyl, C2-10 alkenyl,<br>
C2-10 alkynyl, C6-20 aryl, etc.) refer to the carbon backbone and carbon branching,<br>
but do not include carbon atoms of substituents.<br>
At various places in the present specification substituents of compounds of the<br>
present teachings are disclosed in groups or; in ranges. It is specifically intended<br>
that the present teachings include each and every individual subcombination of the<br>
members of such groups and ranges. For example, the term "C1-6 alkyl" is<br>
specifically intended to individually disclose C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-<br>
C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, G2-P3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and<br>
C5-C6 alkyl. Similarly, the term "C1-10 alkyl" is specifically intended to individually<br>
disclose C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C1-C10, C1-C9, CI-C8, C1-C7, C1-C6,<br>
C1-C5, C1-C4, C1-C3, C1-C2, C2-C10, C2-C9, C2-C8, C2-C7, C2-C6, C2-C5, C2-C4, C2-C3,<br>
C3-C10, C3-C9, C3-C8, C3-C7,  C3-C6,   C3-C5,  C3-C4,  C4-C10,  C4-C9, C4-C8, C4-C7, C4-C6,<br>
C4-C5, C5-C10, C5-C9, C5-C8, C5-C7, C5-C6, C6-C10, C6-C9, C6-C8, C6-C7, C7-C10,<br>
C7-C9, C7-C8, C8-C10, C8-C9, and C9-C10 alkyl.<br>
The compounds of the present teachings can contain an asymmetric atom (also<br>
referred to as a chiral center), and some of the compounds can contain one or more<br>
asymmetric atoms or centers, which can thus give rise to optical isomers<br>
(enantiomers) and diastereomers. The present teachings include such enantiomers<br>
and diastereomers, as well as the racemic and resolved, enantiomerically pure R<br>
and S stereoisomers, as well as other mixtures of the R and S stereoisomers and<br>
pharmaceutically acceptable salts thereof. Optical isomers can be obtained in pure<br>
form by standard procedures known to those skilled in the art, which include, but<br>
are not limited to, diastereomeric salt formation, kinetic; resolution, and asymmetric<br>
synthesis. The present teachings also encompass.cis and trans isomers of<br>
compounds containing alkenyl moieties (e.g., alkenes and imines). It is also<br>
understood that the present teachings encompass all possible regioisomers, and<br>
mixtures thereof, which can be obtained in pure form by standard separation<br><br>
procedures known to those skilled in the art, and include, but are not limited to,<br>
column chromatography, thin-layer chromatography, and high-performance liquid<br>
chromatography.<br>
The terms "intercellular communication modulator", "gap junction facilitator",<br>
"compound that facilitates gap junction cornmunication" and "gap junction opener",<br>
etc., all refer to a compound that facilitates, or maintains, or normalizes, gap<br>
junction intercellular communication (GJIC), irrespective of the particular<br>
mechanism behind this action. More specifically, the term "gap junction opener"<br>
can refer to a substance that normalizes (i.e., increases) the exchange of molecules<br>
that are able to pass through gap junctions between extracellular and intracellular<br>
spaces and/or which can normalize or increase GJIC.<br>
The term "agonist" " refers to an compound that can interact with a tissue, cell or<br>
cell fraction which is the target of an AAP, AAP10, or HP5 compound (or functional<br>
analogue thereof), to cause substantially the same physiological responses in the<br>
tissue, cell or cell fraction as the AAP, AAP10, or HP5 compound (or functional<br>
analogue thereof). In one aspect, the physiological response is one or more of<br>
contraction, relaxation, secretion, enzyme activation, etc.  Preferably, the<br>
compound binds to the tissue, cell or cell fraction. In one aspect, the compound<br>
binds to a receptor on the tissue, cell, or cell fraction, which binds to AAP, AAP10,<br>
or HP5 (or a functional analogue thereof).<br>
The term "antagonist" refers to a compound which inhibits or antagonizes one or<br>
more physiological responses observed in a tissue, cell or cell fraction after<br>
contacting the tissue, cell, or cell fraction with AAP, AAP10, or HP5 compound (or<br><br>
functional analogue thereof), in one aspect, the physiological response is one or<br>
more of contraction, relaxation, secretion, enzyme activation, etc. Preferably, the<br>
compound binds to the tissue, cell or cell fraction.  In one aspect, the compound<br>
binds to a receptor on the tissue, cell, or cell fraction which binds to AAP, AAP10, or<br>
HP5 (or functional analogue thereof) and/or which inhibits binding of one or more of<br>
AAP, AAP10, or HP5 (or functional analogue thereof) to the receptor.<br><br>
As used herein, "normalize" refers to a change in a physiological response such<br>
that the response becomes insignificantly different from one observed in a normal<br>
patient. Thus, normalization can involve an increase or decrease in the response<br>
depending on the pathology involved.<br>
B.         Exemplary compounds<br>
Exemplary compounds according to the present teachings are listed below. In<br>
some cases, alternate names for the compounds are included in parentheses after<br>
the chemical name.<br>
Compound 1: (2S, 4R)1-(2-Amino-acetyl)-4-(4-nitro-benzoylamino)-pyrrolidine-2-<br>
carboxylic acid (H-Gly-(2S, 4R)-4Amp(4-Nitrobenzoyl)-OH)<br>
Compound 2: (2S4R) 1 -(2-Amino-acetyl)-4-benzoylamino-pyrrolidine-2-carboxylic<br>
acid ((2S, 4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid, H-Gly-<br>
(2S, 4R)-4Amp(Benzoyl)-OH)<br>
Compound 3: (2S, 4R)1-(2-Amino-acetyl)-4-(4-methyl-benzoylamino)-pyrrolidine-2-<br>
carboxylic acid (H-Gly-(2S, 4R)-4Amp(4-methylbenzoyl)-OH)<br>
Compound 4: (2S, 4R)1-(2-Amino-acetyl)-4-(4-methoxy-benzoy!amino)-pyrrolidine-<br>
2-carboxylic acid (H-Gly-(2S, 4R)-4Amp(4-methoxybenzoyl)-OH)<br>
Compound 5: (2S, 4R)1-(3-Amino-propionyl)-4-benzoylamino-pyrrolidine-2-<br>
carboxylic acid (H-Ala-(2S, 4R)-4Amp(benzoyl)-OH)<br>
Compound 6: (2S, 4R)1-(2-Amino-4-carboxy-butyryl)-4-benzoylamino-pyrroiidine-<br>
2-carboxylic acid (H-Glu-(2S, 4R)-4Amp(benzoyl)-OH)<br>
Compound 7: (2S, 4R)1-[2-Amino-3-(1H-indol-3-yi)-propionyI]-4-benzoylamino-<br>
pyrrolidine-2-carboxylic acid (H-Trp-(2S, 4R)-4Amp(benzoyl)-OH)<br>
Compound 8: (2S, 4R)1-(2-Amino-4-methyl-pentanoyl)-4-benzoylamino-pyrrolidine-<br>
2-carboxylic acid (H-Leu-(2S, 4R)-4Amp(benzoyl)-OH)<br><br>
Compound 9: (2S, 4R)1-(2-Amino-3-phenyl-propionyl)-4-benzoylarnino-pyrrolidine-<br>
2-carboxylic acid (H-Phe-(2S, 4R)-4Amp(benzoyi)-OH)<br>
Compound 10: (2S, 4R)1-(2-Amino-acetyl)-4-(4-hydroxy-benzoylamino)-pyrrolidine-<br>
2-carboxylic acid (H-Gly-(2S, 4R)-4Amp(4-hydroxybenzoyl)-OH)<br>
Compound 11: (2S, 4S)1-(2-Amino-acetyl)-4-(4-rnethoxy-benzoylamino)-pyrrolidine-<br>
2-carboxylic acid (H-Gly-(2S, 4S)-4Amp(4-methoxybenzoyl)-OH)<br>
Compound 12: (2S, 4S)1-(2-Amino-acetyl)-4-(4-methyl-benzoylamino)-pyrrolidine-<br>
2-carboxylic acid (H-Gly-(2S, 4S)-4Amp(4-methylbenzoyl)-OH)<br>
Compound 13: (2S, 4S)1-(2-Amino-acefyl)-4-(4-nitro-benzoylamino)-pyrrolidine-2-<br>
carboxylic acid (H-Gly-(2S, 4S)-4Amp(4-nitrobenzoyl)-OH)<br>
Compound 14: (2S, 4S)1-(2-Amino-acetyJ)-4-benzoylamino-pyrrolidine-2-carboxylic<br>
acid (H-Gly-(2S, 4S)-4Amp(benzoyl)-OH)<br>
Compound 15:  (2S4S) 1-(2-Amino-4-carboxy-butyryl)-4-benzoylamino-piperidine-2-<br>
carboxylic acid (H-Glu-(2S4S)-4Ampi(benzoyl)-OH)<br>
Compound 16: (2S4S) 1-(2-Amino-4-methyl-pentanoyl)-4-benzoylamino-piperidine-<br>
2-carboxylic acid (H-Leu-(2S4S)-4Ampi(benzoyl)-OH)<br>
Compound 17:  (2S4S) 4-Benzoylamino-1-(2,6-diamino-hexanoyl)-piperidine-2-<br>
carboxylic acid (H-Lys-(2S4S)-4Ampi(benzoyl)-OH)<br>
. Compound 18: (2S4S) 1-(2-Amino-acetyl)-4-benzoylamino-piperidine-2-carboxylic<br>
acid (H-Gly-(2S4S)-4Ampi(Benzoyl)-OH)<br>
Compound 19: (2S4S) 1-(3-Amino-propionyl)-4-benzoylamino-piperidine-2-<br>
carboxylic acid (H-Ala-(2S4S)-4Ampi(benzoyl)-OH)<br>
Compound 20: (2S4S) 1-[2-Amino-3-(1H-indol-3-yl)-propionyl]-4-benzoylamino-<br>
piperidine-2-carboxylic acid (H-Trp-(2S4S)-4Ampi(Benzoyl)-OH)<br><br>
Compound 21: (2S4S) 1-(2-Amino-3-phenyl-propionyl)-4-benzoylamino-piperidine-<br>
2-carboxylic acid (H-Phe-(2S4S)-4Ampi(Benzoyl)-OH)<br>
Compound 22: 1-(2-Amino-4-carboxy-butyroyl)-3-benzoyl-imidazolidine-2-<br>
carboxylic acid (H-Glu-lca(Benzoyl)-OH)<br>
Compound 23: 4-(2-Amino-acetylamino)-1-benzoyl-piperidine-4-carboxylic acid (H-<br>
Gly-Pip(Benzoyl)-OH)<br>
Compound 24: 3-(2-Amino-acetylamino)-5-(4-methyl-benzoylamino)-benzoic acid<br>
(H-Gly-Damba(4-methylbenzoyl)-OH)<br>
Compound 25: 3-(2-Amino-3-carbamoyl-propionylamino)-5-benzoylamino-benzoic<br>
acid (H-Asn-Damba(Benzoyl)-OH)<br>
Compound 26: 3-(2-Amino-acetylamino)-5-benzoylarnino-benzoic acid (H-Gly-<br>
Damba(Benzoyl)-OH)<br>
Compound 27: (2S, 4R) 3-[(4-Benzoy!amino-pyrrolidine-2-carbonyl)-amino]-<br>
propionic acid ((2S4R)H-4Arnp(benzoyl)-betaA!a-OH)<br>
Compound 28: (2S, 4R) {[4-(4-Nitro-benzoylamino)-pyrrolidine-2-carbonyl]-amino}-<br>
acetic acid ((2S4R)H-4Amp(4-Nitrobenzoyl)-Gly-OH)<br>
Compound 29: (2S, 4R) {[4-(4-Methoxy-benzoy!amino)-pyrrolidine-2-carbonyl]-<br>
amino}-acetic acid ((2S4R)H-4Amp(4-Methoxybenzoyl)-Gly-OH)<br>
Compound 30: (2S, 4R) 2-{[4-(4-Methyl-benzoylamino)-pyrrolidine-2-carbonyl]-<br>
amino}-acetic acid ((2S4R)H-4Amp(Toluoyl)-Gly-OH)<br>
Compound 31: (2S, 4R) 2-[(4-Benzoylamino-pyrroIidine-2-carbonyl)-amino]-3-<br>
phenyl-propionic acid ((2S4R)H-4Amp(benzoyl)-Phe-OH)<br><br>
Compound 32:  (2S, 4R) 2-[(4-Benzoylamino-pyrrolidine-2-carbonyi)-amino]-4-<br>
methyl-pentanoic acid ((2S4R)H-4Amp(benzoyl)-Leu-OH)<br>
Compound 33:  (2S, 4R) 4-Benzoylamino-pyrrolidine-2-carboxylic acid (5-amino-1-<br>
formyl-pentyl)amide((2S4R)H-4Amp(benzoyl)-Lys-OH)<br>
Compound 34:  (2S, 4R) 2-[(4-Benzoylamino-pyrrolidine-2-carbonyl)-amino]-<br>
succinamic acid ((2S4R)H-4Amp(benzoyl)-Asn-OH)<br>
Compound 35:  (2S, 4S) [(4-Benzoylamino-pyrrolidine-2-carbonyl)-amino]-acetic<br>
acid ((2S4S)H-4Amp(Benzoyl)-Gly-OH)<br>
Compound 36: (2S, 4S) [(4-(4-Methoxy-benzoylamino)-pyrrolidine-2-carbonyl)-<br>
amino]-acetic acid ((2S4S)H-4Amp(4-Methoxybenzoy!)-Gly-OH)<br>
Compound 37: (2S, 4S) [(4-(4-Nitro-benzoy!amino)-pyrrolidine-2-carbonyl)-amino]-<br>
acetic acid ((2S4S)H-4Amp(4-Nitrobenzoyl)-Gly-OH)<br>
Compound 38: (2S, 4S) [(4-(4-Methyl-benzoylamino)-pyrrolidine-2-carbonyl)-<br>
amino]-acetic acid ((2S4S)H-4Amp(Toluoyl)-Gly-OH)<br>
Compound 39: [2-Amino-3-(4-benzoylarnino-phenyl)-propionylamino]-acetic acid<br>
(H-4AmF(Benzoyl)-GIy-OH)<br>
Compound 40: [2-Amino-3-(4-(4-Methoxy-benzoylamino-phenyl)-propionylarnino]-<br>
acetic acid (H-4AmF(4-Methoxybenzoyl)-Gly-OH)<br>
Compound 41: [2-Amino-3-(4-(4-Nitro-benzoylamino-phenyl)-propionylamino]-<br>
acetic acid (H-4AmF(4-Nitrobenzoyl)-Gly-OH)<br>
Compound 42: [2-Amino-3-(4-(4-Methyl-benzoylamino-phenyl)-propionylamino]-<br>
acetic acid (H-4AmF(Toluoyl)-Gly-OH)<br>
Compound 43: [(1-Benzoyl-imidazolidine-2-carbonyl)-aminolacetic acid (H-<br>
Ica (BenzoyI)-Gly-OH)<br><br>
Compound 44: {[1-(4-Nitro-benzoyl]-imidazolidine-2-carbonyl]-amino}acetic acid<br>
(H-lca(4-Nitrobenzoyl)-Gly-OH)<br>
Compound 45:  (2S, 4S) {[4-Benzoylamino-piperidine-2-carbonyl]-amino}-acetic<br>
acid((2S4S)H-4Ampi(Benzoyl)-G!y-OH)<br>
Compound 46: (2S, 4S) {[4-Benzoylamino-piperidine-2-carbonyl]-amino}-propionic<br>
acid((2S4S)H-4Ampi(benzoyl)-betaAla-OH)<br>
Compound 47: [(4-Amino-1-benzoyl-piperidine-4-carbonyl)-amino]-acetic acid (H-<br>
Pip(Benzoyi)-Gly-OH)<br>
Compound 48:  (3-Amino-5-benzoylamino-benzoylamino)-acetic acid (H-<br>
Damba(Benzoyl)-Gly-OH)<br>
Compound 49: (3-Amino-5-(4-Methoxy-benzoylamino)-benzoylamino)-acetic acid<br>
(H-Damba(4-MethoxybenzoyI)-Gly-OH)<br>
Compound 50: (3-Amino-5-(4-Methyl-benzoylamino)-benzoylamino)-acetic acid (H-<br>
Damba(Toluoyl)-Gly-OH)<br>
Compound 51: (3,5-Diamino-benzoylamino)-acetic acid (H-Damba-Gly-OH)<br>
Compound 52: (2S, 4R) 4-Benzoylamino-1-(2-hydroxy-acetyl)-pyrrolidine-2-<br>
carboxylic acid (HAA-(2S, 4R)4-Amp(benzoyl)-OH)<br>
Compound 53: 4-Benzoylamino-1-(2-hydroxy-acetylamino)-cyclohexanecarboxylic<br>
acid (HAA-Pip(benzoyl)-OH)<br>
Compound 54: 3-Benzoylamino-5-(2-hydroxy-acetylarnino)-benzoic acid (HAA-<br>
Damba(benzoyJ)-OH)<br>
Compound 55:  (2S, 4S) 4-Benzoylamino-1-(2-hydroxy-acetyI)-piperidine-2-<br>
carboxylic acid (HAA-(2S4S)4-Ampi(benzoy!)-OH)<br><br>
Compound 56: 1-Benzoyl-3-(2-hydroxy-acetyl)-imidazolidine-2-carboxylic acid<br>
amide (HAA-lca(benzoyl)-NH2)<br>
Compound 57: 1-Benzoyl-3-(2-hydroxy-acetyl)-imidazolidine-2-carboxylic acid<br>
(HAA-lca(benzoyl)-OH)<br>
Compound 58: 3-(4-Benzoylamino-phenyl)-2-(2-hydroxy-acetylamino)-propionic<br>
acid (HAA-4AmF(benzoyl)-OH)<br>
Compound 59: N-{4-[2-Carbamoyl-2-(2-hydroxy-acetylamino)-ethyl]-phenyl}-<br>
benzamide (HAA-4AmF(benzoyl)-NH2)<br>
Compound 60: (2S, 4R) 4-Benzoylamino-1-(2-mercapto-acetyl)-pyrrolidine-2-<br>
carboxylic acid (THAA-(2S4R)-4Amp(benzoyl)-OH)<br>
Compound 61: (2S, 4S) 4-Benzoylamino-1-(2-mercapto-acetyl)-piperidine-2-<br>
carboxylic acid (THAA-(2S4S)-4Ampi(benzoyl)-OH)<br>
Compound 62: (2S, 4S) 1-(2-Amino-acetyl)-4-benzoy!amino-piperidine-2-carboxylic<br>
acid (H-Gly-(2S4S)-4Ampi(benzoyl)-OH)<br>
Compound 63: (2S, 4S) [(4-Benzoylamino-piperidine-2-carbonyl)-amino]-acetic<br>
acid ((2S4S) H-4Ampi(benzoy!)-Gly-OH)<br>
Compound 64: (2S.4R) 1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxamide<br>
Compound 65: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-rnethylpyrrolidine-2-<br>
carboxamide<br>
Compound 66: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-ethylpyrrolidine-2-<br>
carboxamide<br>
Compound 67: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-isopropylpyrrolidine-2-<br>
carboxamide<br><br>
Compound 6ES: (2S,4R) 1-(2-aminoacetyl)-4-benzarniclo-txI-cyclopropylpyrrolidine-2-<br>
carboxamide<br>
Compound 69: (2S,4R) 4-benzamido-1-(2-(tert-butoxycarbonylamino)acetyl)<br>
pyrrolidine-2- carboxamide<br>
Compound 70: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(pentan-3-yl)pyrrolidine-<br>
2-carboxamide<br>
Compound 71: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-cyclopentylpyrrolidine-2-<br>
carboxamide<br>
Compound 72: (2S,4R) 1-(2-aminoacetyI)-4-benzamido-N-isobutylpyrrolidine-2-<br>
carboxamide<br>
Compound 73: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-cyclobutylpyrrolidine-2-<br>
carboxamide<br>
Compound 74: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-tert-butylpyrrolidine-2-<br>
carboxamide<br>
Compound 75: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(tetrahydro-2H-pyran-4-<br>
yl)pyrrolidine-2-carboxamide<br>
Compound 76: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-((R)-3-methylbutan-2-<br>
yl)pyrrolidine-2-carboxamide<br>
Compound 77: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-((R)-3,3-dimethylbutan-2-<br>
yl)pyrrolidine-2-carboxamide<br>
Compound 78: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-phenylpyrrolidine-2-<br>
carboxamide<br>
Compound 79: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-((R)-tetrahydrofuran-3-<br>
yl)pyrro!idine-2-carboxamide<br><br>
Compound 80: (2S,4R) 1-(2-acetamidoacetyl)-4-benzamidopyrrolidine-2-carboxylic<br>
acid<br>
Compound 81: (2S,4R) 4-benzamido-1-(2-(methylamino)acetyl)-pyrrolidine-2-<br>
carboxylic acid<br>
Compound 82: (2S,4R) 4-benzamido-1-(2-(2,2,2-<br>
trifluoroacetarnido)acetyl)pyrrolidine-2-carboxylic acid<br>
Compound 83: (2S,4R) 4-benzamido-1-(2-(tert-butoxycarbonylamino)acetyl)<br>
pyrrolidine-2-carboxylic acid<br>
Compound 84: (2S,4R) 4-benzamido-1-(2-(dimethylarnino)acetyI)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 85: (2S,4R) 4-benzamido-1-(2-formamidoacetyl)pyrrolidine-2-carboxylic<br>
acid<br>
Compound 86: (2S,4R) 4-benzamido-1-(1H-imidazole-2-carbonyl)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 87: (2S,4R) 4-benzamido-1-(1H-pyrazole-5-carbonyl)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 88: (2S,4R) 4-benzamido-1-(1H-imidazole-5-carbonyl)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 89: (2S,4R) 1-(2-aminoacetyl)-4-(picolinamido)pyrrolidine-2-carboxylic<br>
acid<br>
Compound 90: (2S,4R) 1-(2-aminoacetyl)-4-(nicotinamido)pyrrolidine-2-carboxylic<br>
acid<br><br>
Compound 91: (2S,4R) 1-(2-aminoacetyl)-4-(isonicotinamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 92: (2S,4R) 1-(2-aminoacetyl)-4-(pyrimidine-5-carboxamido)pyrrolidine-<br>
2-carboxylic acid<br>
Compound 93: (2S,4R) 1-(2-arninoacetyl)-4-(2-fluorobenzamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 94: (2S,4R) 1-(2-aminoacetyl)-4-(3-fluorobenzamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 95: (2S,4R) 1-(2-aminoacetyl)-4-(4-fluorobenzamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 96: (2S,4R) 1-(2-aminoacetyl)-4-(2-methyIbenzamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 97: (2S,4R) 1-(2-aminoacetyl)-4-(3-methylbenzamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 98: (2S,4R) 1-(2-aminoacetyl)-4-(4-methylbenzamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 99: (2S,4R) 1-(2-aminoacetyl)-4-(4-methoxybenzamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 100: (2S,4R) 1-(2-aminoacetyl)-4-(3-methoxybenzamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 101: (2S,4R) 1-(2-aminoacetyl)-4-(4-hydroxybenzamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 102: (2S,4R) 1-(2-aminoacetyl)-4-(3-hydroxybenzamido)pyrrolidine-2-<br>
carboxylic acid<br><br>
Compound 103: (2S,4R) 1-(2-aminoacetyl)-4-(2-phenylacetamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 104: (2S,4R) 1-(2-aminoacetyl)-4-(2-oxo-2-<br>
phenylethylamino)pyrrolidine-2-carboxylic acid<br>
Compound 105: (2S,4R) 1-(2-aminoacetyl)-4-(phenylamino)pyrrolidine-2-carboxylic<br>
acid<br>
Compound 106: (2S,4R) 1-(2-aminoacetyl)-4-(benzy!amino)pyrrolidine-2-carboxylic<br>
acid<br>
Compound 107: (2S,4R) 1-(2-aminoacetyl)-4-(phenylsulfonamido)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 108: N-((3R,5S) 1-(2-aminoacetyl)-5-(1H-tetrazol-5-yl)pyrrolidin-3- '<br>
yl)benzamide<br>
Compound 109: N-((3R,5S) 1-(2-aminoacetyl)-5-(1H-imida2ol-2-yl)pyrrolidin-3-<br>
yl)benzamide<br>
Compound 110: N-((3R,5S) 1-(2-aminoacetyl)-5-(5-methyl-1H-imidazol-2-<br>
yl)pyrrolidin-3-yl)benzamide<br>
Compound 111: N-((3R,5S) 1-(2-aminoacetyl)-5-(5-isopropyl-1H-imidazol-2-<br>
yl)pyrrolidin-3-yl)benzamide<br>
Compound 112: N-((3R,5S) 1-(2-aminoacetyl)-5-(oxazol-2-yl)pyrrolidin-3-<br>
yl)benzamide<br>
Compound 113: N-((3R,5S) 1-(2-aminoacetyl)-5-(5-isopropyloxazol-2-yl)pyrrolidin-<br>
3-yl)benzamide<br><br>
Compound 114: N-((3R,5S) 1-(2-aminoacetyl)-5-(5-methyloxazo|-2-yl)pyrrolidin-3-<br>
yl)benzamide<br>
Compound 115: N-((3R,5S) 1-(2-aminoacetyl)-5-(4-methyloxazol-2-yl)pyrrolidin-3-<br>
yl)benzamide<br>
Compound 116: N-((3R,5S) 1-(2-aminoacetyl)-5-(1H-pyrazol-5-yl)pyrrolidin-3-<br>
yl)benzamide<br>
Compound 117: N-((3R,5S) 1-(2-aminoacetyl)-5-(3-isopropyi-1H-pyrazol-5-<br>
yl)pyrrolidin-3-yl)benzamide<br>
Compound 118: N-((3R,5S) 1-(2-aminoacetyl)-5-(3-methyl-1H-pyrazol-5-<br>
yl)pyrrolidin-3-yl)benzamide<br>
Compound 119: N-((3R,5S) 1-(2-aminoacetyl)-5-(1H-1,2,4-triazol-5-yl)pyrrolidiri-3-<br>
yl)benzamide<br>
Compound 120: N-((3R,5S) 1-(2-aminoacetyl)-5-(3-methyl-1H-1,2,4-triazol-5-<br>
yl)pyrrolidin-3-yl)benzarnide<br>
Compound 121: N-((3R,5S) 1-(2-aminoacetyl)-5-(3-isopropyl-1H-1,2,4-triazo!-5-<br>
yl)pyrrolidin-3-yl)benzamide<br>
Compound 122: N-((3R,5S) 1-(2-aminoacetyl)-5-(1,3,4-oxadiazol-2-yl)pyrrolidin-3-<br>
yl)benzamide<br>
Compound 123: N-((3R,5S) 1-(2-aminoacetyl)-5-(5-methyl-1,3,4-oxadiazol-2-<br>
yl) pyrrolidin-3-yl)benza mid e<br>
Compound 124: (2S,4R) 4-benzamido-1-(2-(4,5-dihydro-1H-imidazol-2-<br>
ylamino)acetyl)pyrrolidine-2-carboxylicacid<br>
Compound 1.25: (2S,4R) 1-(2-(1H-imidazol-2-ylamino)acetyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid<br><br>
Compound 126: (2S,4R) 1-(2-(iH-pyrazol-5-ylamino)acetyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid<br>
Compound 127: (2S,4R) 4-benzamido-1-(2-(pyridin-2-ylamino)acetyi)pyrroIidine-2-<br>
carboxylic acid<br>
Compound 128: (2S,4R) 4-benzamido-1-(2-(pyrimidin-4-ylamino)acetyl)pyrrolidine-<br>
2-carboxylic acid<br>
Compound 129: (2S,4R) 4-benzamido-1-(2-(pyrimidin-2-yfamino)acetyl)pyrrolidine-<br>
2-carboxylic acid<br>
Compound 130: (2S,4R) 1-(2-(1H-imidazol-4-ylamino)acetyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid<br>
Compound 131: (2S,4R) 4-benzamido-1-(2-(3-phenylureido)acetyl)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 132: (2S,4R) 4-benzamido-1-(2-(3-methylureido)acetyl)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 133: (2S,4R) 4-benzamido-1-(2-(3-isopropylureido)acetyl)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 134: (2S,4R) 4-benzamido-1-(2-(methylsuIfonamido)acetyl)pyrro!idine-<br>
2-carboxylic acid<br>
Compound 135: (2S,4R) 4-benzamido-1-(2-(phenylsulfonamido)acetyl)pyrrolidine-<br>
2-carboxylic acid<br>
Compound 136: (2S,4R) 4-benzamido-1-(2-(1-methylethylsulfonamido)acetyl)<br>
pyrrolidine-2-carboxyiic acid<br><br>
Compound 137: (2S,4R) 4-benzamido-1-(2-(ethylsulfonamido)acetyl)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 138: (2S,4R) 1-(2-aminoacetyl)-4-(4-phenyloxazol-2-yl)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 139: (2S,4R) 1-(2-aminoacetyl)-4-(5-phenyloxazol-2-yl)pyrrolidine-2-<br>
carboxylic acid<br>
Compound 140: (2S,4R) 1-(2-aminoacetyl)-4-(5-phenyMH-imidazol-2-<br>
yl)pyrrolidine-2-carboxylic acid<br>
Compound 141: (2S,4R) 1-(2-aminoacetyl)-4-(4-phenyi-1H-imidazol-2-<br>
yl)pyrrolidine-2.-carboxylic acid<br>
Compound 142: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(furan-3-y!)pyrrolidine-<br>
2-carboxamide!<br>
Compound 143: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-{piperidin-4-<br>
yl)pyrrolidine-2-carboxamide<br>
Compound 144: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(oxazol-4-yl)pyrrolidine-<br>
2-carboxamide<br>
Compound 145: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(isoxazol-4-<br>
yl)pyrrolidine-2-carboxamide<br>
Compound 146: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(oxazol-2-yl)pyrrolidine-<br>
2-carboxamide<br>
Compound 147: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-benzylpyrrolidine-2-<br>
carboxamide<br>
Compound 148: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(pyridin-4-<br>
ylmethyl)pyrrolidine-2-carboxamide<br><br>
Compound 149: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(pyridin-4-yl)pyrrolidine-<br>
2-carboxamide<br>
Compound 150: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(pyridin-2-yl)pyrrolidine-<br>
2-carboxamide<br>
Compound 151: (2S,4R) 1-(2-aminoacetyl)-4-benzamido-N-(pyridin-3-yl)pyrrolidine-<br>
2-carboxamide<br>
The present teachings also encompass isomers and/or enantiomers of the<br>
compounds listed above (e.g., 2S4S, 2S4R, 2R4R, 2R.4S, 3S5S, 3S5R, 3R5R,<br>
3R5S), as well as their salts, esters, hydrates, and prodrugs.<br>
Pharmaceutically acceptable salts of the compounds of the present teachings<br>
having an acidic moiety can be formed using organic and inorganic bases. Suitable<br>
salts formed with bases; include metal salts, such as alkali metal or alkaline earth<br>
metal salts, for example sodium, potassium, or magnesium salts; ammonia salts<br>
and organic amine salts, such as those formed with morpholine, thiomorpholine,<br>
piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine (e.g., ethyl-tert-butyl-,<br>
diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine), or a mono-, di- or<br>
trihydroxy lower alkylamine (e.g., mono-, di- or triethanolamine). Internal salts also<br>
can be formed. Similarly, when a compound of the present teachings contains a<br>
basic moiety, salts can be formed using organic and inorganic acids. For example,<br>
salts can be formed from the following acids: acetic, propionic, lactic, citric, tartaric,<br>
succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric,<br>
hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic,<br>
benzenesulfonic, toluenesulfonic, and camphorsulfonic as well as other known<br>
pharmaceutically acceptable acids. Amino acid addition salts can also be formed<br>
with amino acids such as lysine, glycine, or phenylalanine.<br>
The present teachings also include prodrugs of the compounds described herein.<br>
As used herein, "prodrug" refers to a moiety that produces, generates or releases a<br>
compound of the present teachings when administered to a mammalian subject.<br>
Prodrugs can be prepared by modifying functional groups present in the<br>
compounds in such a way that the modifications are cleaved, either by routine <br><br>
manipulation or in vivo, from the parent compounds.  Examples of prodrugs include<br>
compounds of the present teachings as described herein that contain one or more<br>
molecular moieties appended to a hydroxyl, amino, sulfhydryl, or carboxyl group of<br>
the compound, and that when administered to a mammalian subject, is cleaved in<br>
vivo to form the free hydroxyl, amino, sulfhydryl, or carboxyl group, respectively.<br>
Examples of prodrugs include, but are not limited to, acetate, formate and benzoate<br>
derivatives of alcohol and amine functional groups in the compounds of the present<br>
teachings. Examples of preferred prodrugs include oxazolidinone or<br>
imidazolidinone prodrugs.  Ester prodrugs are preferably formed with lower<br>
alcohols, such as C1-6 alcohols. Preparation and use of prodrugs is discussed in T.<br>
Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S.<br>
Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B.<br>
Roche, American Pharmaceutical Association and Pergarnon Press, 1987.<br>
In a further aspect, the present teachings provide derivatives of the compounds,<br>
and more particularly protected forms of the compounds. By way of example, the<br>
compounds can be protected at their N- and/or C-terrnini, and/or at the amino acid<br>
side chain (in those compounds wherein R1 is an amino acid side chain). Examples<br>
of protecting groups include tBu, Boc, Fmoc, Fm, Benzyl, Dde and Z and also<br>
include the compounds when coupled to a solid phase, e.g. when they have been<br>
made by solid phase synthesis.<br>
C.         Pharmaceutical compositions<br>
The compounds of the present teachings can serve as medicaments in their pure<br>
form or as pharmaceutical compositions, which can be administered via any<br>
acceptable method known in the art, either singly or in combination.<br>
Pharmaceutical compositions according to the present teachings can comprise a<br>
compound of the present teachings in admixture with one or more pharmaceutically<br>
acceptable carrier, diluent, vehicle or excipient. Such compositions can be<br>
formulated to oral administration (including buccal cavity or sublingually) or by<br>
parenteral administration (including intravenous (i.v.), subcutaneous (s.c),<br>
intramuscular (i.m.), intraperitoneal (i.p.)) administration. Other administration<br>
routes include epidural, rectal, intranasal or dermal administration or by pulmonary<br>
inhalation.  Especially preferred formulations provide sustained release of the<br>
compounds of the present teachings. The compositions are preferably in the form<br><br>
of solid or liquid formulations and methods for their preparation are generally<br>
described in "Remington's Pharmaceutical Sciences", 17th Ed., Alfonso R. Gennaro<br>
(Ed.), Mark Publishing Company, Easton, PA, U.S.A., 1985.<br>
Such compositions generally contain an effective amount of the one or more active<br>
compounds of the present teachings, together with a suitable carrier in order to<br>
provide the dosage in a form compatible with the route of administration selected.<br>
Preferably, the carrier is in the form of a vehicle, a diluent, a buffering agent, a<br>
tonicity adjusting agent, a preservative and stabilizers. The excipients constituting<br>
the carrier must be compatible with the active pharmaceutical ingredient(s) and are<br>
preferably capable of stabilizing the compounds without being deleterious to the<br>
subject being treated.<br>
A form of repository or sustained-release formulation can be used so that<br>
therapeutically effective amounts of the preparation are delivered into the<br>
bloodstream over many hours or days following administration of the compound or<br>
composition, e.g., by transdermal injection or deposition.  Formufations suitable for<br>
sustained release include biodegradable polymers, such as L-lactic acid, D-lactic:<br>
acid, DL-lactic; acid, glycolide, glycolic acid, and isomers thereof. Similarly, the<br>
carrier or diluent can include any sustained release material known in the art, such<br>
as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.<br>
Other sustained release formulations can include, but are not limited to,<br>
formulations that include at least one of the compounds disclosed herein combined<br>
with liposomes, microspheres, emulsions or micelles and liquid stabilizers.<br>
The doses the compounds and compositions of the present teachings required for<br>
the desired therapeutic effects will depend upon on the potency of the compound,<br>
the particular composition used and the route of administration selected. The<br>
compounds will typically be administrated in the range of about 0.001 g to 10 g per<br>
patient per day. For example, the compounds can be administered in the range<br>
from about 1 mg to about 1000 mg per patient per day, from about 10 mg to about<br>
100 mg per patient per day, or about 50 mg per patient per day.<br><br>
The most suitable dosing regimen can best be determined by a medical practitioner<br>
for each patient individually. The optimal dosing regimen with the compounds and<br>
pharmaceutical compositions according to the present teachings depends on<br>
factors such as the particular disease or disorder being treated, the desired effect,<br>
and the age, weight or body mass index:, and general physical conditions of the<br>
patient. The administration can be conducted in a single unit dosage form to<br>
alleviate acute symptoms or as a continuous therapy in the form of multiple doses<br>
over time. Alternatively, continuous infusion systems or slow release depot<br>
formulations can be employed. Two or more compounds or pharmaceutical<br>
compositions according to the present teachings can be co-administered<br>
simultaneously or sequentially in any order. In addition, the compounds and<br>
compositions can be administered in a similar manner for prophylactic purposes.<br>
Ultimately, the; best dosing regimen will be decided by the attending physician for<br>
each patient individually.<br>
D.        Therapeutic uses<br>
Compounds according to the present teachings can facilitate and/or maintain the<br>
intercellular communication mediated by gap junctions. In one aspect, the<br>
compounds according to the present teachings target the same cells targeted by<br>
AAP, AAP10, HP5, and/or functional analogues thereof, i.e. the compounds are<br>
able to modulate the function of these cells by agonizing or antagonizing the<br>
function of AAP, AAP10, HP5, and/or functional analogues thereof. The scope of<br>
the present teachings is, however, not limited to compounds having specific AAP<br>
agonistic or antagonistic properties. The present teachings also relate to the<br>
preparation and use of pharmaceutical compositions for the treatment of<br>
pathologies which can be associated with impaired intercellular gap junction<br>
communication and methods for using these compositions, e.g. as disclosed in WO<br>
02/077017 "New Medical Uses of Intercellular Communication Facilitating<br>
Compounds".<br>
The present also provides methods of treating a subject having, or preventing a<br>
subject at risk from developing, a condition associated with impaired GJIC (e.g.,<br>
cardiac arrhythmia or osteoporosis) comprising administering a therapeutically<br>
effective amount of any of the compounds of the present teachings. Individuals<br>
who can be treated using compounds according to the present teachings include,<br><br>
but are not limited to, animals, preferably mammals, e.g., rodents (including mice,<br>
rats, hamsters, and lagomorphs, such as rabbits), dogs, pigs, goats (generally any<br>
domestic animal), and primates. In one preferred aspect, the subject is a human<br>
being.<br>
Examples of conditions which can be treated or prevented using compounds of the<br>
present teachings include, but are not limited to, cardiovascular disease;<br>
osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue;<br>
bladder incontinence; impaired hearing (e.g. due to diseases of the cochlea);<br>
endothelial lesions; diabetes (Type I or Type II) and diabetic complications<br>
(including diabetic retinopathy and diabetic neuropathy); atherosclerosis; CNS<br>
related conditions; seizures; ischemia (e.g. ischemia of the central nervous system,<br>
spinal cord, brain or brain stem); dental tissue disorders (including periodontal<br>
disease); kidney diseases; haematologic manifestations (e.g., anaemia, leukopenia,<br>
thrombocytopenia, and pancytopenia, especially following treatment with cytostatic<br>
compounds or irradiation therapy); wounds (e.g., superficial wounds and deep<br>
wounds resulting trauma); bone fracture; erectile dysfunction; urinary bladder<br>
incontinence; neuropathic pain; subchronic and chronic inflammation; cancer;<br>
failure of bone marrow and stem cell transplantation; conditions which arise during<br>
transplantation of cells and tissues or during medical procedures such as surgery;<br>
conditions caused by an excess of reactive oxygen species and/or free radicals<br>
and/or nitric oxide; diseases or disorders of pregnancy (e.g., preeclampsia and<br>
preterm labor); female infertility; and stroke. Compounds accroding to the present<br>
teachings can also be used to induce labor (e.g., by facilitating the effect of oxytocin<br>
on uterus contraction).<br>
In one preferred aspect, the present teachings provide; a pharmacologically active<br>
antiarrhythmic compound for treatment or prevention of arrhythmias and thrombotic<br>
complications arising during cardiovascular disorders, such as acute ischemic heart<br>
disease (e.g., stable angina pectoris, unstable angina pecloris, acute myocardial<br>
infarction), congestive heart failure (e.g., systolic, diastolic, high-output, low-output,<br>
right or left sided heart failure), congenital heart diseases, cor pulmonale,<br>
cardiomyopathies, myocarditis, hypertensive heart disease, during coronary<br>
revascularization, and the like. In specific embodiments, compounds according to<br>
the present teachings can be used to treat and/or prevent bradyarrhythmias (e.g.,<br><br>
due to disease in sinus node, AV node, bundle of His, right or left bundle branch),<br>
and tachyarrhythmias associated with reentry (e.g., atrial premature complexes, AV<br>
junctional complexes, ventricular premature complexes, atrial fibrillation, atrial<br>
flutter, paroxymal supraventricular tachycardia, sinus node reentrant tachycardia,<br>
AV nodal reentrant tachycardia, and non-sustained ventricular tachycardia).<br>
Furthermore, compounds according to the present teachings can be useful in<br>
alleviation of a pathological condition wherein slowing of conduction velocity is an<br>
important factor, e.g. ventricular tachycardia, ventricular fibrillation, and atrial<br>
fibrillation. Compounds according to the present teachings can be administered<br>
either alone or in combination with other antiarrhythmic compounds, such as class I<br>
agents (e.g., lidocaine), class II agents (e.g., metoprolol or propranolol), class III<br>
agents (e.g., amiodarone or sotalol) or class IV agents (e.g., verapamil).<br>
Compounds according to the present teachings can also be used to treat or prevent<br>
one or more of reentry arrhythmia, ventricular reentry (e.g., arising during acute<br>
myocardial infarction, chronic myocardial infarction, stable angina pectoris and-<br>
unstable angina pectoris), infectious or autonomic cardiomyopathy, atrial fibrillation,<br>
repolarization alternans, monomorphic ventricular tachycardia, T-wave altemans,<br>
bradyarrhythmias, reduced contractility of cardiac tissue, thrombosis, and the like.<br>
Additional functions in which endothelialgap-junctional intercellular communication<br>
has been implicated are the migratory behavior of endothelial cells after injury,<br>
angiogenesis, endothelial growth and senescence and the coordination of<br>
vasomotor responses (Christ et al. Braz. J Med BioI.Res., 33, 423-429 (2000)).<br>
Therefore, compounds according to the present teachings can be used to enhance<br>
conducted vascular responses and to improve blood supply during conditions with<br>
increased metabolic demand (e.g., physical exercise, tachycardia), and during<br>
ischemia.<br>
Compounds according to the present teachings can be used to cytoprotect a tissue<br>
or organ of a mammal in need of such treatment. Cytoprotecting refers to reducing,<br>
preventing or alleviating symptoms associated with unwanted cell swelling.<br>
Particular tissues and organs that will benefit from the method include those    .<br>
confined or otherwise impacted by a fiborous capsule such as heart or kidney. Also<br>
included are tissues associated with bone such as brain, spinal cord and bone<br><br>
marrow. Compounds of the present teachings can be used to prevent or treat<br>
ischemic injury in the organs of a mammal in need of such treatment, including, for<br>
example, the heart, central nervous system, kidney, gastrointestinal tract, liver,<br>
lungs, and limbs.<br>
In another aspect, the present teachings provide the use of the compounds to treat<br>
or prevent haematologic manifestations following treatment with cytostatic<br>
compounds or irradiation therapy. Impaired haematopoiesis recovery is observed<br>
in patients alter 5-fluorouracil (5-FU) cytostatic treatment.  This includes absence of<br>
recovery of peripheral blood counts, including severe neutropenia, severe anemia<br>
with reticulocytopenia and presence of abnormal peripheral erythrocytes and<br>
severe thrombocytopenia. In addition, 5-8-fold decreases of bone marrow<br>
cellularity and hematopoietic progenitor content (granulornacrophagic colony-<br>
forming-units (CFU-GM), erythroid burst forming units (BFU-E), mixed colony<br>
forming units (CFU-mix), and overall colony forming units (CFU-C) in bone marrow<br>
are observed. (See, e.g., Montecino-Rodriguez et al., Blood, 96, 917-924, (2000);<br>
Presley et al., Abstract #55, IGJC 2005, Whistler, Canada (2005)). Included in this<br>
aspect of the present teachings are the treatment or prevention of general clinical<br>
situations commonly associated with iatrogenic pancytopenia.<br>
Compounds according to the present teachings can be use to treat or prevent<br>
osteoporosis.  It is known that that GJIC is important in bone formation. The<br>
efficacy of the compounds can be assessed, for example, by an increase in<br>
osteoblast activity in a standard osteoblast activity assay which measures either<br>
calcium wave formation and/or alkaline phosphatase activity of osteoblast cells in<br>
the presence of the compounds. Alkaline phosphatase activity also can be used to<br>
provide a measure of osteoblast activity using standard colorimetric assays.<br>
Preferably, one or more of the compounds or pharmaceutical compositions<br>
according to the present teachings are administered to an individual in need thereof<br>
in a therapeutically effective amount. As used herein, "a therapeutically effective<br>
amount" refers to an amount that reduces symptoms of a given condition or<br>
pathology, and preferably which normalizes physiological responses in a subject<br>
with the condition or pathology. Reduction of symptoms or normalization of<br>
physiological responses can be determined using methods routine in the art arid<br><br>
can vary with a given condition or pathology. In one aspect, a therapeutically<br>
effective amount of one or more compounds or pharmaceutical compositions is an<br>
amount which restores a measurable physiological parameter to substantially the<br>
same value (preferably to within +30%, more preferably to within 20%, and still<br>
more preferably, to within 10% of the value) of the parameter in a subject without<br>
the condition or pathology.<br>
The effective amount will be determined by the skilled person taking into account<br>
such factors as potency of the drug, age and constitution of the patient, body<br>
weight, pharmacokinetic profile of the drug, and in general the drug will be<br>
prescribed for each patient or group of patients. However, the effective amount of<br>
the compound can be at least about 10 g/kg body weight/day, such as at least<br>
about 100 g/kg body weight/day, at least about 300 g/body weight/day, and at<br>
least about 1000 g/kg body weight/day.  On the other hand, the effective amount<br>
of the compound or dimer can be at most about 100 mg/kg body weight/day, such<br>
as at most about 50 mg/kg body weight/day and at most about 10 mg/kg body<br>
weight/day.  It is expected that the effective amount of the compound will be about<br>
100 g/kg body weight/day, about 300 g/kg body weight/dayor about 1000 g/kg<br>
body weight.<br>
E.         Biological assays<br>
Preferred compounds of the present teachings can show binding, preferably<br>
specific binding, to a tissue, cell, or cell fraction in what is referred to herein as a<br>
"standard AAP site binding test". The test can detect and optionally quantify<br>
binding of a subject compound, e.g., AAP, AAP10, HP5, or a functional analogue<br>
thereof.  In one preferred embodiment, the compound can be a modulator of the<br>
function of such a tissue, cell, or cell fraction (i.e. the compound agonizes or<br>
antagonizes the function of the antiarrhythmic peptide). In another embodiment,<br>
the compound can be a modulator of a receptor for the antiarrhythmic peptide (i.e.<br>
the compound is an agonist or antagonist of the receptor). Additionally preferred<br>
compounds according to the present teachings can show good function as<br>
modulators of gap junctional communication (e.g., as agonists or antagonists of<br>
AAP). In one aspect, the compounds can function as antiarrhythmic drugs.<br><br>
Preferred agonist compounds of the present teachings can provide an intracellular<br>
conductance (Gj) that is substantially the same as, or is greater than, the G] of AAP<br>
in what is referred to herein as a "standard cardiomyocyte assay". Preferred<br>
antagonist compounds can provide a Gj that is less (e.g., at least about 10%, or at<br>
least about 20% less) than the Gj of AAP and/or block the ability of AAP to<br>
normalize the; Gj of an ischemic cell, i.e., to return the Gj to substantially the same<br>
values found in non-ischemic cells. Additionally preferred compounds according to<br>
the present teachings can increase the time to an AV block in a mouse after<br>
infusion of CaCI2, in what is referred to herein as a "standard calcium-induced .<br>
arrhythmia assay." Compounds of the present teachings can prevent cardiac<br>
conduction slowing in the presence of various form of metabolic stress (e.g.<br>
ischemia, hypoglycaemla or acidosis) in what is referred to herein as a "standard<br>
isolated atrial strip model of metabolic stress induced conduction slowing."<br>
Compounds of the present teachings can additionally show decreases in the<br>
incidence of reentry arrhythmias or in the size of an infarct zone observed in what is<br>
referred to herein as a "standard ventricular reentry assay."<br>
In some embodiments, compounds of the present teachings can exhibit a good<br>
half-life according to what is referred to herein as an "in vitro plasma stability<br>
assay". Compounds that show a good stability in the assay have in one<br>
embodiment a half-life of more than about 48 hours, or more than 24 hours, or more<br>
than 12 hours, or more than 6 hours, or more than 3 hours, or more than 1 hour, or<br>
more than 30 minutes, or more than 20 minutes, or more than 15 minutes, or more<br>
than 10 minutes, or more than 5 minutes, or more than 1 minute. In these<br>
embodiments, compounds of the present teachings can show enhanced stability in<br>
the bloodstream.<br>
Particular assays useful for identifying and optionally quantifying the activity of<br>
compounds of the present teachings are further described below.<br>
1.         Standard plasma stability assays<br>
The present teachings provide compounds that have enhanced stability in vitro or in<br>
vivo.  By way of example, compounds of the present teachings that comprise a<br>
peptide bond can be alkylated or otherwise modified to stabilize the compound<br><br>
against enzymatic degradation. Alternatively or additionally, the compounds can<br>
comprise one or more D-amino acids. It is possible to test whether a compound<br>
has enhanced stability in a standard stability assay.<br>
In one example of an in vitro plasma stability assay, compounds are incubated in<br>
plasma or serum and samples are taken at regular intervals for analysis by HPLC<br>
or LC/MS/MS, to quantitate the amount of undegraded compound. (See, e.g., WO<br>
02/077017, the entire disclosure of which is incorporarted by reference herein).<br>
Appropriate conditions (column, solvent, gradient, and temperature) for such<br>
analyses are estimated to ensure that the compound peak and the plasma peaks<br>
do not have the same retention time. This is done by subsequent injections of a<br>
compound, plasma, and a co-injection with the compound and the plasma, followed<br>
by optimization of LC method parameters until a satisfactory separation is obtained.<br>
A control plasma sample without the peptide compound, treated in the same<br>
manner, also is taken and evaluated. The samples can include, but are not limited<br>
to, a blank, the compound at a suitable concentration (e.g., 0.1 mg/mL), plasma<br>
without compound, one or more samples for t = 0, and one or more samples at<br>
each regular interval. Preferably, multiple samples are taken in parallel. The<br>
sample concentrations (peak height in mAU or ion counts) are plotted vs. time and<br>
fitted to a function describing a mono exponential decay (e.g., using a standard<br>
Excel package)-  Preferably, a compound according to the present teachings has a<br>
half-life of more than about 30 minutes (e.g., more than about 1 hour, or more than<br>
about 3 hours, or more than about 6 hours, or more than about 12 hours, or more<br>
than about 24 hours, or more than about 48 hours) as determined using this assay.<br>
Plasma stability can be examined in vivo using standard assays. For example,<br>
compounds can be administered to a mammal, such as a rat, by bolus injections in<br>
volumes of about 1 ml/kg for both i.v. and p.o. dosing.  Preferably, compounds are<br>
tested in parallel with control samples such as buffer or an antiarrythmic peptide<br>
with a known stability. Blood samples are collected at different time periods (e.g.,<br>
at B.D. 5, 15, 30, 60, 90, 120, 180, and 240 minutes, where B.D. refers to before<br>
dose). Amounts of compounds in samples can be quantified using methods of<br>
routine in the art, such as LC/MS/MS. For example, the concentrations of<br>
compounds in plasma samples can be calculated from an external standard curve<br>
covering concentration ranges of compound from 1.00 to 1000 nM. The plasma<br><br>
concentrations versus time data can be used for pharmacokinetic modelling in<br>
WinNonLin 3.5 (Pharsight, Mountain view, CA) using non-compartmental analysis<br>
and the resulting parameters of AUC, Fpo, Clb, t1/2, Cmax and tmax can be<br>
determined as is known in the art.<br>
2.         Standard cardiomyocyte assays<br>
Compounds of the present teachings can be tested in a cardiomyocyte assay,<br>
which measures the gap junction function of cardiac cells after administration of the<br>
compounds. In one exmaple, cardiac cells are isolated from a mammal, such as a<br>
guinea pig hearts, by perfusion with collagenase according to the Langendorf<br>
method. The cells are exposed to compound and evaluated for GJIC by patch<br>
clamp using methods known in the art. Intercellular conductance (Gj) is calculated<br>
using the formula:<br><br>
where Ip,pulse and Ip,rest represent the current in the passive cell during the pulse<br>
and before the pulse respectively, and Up and Ua represent the voltage of the<br>
passive and sactive cell. The change in Gj value upon compound administration is<br>
analyzed by comparing the relative changes in Gj. For example, the relative Gj as<br>
a function of time before, and during, stimulation with compound (e.g., at about 10'8<br>
M) can be determined.  Preferably, the compound provides a Gj, which is<br>
substantially the same as the Gj (+ 10%) of an antiarrhythmic peptide such as AAP,<br>
AAP10, HP5, and functional analogues thereof.  In one example, the cell is an<br>
ischemic cell, and the compound provides a Gj, which is substantially the same as<br>
that of a non-ischemic cell (+20%, preferably, + 10%). Additional details concerning<br>
performing cardiomyocyte assays are provided in WO 02/077017.<br>
3.         Standard calcium-induced arrhythmia assay<br>
Peptides suitable for administration to cardiac cells can be identified in an in vivo<br>
model of calcium-induced arrhythmias according to the model of Lynch et al. (1981)<br>
J Cardiovasc. Pharmacol. 3: 49-60. Male CD-1 mice are anaesthetized with<br>
Ketamine (75 mg/kg) and medetomidine (1 mg/kg) IP. An i.v. cannula is inserted<br>
into the tail vein. A lead II ECG signal is recorded continuously by positioning<br>
stainless steel ECG electrodes on the right forelimb and left forelimb. The ground<br>
electrode is placed on the right hind limb. The signal is amplified and filtered using<br><br>
Gould physiograph components and po-ne-mah data acquisition software.   After a<br>
90 sec equilibration period test compound is injected into the tail vein (over 30<br>
seconds). Mice pre-treated with vehicle are tested as control animals. The<br>
injection volume is 100l / 30g mice in all experiments. Infusion of CaCI2 (30<br>
mg/mL, 0.1 mL/min/30g mice, 100 mg/kg/min) is started 3 min after IV<br>
administration of drug or vehicle (0.9% saline). The time lag to onset of cardiac<br>
conduction block is determined as the time from the start of CaCI2 infusion until the<br>
first arrhythmic event occured. The first conduction block is defined as the first RR-<br>
interval, larger than or equal to 3 times one RR-interval from the pre-treatment<br>
period. The first arrhythmic event occurring is either a second degree AV-block<br>
(intermittent failure of the AV conduction characterized by a P-wave without the<br>
concomitant QRS complex) or a second degree SA block (prolonged RR-interval<br>
and a QRS-complex without a preceding P-wave). Responses are expressed<br>
relative to the time until 2nd degree AV-block occurred in vehicle treated mice.<br>
4.	Standard isolated atrial strip model of metabolic stress induced<br>
conduction slowing<br>
Peptides suitable for administration to cardiac cells can be identified in an in vitro<br>
model as described by Haugan et al. (J. Cardiovasc. Electrophysiol., 16, 537-545<br>
(2005)).<br>
Rats (300-400 g) are killed by a sharp blow on the neck. The heart is rapidly<br>
excised and transferred to a small dish containing 37 oxygenated modified<br>
Tyrodes buffer containing (in mM): NaCI 136, KCI 4, MgCI2 0.8, CaCI2 1.8 HEPES<br>
5,	MES 5, Glucose 6, pH 7.3. The left atrium is carefully dissected and a tissue<br>
sample of approximately 2x6 mm is taken from the left atrial appendage and placed<br>
in a tissue chamber (volume 5 ml), (Steiert Organ Bath, Hugo Sach Electronic,.<br>
Germany). The chamber is perfused throughout the study with 37C oxygenated<br>
Tyrodes buffer at a rate of 10 ml/min.<br>
A bipolar stimulation electrode (Teflon coated stainless steel, diameter 75 uM) is<br>
placed at one end of the tissue. Stimulation is performed at 1 Hz using rectangular<br>
pulses at double threshold (duration of stimulus 0.2 ms) delivered by a stimulator<br>
(Hugo Sachs, Type 215) through an isolation unit (Universal Isolated Stimulator<br>
Unit type 263, Hugo Sachs, Germany).<br><br>
Two separate microelectrodes of pure iridium (World Precision Instruments, tip-<br>
impedance 3.5-4.0 MQ) are placed on a line along the long-axis of the preparation<br>
for recording of atrial CV. The distances from the stimulating electrode to the first<br>
and second microelectrode is 1.5-2.0 mm and 3.0-4.0 mm, respectively. Each<br>
microelectrode is connected to a head-stage preamplifier (10x amplification of the<br>
signals). The preamplifiers are connected to a bio potential amplifier module that is<br>
connected to the data acquisition system through a Hugo Sachs PLUGSYS.<br>
Signals are filtered at 1 kHz and sampled at 10 kHz.<br>
Following a 30 minutes equilibration period, pacing at 1 Hz is initiated. During the<br>
first 20 minutes recording period (baseline period), the chamber is perfused with<br>
37C oxygenated Tyrodes buffer, pH 7.3. Compounds (e.g., modified lysine<br>
mimetic compounds of the present teachings, AAP, AAP10 or controls) are then<br>
added to the perfusion buffer for another 20 minute period (pre-treatment period).<br>
Following the 20 minutes of pretreatment, perfusion is changed to a 37C glucose-<br>
free, non-oxygenated Tyrodes buffer, pH 7.3 (with or without compounds of<br>
interest) for 40 minutes (metabolic stress period).<br>
The change in conduction velocity during metabolic stress is compared to a group<br>
of untreated controls.  In untreated preparations, conduction decreases by 15-45%<br>
during the 40 minute period of metabolic stress. In some embodiments,<br>
compounds according to the present teachings can prevent metabolic stress<br>
induced conduction slowing during the 40 minutes period comparable to the<br>
compounds AAP, AAP10, HP5, or a functional analogue thereof, i.e., the<br>
compounds can preserve normal conduction during an episode of metabolic stress.<br>
5.	Haematologic assay<br>
Compounds of the present teachings can also be tested to determine their effects in<br>
accelerating recovery following 5-fluorouracil (5-FU) induced stress on bone<br>
marrow proliferation. Male rats are treated with 5-FU (75-100 nmol/kg i.p.) for 4<br>
days.  Blood samples are collected from tail tip before 5-FU treatment (Day 0), and<br>
4, 8, 12, 16, 20, 24, 28 days following first 5-FU dose. Measurement of peripheral<br>
blood counts (granulocytes, lymphocytes, erythrocytes, thrombocytes, reticulocytes)<br>
and plasma haemoglobin are taken. After identification of window with severe<br>
pancytopenia, the study is repeated during concomitant treatment with a compound<br>
of the present teachings.<br><br>
F.         Preparation of exemplary compounds<br>
The following non-limiting examples are presented merely in order to illustrate the<br>
present teachings. The skilled person in the area will understand that there are<br>
numerous equivalents and variations not exemplified but still form part of the<br>
present teachings.<br>
Lysine mimetic compounds of the present teachings can be synthesized by means<br>
of solid phase or solution phase synthesis. In this context, reference is given to,<br>
amongst many others. Fields et at., "Principles and practice of solid-phase peptide<br>
synthesis". Synthetic Peptides (2002, 2nd Edition).<br>
Scheme 1 depicts an exemplary synthesis of a compound of Formula III, (2S,4R)-4-<br>
benzamido-1-(2-(4,5-dihydro-1H-imida2o(-2-ylamino)acetyl)pyrrolidine-2-carboxylic<br>
acid, wherein Y" is NHR3 and R3 is not hydrogen.<br><br>
Different N-substituted amino acid derivatives can be used to synthesize other<br>
compounds of Formula III wherein Y' is NHR3 and R3 is not hydrogen. For<br>
example, 2-chloro-1H-imidazole or 4-bromo-1 H-imidazole can be treated with<br>
glycine in water (for example, according to the procedure set forth in European,<br>
Journal of Medicinal Chemistry (1989), 24(6), 623-5) to form 2-(1H-imidazol-2-<br>
ylamino)acetic acid or 2-(1H-imidazol-4-ylamino)acetic acid, respectively, which can<br>
then be used to synthesize (2S,4R)-1-(2-(1H-imidazol-2-ylamino)acetyl)-4-<br>
benzamidopynolidine-2-carboxylic acid or (2S,4R)-1-(2-(1H-imidazol-4-<br>
yiamino)acetyl,)-4-benzamidopyrrolidine-2-carboxylic acid in a manner simi/ar to<br>
Scheme 1. Compounds such as (2S,4R)-4-benzamido-1-(2-(pyridin-2-.<br>
ylamino)acetyl)pyrrolidine-2-carboxylic acid, (2S,4R)-4-benzamido-1-(2-(pyrimidin-<br>
4-y!amino)acetyl)pyrroIidine-2-carboxylic acid, and (2S,4R)-4-benzamido-1-(2-<br>
(pyrlmidin-2-ylamino)acetyl)pyrrolidine-2-carboxylic acid can be similarly<br><br>
synthesized from 2-(pyridin-2-ylamino)acetic acid, 2-(pyrimidin-4-ylamino)acetic<br>
acid, and 2-(pyrimidin-2-ylamino)acetic acid, respectively.<br>
Alternatively, the glycine derivative can be synthesized according to Scheme 2:<br><br>
In the above example, the 2-(1H-pyrazol-5-ylamino)acetic acid thus produced can<br>
be used to synthesize (2S,4R)-1-(2-(1H-pyrazol-5-ylamino)acetyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid using the method shown in Scheme 1.<br>
Compounds of Formula II wherein A and R1 together with the carbon to which they<br>
are bound form a 5-20 membered heteroaryl containing one or more N, O, or S<br>
atoms can be synthesized according to Scheme 1 utilizing the appropriate<br>
carboxylic acid starting materials. For example, (2S,4R)-4-benzamido-1-(1H-<br>
irnidazole-2-carbonyl)pyrrolidine-2-carboxylic acid, (2S,4R)-4-benzamido-1-(1H-<br>
pyrazole-5-carbonyl)pyrrolidine-2-carboxylic acid, or (2S,4R)-4-benzamido-1-(1H-<br>
imidazole-5-carbonyl)pyrrolidine-2-carboxylic acid can be synthesized according to<br>
Scheme 1 using 1H-imidazo!e-2-carboxylic acid, 1 H-pyrazole-5-carboxylic acid, or<br>
1 H-imidazole-5-carboxyIic acid, respectively.<br>
Scheme 3 depicts another exemplary synthesis of a compound of Formula III<br>
wherein Y' is NHR3 and R3 is not hydrogen. In this example, (2S,4R)-4-benzamido-<br>
1-(2-(3-phenylureido)acetyl)pyrrolidine-2-carboxylic acid, R3 is C(O)NR6R7.<br><br><br>
Different isocyanates (e.g., methylisocyanate or isopropylisocyanate) can be<br>
employed in the sysnthesis of Scheme 3 to produce other ureas of Formula III (e.g.,<br>
(2S,4R)-4-benzamido-1-(2-(3-methylureido)acetyl)pyrrolidine-2-carboxylic acid or<br>
(2S,4R)-4-benzamido-1-(2-(3-isopropylureido)acetyl)pyrrolidine-2-carboxylicacid).<br>
Scheme 4 depicts an exemplary synthesis of (2S,4R)-4-benzamido-1-(2-<br>
(methylsulfonamido)acetyl)pyrrolidine-2-carboxylic acid, a compound of Formula III<br>
wherein Y' is NHR3 and R3 is S(O)R6.<br><br>
Starting with other sulfonyl chlorides (e.g., ethanesulfonyl chloride or proane-2-<br>
sulfonyl chloride), different sulfonamides of Formula III (e.g., (2S,4R)-4-benzamido-<br>
1-(2-(ethylsulfonamido)acetyl)pyrrolidine-2-carboxylic acid or (2S,4R)-4-benzamido-<br><br>
1-(2-(1-methylethylsulfonamido)acetyl)pyrrolidine-2-carboxylic acid) can be<br>
prepared using the method shown in Scheme 4.<br>
Compounds of Formula III wherein k is 1 or 2 (e.g., (2S,4R)-1-(3-aminopropanoyl)-<br>
4-benzamidopyrrolidine-2-carboxylic acid) can be synthesized, for example,<br>
according to Scheme 5.<br><br>
Scheme 6 shows an exemplary synthesis of a compound of Formula III, (2S,4R)-1-<br>
(2-aminoacetyl)-4-(phenylamino)pyrrolidine-2-carboxylic acid, wherein Z' is (CH2)m-<br>
C6-20 aryl and m is 0.<br><br><br>
Similarly, Scheme 7 depicts an exemplary synthesis a compound of Formula III,<br>
(2S,4R)-1-(2-aminoacetyl)-4-(benzylamino)pyrrolidine-2-carboxylic acid, wherein Z'<br>
is (CH2)m-C6-20 aryi and m is 1.<br><br>
Compounds wherein Z' is (CH2)m-5-20 membered heteroaryl and m is 0 or 1 also<br>
can be prepared using the appropriate starting materials according to the methods<br>
of Schemes 6 or 7.<br>
Scheme 8 shows an exemplary synthesis of a compound Formula III, (2S,4R)-1-(2-<br>
aminoacetyl)-4-(2-phenylacetamido)pyrrolidine-2-carboxy]ic acid, wherein 72 is<br>
C(O)(CH2)m-C6-20 aryl and m is 1.<br><br><br>
Compounds wherein Z' is C(O)(CH2)m-C6-20 aryl and m is 2, or Z' is C(O)(CH2)m-5-<br>
20 membered heteroaryl and m is 1 or 2, also can be prepared using the<br>
appropriate starting materials according to the method of Scheme 8.<br>
Compounds of Formula III wherein Z" is S(O)2(CH2)m-C6-20 aryl or S(O)2(CH2)m-5-20<br>
membered heteroaryl can be synthesized, for example, according to Scheme 9,<br>
which depicts the synthesis of (2S,4R)-1-(2-aminoacetyl)-4-(phenylsulfonamido)<br>
pyrrolidine-2-carboxylic acid.<br><br>
Scheme 10 shows an exemplary synthesis of (2S,4R)-1-(2-aminoacetyl)-4-(4-<br>
phenyloxazol-2-yl)pyrro!idine-2-carboxy!ic acid, a compound of Formula II wherein<br>
B is an amide bioisostere (see, e.g., Tetrahedron: Asymmetry, 14(20), 3141-3152;<br>
2003).<br><br><br>
Scheme 11 depicts the synthesis of another compound of Formula II, (2S,4R)-1-(2-<br>
aminoacetyl)-4-(5-phenyloxazol-2-y!)pyrrolidine-2-carboxylic acid, wherein B is a<br>
different amide bioisostere (see, e.g., Journal of Heterocyclic Chemistry (1998),<br>
35(6),  1533-1534).<br><br><br>
The synthesis of yet another compound of Formula II wherein B is an amide<br>
bioisostere, (2S,4R)-1-(2-aminoacetyl)-4-(4-phenyl-1H-imidazol-2-yl)pyrrolidine-2-<br>
carboxylic acid, is shown in Scheme 12 (see, e.g., Tetrahedron: Asymmetry,<br>
14(20), 3141-3152; 2003; Journal of Medicinal Chemistry, 44(18), 2990-3000; <br>
2001).<br><br>
Scheme 13 depicts an exemplary synthesis of a compound of Formula II, N-<br>
((3R,5S)-1-(2-aminoacetyl)-5-(1H-tetrazol-5-yl)pyrrolidin-3-yl)benzamide, wherein E<br>
is a carboxylic acid bioisostere.<br><br><br>
Scheme 14 shows another method by which compounds of Formula II, wherein EE is<br>
a carboxylic acid bioisostere, can be synthesized (see, e.g., Journal of Medicinal<br>
Chemistry, 44(18), 2990-3000; 2001).<br><br>
In addition to N-((3R,5S)-1-(2-aminoacetyl)-5-(5-methyl-1H-imidazol-2-yl)pyrrolidin-<br>
3-yl)benzamide shown in Scheme 14, compounds of Formula II having different<br>
carboxylic acid bioisosteres can be synthesized according to this method by using<br>
different bromocarbonyl reagents (e.g., N-((3R,5S)-1-(2-arninoacetyl)-5-(1H-<br>
imidazol-2-yl)pyrrolidin-3-yl)benzamide or N-((3R,5S)-1 -(2-aminoacetyl)-5-(5-<br>
isopropyl-1H-imidazol-2-yl)pyrrolidin-3-yl)benzamide).<br>
Schemes 15-17 depict other exemplary methods for sythesizing compounds of<br>
Formula II wherein E is a carboxylic acid bioisostere.<br><br><br><br>
In addition to the compounds shown in Schemes 15-17, compounds having<br>
different carboxylic bioisosteres can be synthesized according to these methods by<br>
varying the reagents. For example different bromide reagents can be used in<br>
Scheme 15 (e.g., to produce N-((3R,5S)-1-(2-aminoacetyl)-5-(oxazol-2-yl)pyrrolidin-<br>
3-yl)benzamide); different dimethylaminoketals can be used in Scheme 16 (e.g., to<br>
produce N-((3R,5S)-1-(2-aminoacetyl)-5-(4H-1,2,4-triazol-3-yl)pyrrolidin-3-<br>
y!)benzamide or N-((3R,5S)-1-(2-aminoacetyl)-5-(5-isopropyl-4H-1,2,4-triazol-3-<br>
yl)pyrrolidin-3-yl)benzamide); and different ortho esters can be used in Scheme 17<br>
(e.g., to produce N-((3R,5S)-1-(2-aminoacetyl)-5-(1,3,4-oxadiazoI-2-yl)pyrrolidin-3-<br>
yl)benzamide).<br>
1.	General peptide synthesis<br>
Compounds of the present teachings can be prepared using the method of<br>
synthesis disclosed, for example, in WO 98/11125 (the entire disclosure of which is<br>
incorporated by reference herein). Said methods of synthesis will result in a    <br>
primary peptide or peptide like product having a trifluoroacetate counterion and<br>
which can be suitable for the preparation of a medicament.  In some instances,<br>
however, it can be advantageous to perform a counter ion exchange from<br>
trifluoroacetate to a pharmaceutically acceptable or preferred anion (e.g., acetate)<br>
by, for example, ion exchange chromatography. Alternatively, the primary peptide<br>
or peptide like product can be repeatedly freeze dried and dissolved in diluted<br>
hydrochloric acid to obtain the purified hydrochloride.<br>
Apparatus and synthetic strategy<br>
When using solid phase methodology, the modified peptides were synthesized<br>
batchwise in a polyethylene vessel equipped with a polypropylene filter for filtration<br>
using 9-fluorenylmethyloxycarbonyl (Fmoc) and tert.-butyloxycarbonyl (Boc) or<br>
otherwise suitable protecting groups for the N-amino and the side chain<br>
functionalities such as AllyI, Alloc, Dde, Z etc.. When using solution phase<br>
techniques, the modified peptides were synthesized using standard equipment<br>
throughout the syntheses.<br>
Solvents<br>
Solvent DMF (N,N-dimethylformamide, Riedel de-Haen, Germany) was purified by<br>
passing through a column packed with a strong cation exchange resin (Lewatit S<br>
100 MB/H strong acid, Bayer AG Leverkusen, Germany) and analyzed for free<br><br>
amines prior to use by addition of 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine<br>
(Dhbt-OH) giving rise to a yellow colour (Dhbt-O- anion) if free amines are present.<br>
Solvent DCM (dichloromethane, analytical grade, Riedel de-Haen, Germany) was<br>
used directly without purification. Acetonitril ( HPLC-grade, Lab-Scan, Dublin<br>
Ireland) was used directly without purification.<br>
Amino Acids<br>
Fmoc- and Boc-protected amino acids were purchased from Advanced ChemTech<br>
(ACT), Bachem and NeoMPS in suitable side-chain protected forms.<br>
Benzole acid Derivatives<br>
Benzoic acid derivatives were purchased from Aldrich and used without further<br>
purification.<br>
Coupling Reagents<br>
Coupling reagent diisopropylcarbodiimide (DIC) was purchased from (Riedel de-<br>
Haen, Germany).<br>
Solid Supports<br>
Peptides were; synthesized on TentaGel (e.g. SRam) and Polystyrene (e.g. PAM<br>
resin) from Advanced ChemTech and Rapp.<br>
Catalysts and Other Reagents<br>
Diisopropylethylamine (DIEA) was purchased from Aldrich, Germany, and<br>
ethylenediamine from Fluka, hydrazine, piperidine and pyridine from Riedel-de<br>
Haen, Frankfurt, Germany. 4-(N,N-dimethylamino)pyridine (DMAP) was purchased<br>
from Fluka, Switzerland and used as a catalyst in coupling reactions involving<br>
symmetrical anhydrides. Ethandithiol and Thioanisol were purchased from Riedel-<br>
de Haen, Frarkfurt, Germany. 3,4-dihydro-3-hydroxy-oxo-1,2,3-benzotriazine<br>
(Dhbt-OH), 1-hydroxybenzotriazole (HOBt) (HOAt) were obtained from Fluka.<br>
Switzerland.<br>
Coupling Procedures<br>
The first amino acid can be coupled as a symmetrical anhydride in DMF generated<br>
from the appropriate N-D-protected amino acid and the subsequent amino acids<br>
can be coupled as in situ generated HOBt or HOAt esters made from appropriate<br><br>
N--protected amino acids and HOBt or HOAt by means of DIC in DMF. The<br>
acylations were checked by the ninhydrin test performed al 80C in order to prevent<br>
Fmoc deprotection during the test (B. D. Larsen, A. Holm, Int. J. Pept. Protein Res.,<br>
43, 1-9(1994)).<br>
Deprotection of the Protecting Group (Fmoc and Fm)<br>
Deprotection of the Fmoc and the Fm group was performed by treatment with 20%<br>
piperidine in DMF (1x5 and 1x10 min.), followed by washing with DMF (5 x 15 ml, 5<br>
min. each) until no yellow colour could be detected after addition of Dhbt-OH to the<br>
drained DMF.<br>
Deprotection of the Protecting Group (Boc and tBu)<br>
Deprotection of the Boc and tBu group was performed by treatment with 50% TFA<br>
in DCM v/v (2 x 2min, 1 x 30 min) followed by washing with DCM (6x2 min) and<br>
then with DMF (2x2 min) treatment with 5% DIEA in DMF v/v ( 3 x 2min) and<br>
finally followed by washing with DMF (6 x 2min).<br>
Deprotection of the Aloe and Allyl<br>
A solution of 3 eq. Pd(PPh3)4 dissolved in 15-20 ml CHCI3, AcOH, NMM (37:2:1)<br>
was added to the peptid resin. The treatment was continued for three hours at room<br>
temperature accompanied by bubbling a stream of N2 through the mixture.<br>
Coupling Of Hobt-Esters<br>
3 eq N--amino protected amino acid was dissolved in DMF together with 3 eq.<br>
HOBt and 3 eq. DIC and then added to the resin.<br>
Preformed Symmetrical Anhydride<br>
Six eq. N-a-amino protected amino acid was dissolved in DCM and cooled to 0C.<br>
DIC (3 eq.) was added and the reaction continued for 10 minutes. The solvent was<br>
removed in vacuo and the remainder dissolved in DMF. The solution was<br>
immediately added to the resin followed by 0.1 eq. of DMAP.<br>
Cleavage Of the Compound from the resin using TFMSA<br>
The Peptidyl-resin was treated with 90% trifluoroacetic acid (TFA, Riedel-de Haen,<br>
Frankfurt, Germany) 4% trifluoromethanesulfonic acid (TFMSA, Aldrich) 2%<br><br>
ethandithiol, 4% thioanisol v/v at r.t. for 30-60 minutes. The filtered resin was<br>
washed with TFA and filtrates and washings evaporated under reduced pressure.<br>
The residue was washed with ether and freeze-dried from trifluoroacetic acid-water.<br>
The crude freeze-dried product was analyzed by high-performance liquid<br>
chromatography (HPLC) and identified by electrospray ionisation mass<br>
spectrometry (ESMS).<br>
Cleavage Of the Compound from Resin using TFA<br>
The Peptidyl-resin was treated with 95% trifluoroacetic acid (TFA, Riedel-de Haen,<br>
Frankfurt, Germany)-water v/v or with 95% TFA and 5% ethandithiol v/v at r.t. for 2<br>
hours. The filtered resin was washed with 95% TFA-v/ater and filtrates and<br>
washings evaporated under reduced pressure. The residue was washed with ether<br>
and freeze-dried from acetic acid-water. The crude freeze-dried product was<br>
analyzed by high-performance liquid chromatography (HPLC) and identified by<br>
electrospray ionisation mass spectrometry (ESMS).<br>
Preparative HPLC conditions<br>
Preparative chromatography was carried out using a VISION Workstation<br>
(PerSeptive Biosystem) equipped with AFC2000 autoimatic fraction<br>
collector/autosampler. VISION-3 software was used for instrument control and data<br>
acquisition.<br>
Column<br>
Kromasil (EKA Chemicals) KR100-10-C8 100A, C-8, 10 urn; CER 2230, 250 x 50,8<br>
mm or a VYDAC 218TP101550, 300A, C-18, 10-15 jam, 250 x 50 mm. The buffer<br>
system used Included A: 0,1% TFA in MQV; B: 0,085% TFA, 10% MQV, 90%<br>
MeCN.  Flow rates were 35-40 ml/min and the column temperature was 25C. UV<br>
detection was performed at 215 nm and 280 nm. Suitable gradients were optimized<br>
for individual peptides.<br>
Analytical HPLC Conditions<br>
Gradient HPLC analysis was done using a Hewlett Packard HP 1100 HPLC system<br>
consisting of a HP 1100 Quaternary Pump, a HP 1100 Autosampler a HP 1100<br>
Column Thermostat and HP 1100 Multiple Wavelength Detector.  Hewlett Packard<br>
Chemstation for LC software (rev. A.06.01) was used for instrument control and<br><br>
data acquisition. For analytical HPLC, different columns were used as appropriate,<br>
such as VYDAC 238TP5415, C-18, 5m, 300A, or a Jupiter, Phenomenex 00F-<br>
4053-EO; 5 m C-18, 300A 150 x 4,6 mm and others. The buffer system included<br>
A: 0,1% TFA in MQV; B: 0,085% TFA, 10% MQV, 90% MeCN.  Flow rates were 1<br>
ml/min. The preferred column temperature was 40C,  UV detection was performed<br>
at 215 nm. As above, suitable gradients were optimized for the individual peptides.<br>
Mass Spectroscopy<br>
The peptides were dissolved in super gradient methano! (Labscan, Dublin, Ireland),<br>
Milli-Q water (Millipore, Bedford, MA) and formic acid (Merck, Damstadt, Germany)<br>
(50:50:0.1 v/v/v) to give concentrations between 1 and 10 mg/ml. The peptide<br>
solutions (20 ml) were analysed in positive polarity mode by ESI-TOF-MS using a<br>
LCT mass spectrometer (Micromass, Manchester, UK) accuracy of +/- 0.1 m/z.<br>
Solid phase synthesis<br>
In all syntheses, dry resin was placed in a polyethylene vessel equipped with a<br>
polypropylene filter for filtration. The resin was swelled in DMF.  The first amino<br>
acid was coupled either as a preformed symmetrical anhydride or as a preactivated<br>
HOBt ester as described above. The following amino acid according to the<br>
sequence was coupled as a preformed HObt ester as described above. All<br>
couplings were continued for at least 2 hours unless otherwise specified. Coupling<br>
of the benzoic acid derivative to the side-chain amino functionality on the lysine<br>
mimetic amino acid was in all cases performed using a preformed HObt-ester. The<br>
final peptide product were cleaved from the solid support and analysed by HPLC<br>
and MS as described above.<br>
In all cases the benzoic acid derivative is functionalised as a carboxylic acid and<br>
was coupled as an in situ generated HOBt ester by means of DIC in THF.<br>
All couplings were continued for at least 2 hours. The acylations were checked by<br>
the ninhydrin test performed at 80 C as earlier described. After completed<br>
synthesis the peptide-resin was washed with DMF (3x 15 ml, 1 min each), DCM (3x<br>
15 ml, 1 min each), diethyl ether (3x 15 ml, 1 min each) and dried in vacuo. The<br>
peptide was then cleaved from the resin as described above and freeze-dried. <br><br>
After purification using preparative HPLC as described above, the peptide product<br>
was collected and the identity of the peptide was confirmed by ES-MS .<br>
Exemplary Solution phase synthesis<br>
A suitable protected amino acid or a hydroxy- or thiohydroxy acetic acid with a non-<br>
protected carboxylic acid (1 eq) is dissolved in DMF together with DIC (1 eq) and<br>
HOBt (1 eq). After 1 hour of pre-activation a suitable protected lysine mimetic<br>
building block (LM) is added with a non-protected amino group (1.1 eq) together<br>
with TEA (1.3 eq) and the mixture is stirred over night at room temperature.<br>
The reaction mixture is evaporated to dryness and the residue is dissolved in ethyl<br>
acetate. The ethyl acetate phase is extracted with (1) an aqueous solution of<br>
hydrochloric acid (0.1 M) and (2) an aqueous solution of sodium hydroxide (0.1 M)<br>
(3) water in order to remove excess of starting material. The organic phase is<br>
treated with MgSO4 (dessicated) filtered and evaporated to dryness.<br>
The remaining protected amino group of the LM is deprotected using TFA/DCM if<br>
the protecting group is based on tBu, Pd cyclohexen if based on benzyl,<br>
piperidine/DC M if based on fluorenyl, hydrazine if based on Dde. After finishing the<br>
deprotection reaction (1-2 hours) the reaction mixture is evaporated to dryness.<br>
The residue is washed with diethyl ether and dissolved in DMF together with 1.3 eq<br>
TEA and finally added to a solution of a substituted benzoic acid (1eq) that has<br>
been preactivated by treatment with DIC (1eq) and HOBt (1eq) in DMF. The<br>
coupling reaction is continued over night.<br>
The reaction mixture is evaporated to dryness and the residue is dissolved in ethyl<br>
acetate. The ethyl acetate phase is extracted with (1) an aqueous solution of<br>
hydrochloric acid (0.1 M) and (2) an aqueous solution of sodium hydroxide (0.1 M)<br>
(3) water in order to remove excess of starting material. The organic phase is<br>
treated with MgSO4 (dessicated) filtered and evaporated to dryness.<br>
The remaining protecting groups are deprotected using TFA/DCM if the protection<br>
groups are based on tBu, Pd Cyclohexen if based on Benzyl, Piperidine/DCM if<br>
based on Fluorenyl, Hydrazine if based Dde. After finishing the deprotection<br>
reaction (1-2 hours) the reaction mixture is evaporated to dryness. The residue is<br><br>
washed with diethyl ether and dissolved in TFA/Water and purified using<br>
preparative HPLC. After purification using preparative HPLC as described above,<br>
the peptide product was collected and the identity of the peptide was confirmed by<br>
ES-MS.<br>
2.         Solid Phase Synthesis of Compound 2: (2S4R) 1-(2-Amino-acetyl)-4-<br>
benzoylamino-pyrrolidine-2-carboxylic acid<br>
PAM-resin (Advanced Chemtech) was swelled in DMF, washed with 5% Triethyl<br>
amine (TEA) in DMF and washed with DMF until no yellow color could be detected<br>
after adding Dhbt-OH to the drained DMF.  (2S4R) Boc-4Amp(Fmoc)-OH was<br>
coupled as symmetrical anhydride as follows.<br>
3eq (2S4R) Boc-4Amp(Fmoc)-OH was dissolved in DCM and cooled to 0C. DIG<br>
(1.5 eq.) was added and the reaction continued for 10 minutes. The solvent was<br>
removed in vacuo and the residue dissolved in DMF. The solution was immediately<br>
added to the resin followed by 0.1 eq. of DMAP. The coupling was continued over<br>
night. Excess; coupling reagent was removed by washing with DMF.  Deprotection<br>
of the Fmoc group was performed by treatment with 20% piperidine in DMF (1x5<br>
and 1x10 min.), followed by washing with DMF until no yellow colour could be<br>
detected after addition of Dhbt-OH to the drained DMF.<br>
Coupling of benzoic acid was carried out as follows. 3 eq. benzoic acid was<br>
dissolved in DMF together with 3 eq. HOBt and 3 eq. DIC and then added to the<br>
resin. The coupling was continued over night. Excess coupling reagent was<br>
removed by washing with DMF. Prior to the deprotection of the Boc group the resin<br>
was treated with DCM. Deprotection of the Boc group was performed by treatment<br>
with 50% TFA in DCM v/v (2 x 2min, 1 x 30 min) followed by washing with DCM<br>
and then with DMF and then treatment with 5% DIEA in DMF v/v and finally<br>
followed by washing with DMF.<br>
Coupling of Boc-Gly-OH was carried out as follows. 3 eq. Boc-Gly-OH was<br>
dissolved in DMF together with 3 eq. HOBt and 3 eq. DIC and then added to the<br>
resin. The coupling was continued 2 hours. Excess coupling reagent was removed<br>
by washing with DMF. The coupling was repeated and continued over night.  Before<br><br>
cleavage of thes peptide from the solid support the peptide resin was washed with<br>
DCM and then with ether and finally dried under vacuum.<br>
Cleavage of the dipeptide from the PAM-Resin was carried out as follows. The<br>
peptide-resin was treated with trifluoroacetic acid (TFA, Riedel-de Haen) and after<br>
10 min a volume corresponding to 10% of the TFA total volume of<br>
trifluoromethanesulfonic acid (TFMSA, Aldrich) was added at room temperature and<br>
the reaction WEIS continued for 2 hours. The filtered resins were washed with TFA.<br>
The raw material was precipitated from the TFA-solution by adding diethylether.<br>
The raw material was collected as a brown oil. The ether solution was further<br>
extracted with water and the water phase was evaporated. The total amount of raw<br>
material was purified using prep. HPLC (Vydac C18 - column): Buffer A: 0.1% TFA<br>
in Water; Buffer B: 90% AcCN; 0.1% TFA; 9.9% Water. Flow: 35ml/min. Gradient:<br>
0-47 min 100% A to 75% A (Linear). HPLC purity: 99%. MS: calculated M+H =<br>
291.12; found M+H = 291.7.<br>
3.	Solution Phase Synthesis of Compound 2<br>
To a solution cf NaHCO3 (58.64 g, 0.698 mol) in water (625 mL) N-BOC-trans-4-<br>
amino-L-proline methyl ester hydrochloride (50 g, 0.1745 mol, CNH Technologies,<br>
98%) was added in portions, followed by EtOAc (500 mL). The mixture was cooled<br>
to 0 C. A solution of benzoyl chloride (20.26 mL, 0.1745 mol) in EtOAc (100 mL)<br>
was added over 25 min at 0 C. The reaction mixture was stirred at 0 C for 1 h.<br>
The phases were separated and the aqueous phase was extracted with 2x200 mL<br>
of EtOAc. The; combined organic fraction was washed with 200 mL of 1N HCI, 100<br>
mL of saturated NaHCO3 solution, 100 mL of brine, dried over MgSO4, and<br>
concentrated to afford 60.67 g of (2S,4R)-1-tert-butyl-2-methyl-4-<br>
benzamidopyrirolidine-l,2-dicarboxylate as a heavy oil (99.8% yield; 94% yield<br>
adjusted to residual EtOAc). 1H NMR (CDCI3, , ppm; for two conformers): 7.78-7.7<br>
(m, 2 H), 7.56-7.4 (m, 3 H), 6.25-6.1 (m, 1 H), 4.8-4.67 (m, 1 H), 4.51-4.41 (m, 0.4<br>
H), 4.34 (dd, J = 7, 7 Hz, 0.6 H), 3.97-3.84 (m, 1 H), 3. 76 (s, 3H), 3.52 (dd, J= 11,<br>
4 Hz, 0.6 H), 3.39 (dd, J= 11,4 Hz, 0.4 H), 2.47-2.21 (m 2 H), 1.46 (s, 3.6 H), 1.43<br>
(s, 5.4 H). MS (m/z, positive ESI, for M+Na): 371.<br><br>
(2S,4R)-1-tert-Butyl-2-rnethyl-4-benzamidopyrrolidine-1,2-dicarboxylate (60.19 g,<br>
contains 5.6% EtOAc; 0.1631 mol) was dissolved in Et2O (100 mL), and the solvent<br>
was evaporated under vacuum to remove residual EtOAc. The residual oil was<br>
dissolved in E12O (100 mL). 2N HCI solution in Et2O (700 mL) was added (mild<br>
exotherm; precipitation commenced after about 5 min). The mixture was stirred at<br>
ambient temperature for 21 h. At that point, 200 mL of 2N HCI solution in Et2O was<br>
added, and the mixture was stirred for additional 24 h. The precipitate was filtered,<br>
washed with 500 mL of diethyl ether, and dried in vacuum at ambient temperature<br>
for 24 h to afford 46.03 g of (2S, 4R)-methyl 4-benzamidopyrrolidine-2-carboxylate<br>
hydrochloride (99% yield). 1H NMR (CD3OD, , ppm): 7.91-7.84 (m, 2 H), 7.6-7.44<br>
(m, 3H), 4.78 (t, J = 8.5 Hz, 1 H), 4.69-4.59 (m, 1 H), 3.77 (dd, J= 12, 6.6 Hz, 1 H),<br>
3.52 (dd, J = 12, 5 Hz, 1 H), 2.67-2.5 (m, 2 H). MS (m/z, positive ESI, for M+H):<br>
249.<br>
To a solution of BOC-Gly-OH (28.13 g, 0.1606 mol) and 1-hydroxybenzotriazole<br>
(0.1686 mol, 25.64 g; contains 11.12 wt% H2O) in THF (1.3 L) was added N-(3-<br>
dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.1686 mol, 32.328 g)<br>
(Flask A). The mixture was stirred at ambient temperature for 4 h, then the stirring<br>
was stopped and the oily residue was allowed to settle. In a separate flask (Flask<br>
B), NaOH (0.1606 mol; 32 mL of 5N solution) was added to a suspension of (2S,<br>
4R)-methyl 4-benzamidopyrrolidine-2-carboxylate hydrochloride (0.1606 mol, 45.73<br>
g) in THF (0.52 L) over 15 min. The mixture was stirred at ambient temperature for<br>
10 min, during which time the solids mostly dissolved. The solution of HOBt ester<br>
prepared in Flask A was added to Flask B at ambient temperature over 15 min,<br>
leaving the oily residue behind. The residue in Flask A was washed with 250 mL of<br>
THF, and the THF solution was decanted from the heavy oil and added to the<br>
mixture in Flask B. The reaction mixture was stirred at ambient temperature for 40<br>
min. Water (500 mL) was added, and the mixture was concentrated under vacuum<br>
to remove THF (-550 mL residual volume). EtOAc (500 mL) was added, followed<br>
by brine (300 mL).  The phases were separated and the aqueous phase was<br>
extracted with 2x300 mL of EtOAc.  The combined organic fraction was washed<br>
with 2x250 ml. of 1N HCI, 2x250 mL of sat. NaHCO3 solution, and 150 mL of brine,<br>
then dried over MgSO4, and concentrated to afford 48.31 g of (2S, 4R) methyl-4-<br>
benzamido-1-(2-(tert-butoxycarbonylamino)acetyl)pyrrolidine-2-carboxylate as a<br>
foamy solid (74% yield). 1H NMR (CDCl3, , ppm; for two conformers): 7.81-7.72<br><br>
(m, 2 H), 7.57-7.39 (m, 3 H), 6.41 (d, J= 6 Hz, 0.8 H), 6.25 (d, J= 6 Hz, 0.2 H).<br>
5.32 (br. s, 1 H), 4.88-4.74 (m, 1 H), 4.65 (t, J = 7 Hz, 1 H), 4.11-3.86 (m, 2 H),<br>
3.83-3.78 (m, 1 H), 3.76 (s, 3 H), 3.69-3.56 (M, 1 H), 2.65-2.3 (m, 2 H), 1.43 (s, 9<br>
H). MS (m/z, positive ESI, for M+Na): 428.<br>
To a solution of (2S, 4R) methyl-4-benzamido-1-(2-(tert-butoxycarbonyl-<br>
amino)acetyl)pyrrolidine-2-carboxylate (23.33 g, 0.0575 mol) in methanol (450 ml.)<br>
was added NaOH (0.2875 mol, 144 mL of 2N aqueous solution) at -1 to 1 C over<br>
15 min. The mixture was stirred at -5 to -1 C for 2.5 h.  HCI (0.2875 mol, 144 mL<br>
of 2N aqueous solution) was added at -3 to 1 C over 25 min. MeOH was distilled<br>
off under vacuum, then 500 mL of EtOAc was added.  The aqueous phase was<br>
saturated with NaCI and the phases were separated. The aqueous phase was<br>
extracted with 2x250 mL EtOAc and the combined EtOAc solution was dried over<br>
MgSO4, and concentrated to afford 22.54 g of (2S, 4R) 4-benzamido-1-(2-(tert-<br>
butoxycarbonylamino)acetyl)pyrrolidine-2-carboxylic acid as a white foamy solid<br>
(contains 6.6 wt % EtOAc; 94% yield adjusted to residual EtOAc). 1H NMR (CD3OD,<br>
, ppm): 7.87-7.79 (m, 2 H), 7.58-7.42 (m, 3 H), 4.81-4.7 (m 1 H), 4.69-4.56 (m, 1<br>
H), 4.05-3.72 (m, 3 H), 3.67-3.49 (m, 1 H), 2.64-2.28 (m, 2 H), 1.43 (s, 9 H). MS<br>
(m/z, positive ESI) for M+H: 392; for Mn-Na: 414.<br>
(2S. 4R) 4-Benzamido-1-(2-(tert-butoxycarbonylamino)acetyl)pyrrolidine-2-<br>
carboxylic acid (21.97 g; contains 6.6 wt % EtOAc; 0.0524 mol, adjusted to residual<br>
EtOAc) was dissolved in dioxane (100 mL). The solvent was evaporated under<br>
vacuum to remove residual EtOAc. The residue was dissolved in anhydrous<br>
dioxane (200 mL) and HCI (100 mL of freshly prepared ~3.6 N solution in dioxane)<br>
was added at 10-12 C. The solution was allowed to warm to ambient temperature<br>
(precipitation commenced after about 2 min). The reaction mixture was stirred'at<br>
ambient temperature for 21 h, at which time 30 mL of ~3.6N HCI solution was<br>
added, and the mixture was stirred for additional 5.5 h.  Precipitated solids were<br>
filtered using N2 pressure, washed with 4x25 mL of dioxane, and dried under<br>
vacuum at room temperature for 24 h to afford 18.7 g of crude product as white<br>
solid. The crude product was dissolved in r-PrOH (104 mL) and 210 mL of diethyl<br>
ether was added over 1 h (precipitate formed immediately upon ether addition).<br>
The mixture was stirred for 1 h, filtered using N2 pressure, washed with 2x50 mL of<br>
3:1 Et2O-i-PrOH solution, and dried under vacuum at room temperature for 24 h<br><br>
and at 40 C for 48 h to afford 15.7 g of (2S, 4R)-1-(2-aminoacetyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid hydrochloride. 1H NMR (DMSO-d6, , ppm,<br>
for two conformers): 8.77 (d. J = 7 Hz, 0.8 H), 8.71 (d, J = 7 Hz, 0.2 H), 8.68-7.95<br>
(br, 2 H), 7.92-7.83 (m, 2 H), 7.59-7.43 (m, 3 H), 4.87-4.79 (m, 0.2 H), 4.68-4.54 (m,<br>
0.8 H), 4.54-4.44 (m, 1 H), 4.0 - 3.47 (m, 4 H), 2.47-2.12 (m, 2 H). HRMS calc.for<br>
C14H18N3O4 (M+H): 292.1297, found: 292.1294.<br>
4.         Synthesis of Compounds 64-68 and 70-78<br>
(2S,4R)-4-ben;i:amido-1-(2-(tert-butoxycarbonylamino)acetyl)pyrroIidine-2-<br>
carboxylic acid (0.05 g, 0.1 mmol), 1-hydroxybenzotriazole monohydrate (Atdrich,<br>
0.021 g, 0.15 mmol, 1.2 equivalents) and 1-(3,3-dimethylaminopropyl)-3-<br>
ethylcarbodiimide hydrochloride (Aldrich, 0.029 g, 0.15 mmol, 1.2 equivalents) were<br>
dissolved in acetonitrile (15 mL) under nitrogen atmosphere with ice cooling. The<br>
temperature was gradually increased to room temperature over 2 hour time period,<br>
and the mixture was then stirred at room temperature overnight. The reaction<br>
solution was again cooled to 0 C, 25-30% aqueous solution of the corresponding<br>
amine (prepared from a pure reagent obtained from Atdrich) (0.1 mL) was added,<br>
and stirring was continued with cooling for 30 minutes and then at room<br>
temperature for 2 hours. Acetonirile (5 mL) was added to the reaction mixture, and<br>
the volatiles were removed in vacuo. The semi-solid residue was purified by silica-<br>
gel (EMD, 0.040-0.063 mm) chromatography (developing solvent: 3-5% gradient<br>
methanol-dichloromethane) to afford the corresponding amides in 80-87% yield.<br>
The product from the previous step was dissolved in dry dichloromethane (10 mL)<br>
under nitrogen atmosphere and 1 M ethereal solution of hydrochloric acid (Aldrich)<br>
(1 mL) was added while keeping the temperature below 30 C. The reaction<br>
mixture was stirred overnight under nitrogen atmosphere. The precipitate was-<br>
filtered, washed with dichloromethane (2 mL) and diethyl ether (2 mL) and dried<br>
under high vacuum to afford a hydrochloride salt of corresponding compounds 64-<br>
68 and 70-78 in 75-84% yield and at least 98% purity.<br>
5.         Synthesis of Compound 80: (2S,4R)-1-(2-acetamidoacetyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid<br><br>
To a solution of (2S4R) 1-(2-Amino-acetyl)-4-benzoylamino-pyrrolidine-2-carbqxylic<br>
acid (0.05 g, 0.17 mmol) and triethylamine (Aldrich) (0.19 mL, 1.37 mmol, 8<br>
equivalents) in acetone (3 mL) was slowly added acetic anhydride (0.13 mL, 1.37<br>
mmol, 8 equivalents) with stirring at room temperature under nitrogen atmosphere.<br>
The mixture was stirred for 3 hours while monitored by LCMS. Upon completion,<br>
the volatiles were removed in vacua and the residue was purified by preparative<br>
HPLC (column:Xterra MSC18 50 x 250 mm, 10u) using 40/60 to 90/10<br>
methanol/water gradient (0.1% formic acid in methanof and 0.1 formic acid in water)<br>
to afford 0.020 g (35% yield) of the desired product as white solid with limited<br>
solubility in organic solvents.<br>
6.	Synthesis of Compound 81: (2S,4R)-4-benzamido-1-(2-<br>
(methylamino)acetyl) pyrrolidine-2-carboxylic acid<br>
To a solution of (2S,4R)-methyl 4-benzamidopyrrolidine-2-carboxyIate (intermediate<br>
in the synthesis of Compound 2) (0.05 g, 0.20 mmol), 1-(3,3-dimethylaminopropyl)-<br>
3-ethylcarbodiimide hydrochloride (Aldrich) (0.043 g, 0.22 mmol, 1.1 equivalents),<br>
1-hydroxybenzotriazole monohydrate (Aldrich) (0.030 g, 0.22 mmol, 1.1<br>
equivalents) and 2-(tert-butoxycarbonyl(methyl)amino)acetic acid {Aldrich) (0.038 g,<br>
0.20 mmol) in anhydrous dichloromethane (10 mL) was added N-methylmorpholine<br>
(0.05 mL) under nitrogen atmosphere at 0 C. The reaction mixture was allowed to<br>
warm to room temperature during 2 hour time period and stirred overnight at<br>
ambient temperature. The volitiles were removed in vacuo and the residue was<br>
purified by silica-gel {EMD, 0.040-0.063 mm) chromatography (developing solvent:<br>
3-5% gradient methanol/dichloromethane) to afford 0.064 g (75% yield) of the<br>
coupling product (2S,4R)-methyl 4-benzamido-1-(2-(tert-<br>
butoxycarbonyl(methyl)amino)acetyl) pyrrolidine-2-carboxylate.<br>
To a solution of the abovementioned amide (0.064 g, 0.15 mmol) in methanol (5<br>
mL) was added 2N aqueous solution of sodium hydroxide (0.38 mL, 0.75 mmol, 5<br>
equivalents) at 0 C under nitrogen atmosphere over 5 minutes. The reaction was<br>
monitored by LCMS and was finished in 2 hours. 2N aqueous hydrochloric acid<br>
{Aldrich) (0.38 mL, 0.75 mmol, 5 equivalents) was added at 0 C over 5 min.<br>
Methanol was distilled off under vacuum. Ethyl acetate (10 mL) and water (1 mL)<br>
were added. The aqueous phase was saturated with sodium chloride and the<br><br>
phases were separated. The aqueous phase was extracted with ethyl acetate<br>
(2x10 mL). The combined organic fractions were dried over magnesium sulfate and<br>
concentrated to afford a white foamy product (2S,4R)-4-benzamido-1-(2-(tert-<br>
butoxycarbonyl (methyl)amino)acetyl)pyrrolidine-2-carboxylic acid that was used in<br>
the next step without purification.<br>
The acid from the previous step was dissolved in dry dichloromethane (10 mL)<br>
under nitrogen atmosphere and 1 M ethereal solution of hydrochloric acid (Aldrich)<br>
(1 mL) was added while: keeping the temperature below 30 C. The reaction<br>
mixture was stirred overnight under nitrogen atmosphere. The formed precipitate<br>
was filtered, wigished with dichloromethane (2 mL), diethyl ether (2 mL) and dried<br>
under high vacuum. The product was further purified by preparative HPLC<br>
(column: Xterra MSC18 19 x 150 mm) using 5% to 95% methanol/water gradient<br>
(0.1% formic acid in methanol and 0.1% formic acid in water) to afford 0.026 g (38%<br>
over 3 steps) of the desired product.<br>
7.	Synthesis of Compound 82: (2S,4R)-4-benzamido-1-(2-(2,2,2-<br>
trifluoroacetamido)acetyl)pyrrolidine-2-carboxylic acid<br>
To a solution of (2S4R) 1-(2-Amino-acetyl)-4-benzoylamino-pyrrolidine-2-carboxylic<br>
acid (Compound 2, 0.05 g, 0.17 mmol) and triethylamine (Aldrich) (0.048 mL, 0.34<br>
mmol, 2 equivalents) in acetone (3 mL) was added slowly trifluoroacetic anhydride;<br>
(0.024 mL, 0.17 mmol) with stirring at room temperature under nitrogen<br>
atmosphere. The mixture was stirred for 1.5 hours with careful monitoring by LCMS.<br>
Upon completion, the volatiles were removed in vacua and the residue was purified<br>
by preparative HPLC (column: Xterra MSC18 50 x 250 mm, 10u) using 5% to 90%<br>
methanol/water gradient (0.1% formic acid in methanol and 0.1% formic acid in<br>
water) to afford 0.012 g (18% yield) of the desired product.<br>
8.	Synthesis of Compound 84: (2S,4R)-4-benramido-1-(2-(dimethylamino)<br>
acetyl)pyrrolidine-2-carboxylic acid<br>
To a solution of (2S4R) 1-(2-Arnino-acetyl)-4-benzoylamino-pyrrolidine-2-carboxylic<br>
acid (Compound 2, 0.05 g, 0.17 mmol) in methanol (3 mL) at room temperature was<br>
added 37% aqueous formaldehyde (Aldrich) (0.1 mL).  The resulting mixture was<br><br>
stirred at this temperature for 3 hours, then cooled to 0 C, and sodium<br>
cyanoborohydride (Aldrich) (0.043 g, 0.69 mmol, 4 equivalents) was added portion-<br>
wise over 5 minutes. After stirring for 1 hour at room temperature, the solvent was<br>
removed in vacuo and the solid residue was purified by preparative HPLC (column:<br>
XTerra MS C18, 5u, 19x150mm) using 5% to 95% methanol/water gradient (0.1%<br>
formic acid in methanol and 0.1% formic acid in water) to afford 0.017 g (31% yield)<br>
of the desired product.<br>
9.	Synthesis of Compound 85: (2S,4R)-4-benzamido-1-(2-formamidoacetyl)<br>
pyrro!idine-2-carboxylic acid<br>
Acetic anhydride (Acros) (0.32 mL, 3.4 mmol, 10 equivalents) was added dropwise<br>
to a solution of (2S4R) 1-(2-Amino-acetyl)-4-benzoylamino-pyrrolidine-2-carboxylic<br>
acid (Compound 2, 0.1 g, 0.34 mmol, 1 equivalent) in formic acid (J.T.Baker) (1 mL)<br>
at 0 C. After the addition was complete, the reaction mixture was allowed to warm<br>
to room temperature and stirred an additional 24 hours. The reaction mixture was<br>
monitored by TLC and LCMS. An additional amount of acetic anhydride (0.32 mL,<br>
3.4 mmol, 10 equivalents) was added and the reaction mixture stirred for 24 hours<br>
at room temperature. Ice-water (1 mL) was added and the volatiles were removed<br>
in vacuo to yield an oily crude product that was further purified by HPLC (column:<br>
Waters Atlantis 19 x 150 mm) using 0.1% formic acid in H2O/MeOH 20-40% MeOH<br>
over 15 minute gradient to afford 0.031 g (29%) of the desired product.<br>
The general procedures outlined above were used for the synthesis of the<br>
exemplary compounds listed in Table 1.<br><br><br><br><br><br><br><br><br>
G.         Biological assay data<br>
1.	Effect of the compounds on calcium induced arrhythmias<br>
The anti-arrhythmic effect of compounds according to the present teachings was<br>
tested in a model of calcium-induced arrhythmias according to the model of Lynch<br>
et al., J. Cardiovasc. Pharmacol. (1981), 3: 49-60.   Male CD-1 mice were<br>
anaesthetized with Ketamine (75 mg/kg) and medetomidine (1 mg/kg) IP. An i.v.<br>
cannula was inserted into the tail vein. A lead II ECG signal was recorded<br>
continuously by positioning stainless steel ECG electrodes on the right forelimb and<br>
leftforelimb. The ground electrode was placed on the right hind limb. The signal<br>
was amplified and filtered using Gould physiograph components and po-ne-mah<br>
data acquisition software.   After a 90 sec equilibration period test compound was<br>
injected into the tail vein (over 30 seconds). Mice pre-treated with vehicle (0.9%<br>
saline) were tested as control animals. The injection volume was 100l / 30g mice<br>
in all experiments. Infusion of CaCI2 (30 mg/mL, 0.1 mL/min/30g mice, 100<br>
mg/kg/min) was started 3 min after IV administration of drug or vehicle. The time<br>
lag to onset of cardiac conduction block was determined as the time from the start<br>
of CaCI2 infusion until the first arrhythmic event occured. The first conduction block<br>
was defined as the first RR-interval, larger/or equal to, 3 times one RR-interval from<br>
the pre-treatment period. The first arrhythmic event occurring was either a second<br>
degree AV-block (intermittent failure of the AV conduction characterized by a P-<br>
wave without the concomitant QRS complex) or a second degree SA block<br>
(prolonged RR-interval and a QRS-complex without a preceding P-wave).<br><br>
Mice pre-treated with vehicle (0.9% saline) were tested on all days as a measure<br>
for control level in untreated animal. Injection volume was 100 L in all<br>
experiments. The time lag to onset of arrhythmias was determined as the time from<br>
the start of CaCI2 infusion until the first event of conduction block defined as<br>
intermittent failure of the SA or AV conduction characterized by delayed P-wave<br>
activation (SA block) or by a P-wave without the concomitant QRS complex (AV<br>
block). The time lag to onset of AV block is given below in Table 2.<br><br>
It follows from the data presented in Table 2 that pre-treatment of a mouse with a<br>
range of compounds of the present teachings resulted in a consistent increase in<br>
the time to an AV block in the mouse after infusion of CaCI2. Compounds of the<br>
present teachings thus exhibit anti-arrhythmic properties.<br><br>
2.         Effect of the compounds on metabolic stress induced atrial<br>
conduction slowing<br>
The ability to maintain conduction during metabolic stress was tested in an in vitro<br>
model as described by Haugan et al (J. Cardiovasc. Electrophysiol., 2005:16:537-<br>
545). Rats (300-400 g) were killed by a sharp blow on the neck. The heart was<br>
rapidly excised and transferred to a small dish containing 37 oxygenated modified<br>
Tyrodes buffer containing (in mM): NaCI 136, KCI 4. MgCI2 0.8, CaCI2 1.8 HEPES<br>
5, MES 5, Glucose 6, pH 7.3.  The left atrium was carefully dissected and a tissue<br>
sample of approximately 2x6 mm was taken from the left atrial appendage and<br>
placed in a tissue chamber (volume 5 ml), (Steiert Organ Bath, Hugo Sach<br>
Electronic, Germany). The chamber was perfused throughout the study with 37C<br>
Tyrodes buffer at a rate of 10 ml/min.<br>
A bipolar stimulation electrode (Teflon coated stainless steel, diameter 75 uM) was<br>
placed at one end of the tissue. Stimulation was performed at 1 Hz using <br>
rectangular pulses at double threshold (duration of stimulus 0.2 ms) delivered by a<br>
stimulator (Hugo Sachs, Type 215) through an isolation unit (Universal Isolated<br>
Stimulator Unit type 263, Hugo Sachs, Germany).<br>
Two separate microelectrodes of pure iridium (World Precision Instruments, tip-<br>
impedance 3.!5-4.0 MO.) were placed on a line along the long-axis of the preparation<br>
for recording of atrial CV. The distances from the stimulating electrode to the first<br>
and second microelectrode is 1.5-2.0 mm and 3.0-4.0 mm, respectively. Each<br>
microelectrode was connected to a head-stage preamplifier (10x amplification of the<br>
signals). The preamplifiers were connected to a bio potential amplifier module that<br>
was connected to the data acquisition system through a Hugo Sachs PLUGSYS.<br>
Signals were filtered at 1 kHz and sampled at 10 kHz.<br>
Following a 30 minute equilibration period, pacing at 1 Hz was initiated.  During the<br>
first 20 minute recording period (baseline period), the chamber was perfused with<br>
37C oxygenated Tyrodes buffer, pH 7.3. Then the test sample (Compound 2) or<br>
control was added to the perfusion buffer for another 20 minute period (pre-<br>
treatment period). Following the 20 minutes of pretreatment, perfusion was<br>
changed to a 37C glucose-free, non-oxygenated Tyrodes buffer, pH 7.3 (with or<br>
without compounds of interest) for 40 minutes (metabolic stress period). The .<br>
results of these experiments are shown graphically in Figure 1.<br><br>
Referring to Figure 1, in preparations containing the control, conduction velocity<br>
decreased by 22%. In contrast, in preparations treated with Compound 2, atrial<br>
conduction velocity did not change compared to baseline.<br>
It follows from the data presented in Figure 1 that pre-1reatment of an isolated rat<br>
atrial strip with a compound of the present teachings significantly prevented<br>
metabolic stress induced cardiac conduction slowing. Cardiac diseases such as<br>
atrial fibrillation, atrial flutter, ventricular tachycardia and ventricular fibrillation are all<br>
characterized by the presence of abnormal cardiac conduction slowing. Thus,<br>
through the effect on cardiac conduction, compounds of the present teachings are<br>
expected to exert anti-arrhythmic effects.<br>
3.         Plasma Stability Assay<br>
To predict its plasma stability, compounds of the present teachings were incubated<br>
in male rat plasma (1:1 plasma: pH 7.4 buffer) at 1 M concentration at 37C. After<br>
3 hours, the reaction was quenched with cold acetonitrile. The solution was<br>
centrifuged and the supernatant was analyzed with LC-MS using the following<br>
HPLC conditions: Thermo Hypersii-Keystone Aquasil C18 column (50mm x 2.1mm,<br>
5M) at ambient temperature; Solvent A: 0.1% formic acid in water; Solvent B:<br>
0.1% formic acid in acetonitrile; solvent gradient: 100% A to 50% A over 2.5 min, to<br>
10% A over 1.5 min, and returning to 100% A and re-equilibrating for 1.5 min;<br>
flowrate: 0.8 mL/min. The percent of the compound remaining was calculated by<br>
dividing the 3-hour incubation sample LC-MS signal area counts by the time = 0<br>
area counts. The results of these experiments are summarized in Table 3 below.<br><br><br>
4.	Metabolic Stability Assay<br>
To predict the stability of the compound under first pass (Phase I) metabolism,<br>
compounds of the present teachings were incubated with male rat liver microsomes<br>
at 1 M concentration and 0.5 mg/mL protein concentration at 37C. After 15 min,<br>
the reaction was quenched with cold acetonitrile. The solution was centrifuged and<br>
the supernatant was analyzed with LC-MS using the HPLC conditions described in<br>
section 3 above. The percent remaining was calculated by dividing the 15-minute<br>
incubation sample LC-MS area counts by the time = 0 area counts, and the half-life<br>
of the compound was derived using first-order reaction kinetics.  Based on this<br>
assay. Compounds 2, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 80, 81, 82, 83 and 84<br>
had half-lives greater than 30 minutes in male rat liver microsomes.<br><br>
5.	Canine Infarct Size and Reperfusion Arrhythmia Model<br>
Compound 2 was teste:d in dogs subjected to a 60-min coronary artery occlusion<br>
and 4 hr reperfusion, as described by Hennan et al. (J. Exp. Pharmacol. Ther.,317,<br>
236-43 (2006)). Compound 2 was administered IV 10-min before reperfusion as a<br>
bolus + IV infusion at doses of: 0.25 g/kg bolus + 0.19 g/kg/hr infusion (n=6); 2.5<br>
g/kg bolus + 1.9 g/kg/hr infusion (n=7); 25 g/kg bolus + 19 g/kg/hr infusion<br>
(n=6); 75 g/kg bolus + 57 g/kg/hr infusion (n=5); vehicle control (n=7). Premature<br>
ventricular complexes (PVC's) were quantified during reperfusion.  Four or more<br>
consecutive PVC's was defined as ventricular tachycardia (VT). Total incidence of<br>
VT was reduced significantly with the two highest doses of Compound 2 (1.70.8;<br>
2.21.4 events; p
reduced significantly from 11.11.6% in control animals to 2.00.7% and 1.80.8%<br>
after the two highest doses of Compound 2.  Infarct size, expressed as percent of<br>
left ventricle, was reduced significantly from 19.03.5 in controls to 7.91.5 and<br>
7.1 0.8% (p
demonstrate that compounds of the present teachings are potent antiarrhythmic<br>
compounds with cardioprotective effects.<br>
6.         In Vitro Cell Swelling and Dye Uptake Model<br>
Peptides capable of demonstrating cytoprotection can be identified in an in vitro<br>
model of ischemia induced cell swelling and dye uptake. In this experiment, the<br>
effect of Compound 2 on calcein dye-uptake induced by metabolic inhibition in<br>
cultured C6 glioma cells overexpressing connexin43 was studied. Cells were<br>
incubated under control conditions and during simulated ischemia (SI) for 40<br>
minutes in the presence of calcein (200 uM).  Following incubation the cells were<br>
subjected to epifluorescence microscopy to determine the uptake of calcein.<br>
Incubation of C6 cells in SI medium increased dye-uptake to 5-fold above control<br>
values.  The uptake was dose-dependently inhibited by Compound 2, and minimum<br>
uptake was obtained at 100 uM Compound 2 (32% relative reduction of the SI<br>
inducible response; p
the 40 min stress period, whereas cells treated with Compound 2 did not.<br>
Variations, modifications, and other implementations of what is described herein will<br>
occur to those of ordinary skill in the art without departing from the spirit and the<br>
essential characteristics of the present teachings. Accordingly, the scope of the<br><br>
present teachings is to be defined not by the preceding illustrative description but<br>
instead by the following claims, and all changes that come within the meaning and<br>
range of equivalency of the claims are intended to be embraced therein.<br><br><br>
Claims:<br>
1.         A compound having the Formula I:<br>
or a pharmaceutically acceptable salt, ester, hydrate or prodrug thereof;<br>
wherein:<br>
Y is selected from OX, OR2, NXR2, and NR2R3;<br>
k is 0, 1, or 2;<br>
X	is H or a lysine mimetic;<br>
XI	is selected from OR3, NR2R3, and a lysine mimetic;<br>
R1 is selected from H, an optionally substituted C1-10 alkyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, and an amino acid side<br>
chain;<br>
R2 and R3 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C7-20<br>
aralkyl, an optionally substituted C6-20 aryl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R6,<br>
C(O)OR6, C(O)NR6R7, S(O)2R6, and S(O)2NR8R7;<br>
alternatively, R2 and R3 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N or S and optionally substituted with<br>
1-5 Q groups;<br>
R6 and R7 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10alkynyl, an optionally substituted C6-20 aryl. an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R8,<br>
C(O)OR8, and C(O)NR8R9;<br>
alternatively, R6 and R7 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, NorS and optionally substituted with<br>
1-5 Q groups;<br><br>
R8 and R9 each independently is selected from H, an optionally substituted<br>
C1-10alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10 alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, and an optionally substituted 5-20 membered heteroaryl;<br>
Q, at each occurrence, independently is selected from an optionally<br>
substituted C1-10 alkyl, an optionally substituted C2-10 alkenyl, an optionally<br>
substituted C2-10 alkynyl, an optionally substituted C3-20 cycloalkyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, an optionally substituted<br>
3-20 membered cycloheteroalkyl, an optionally substituted 5-20 membered<br>
heteroaryl, F, Cl, Br, I, CN, CF3. OCF3,NO2. OR8, SR8, S+R82. S(O)R8, S(O)2R8.<br>
S(O)2OH, S(O}2NR8R9, NR8S(O)2R9, C(O)R8, C(O)OR8, C(O)NR8R9, OC(O)R8,<br>
NR8R9, NR8C(Q)R9, NR8C(O)OR9. NR8C(O)NR8R9, and N+R83;<br>
provided:<br>
a)	when Y is OX or NXR2 and X is H, X' is a lysine mimetic;<br>
b)	when Y is OR2 or NR2R3, X' is a lysine mimetic; and<br>
c)	the compound is not 1-(2-aminopropanoyl)-4-benzamidopyrrolidine-<br>
2-carboxylic acid or 1-(2-arninopropanoyl)-4-benzarnidlopiperidine-2-carboxylic acid.<br><br>
2.	The compound according to claim 1, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein Y is OX or NXR2.<br>
3.	The compound according to claim 1 or 2, or a pharmaceutically acceptable<br>
salt, ester, hydrate or prodrug thereof, wherein X1 is OR3 or NR2R3.<br>
4.	The compound according to any one of claims 1 to 3, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein X' is OH or NH2.<br><br>
5. The compound according to any one of claims 1 to 4, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein X is a lysine mimetic,<br>
wherein the lysiine mimetic is selected from:<br><br>
wherein:<br>
Z1 is selected from H, (CH2)m-C6-20 aryl, (CH2)m-5-20 membered heteroaryl,<br>
C(O)(CH2)m-C6-20 aryl, C(O)(CH2)m-5-20 membered heteroaryl, (CH2)mC(0)-C6-20<br>
aryl, (CH2)mC(O)-5-20 membered heteroaryl, S(O)2(CH2)m-C6-20 aryl, and<br>
S(O)2(CH2)m-5-20 membered heteroaryl, wherein each of the C6-20 aryl and 5-20<br>
membered heteroaryl is optionally substituted with 1-5 Q groups;<br>
R5 is H or an optionally substituted C1-10alkyl;<br>
m is 0, 1, or 2.<br><br>
6.	The compound according to claim 5, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein:<br>
Z' is C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups; and<br>
m is 0.<br>
7.	The compound according to claim 5 or 6, or a pharmaceutically acceptable<br>
salt, ester, hydrate or prodrug thereof, wherein Z' is benzoyl.<br>
8.	The compound according to any one of claims 1 to 7, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein R1 is H.<br>
9.	The compound according to any one of claims 1 to 7, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein R1 is an amino acid side<br>
chain, wherein the amino acid is selected from valine, norvaline, leucine,<br>
norleucine, isoleucine, imethionine, alanine, phenylalanine, tyrosine, tryptophan,<br>
serine, threonine, cysteine, lysine, argenine, histidine, aspartic acid, glutamic acid,<br>
asparagine, glutamine, ornithine, 2,4-diaminobutyric acid, and 2,6-diaminopimelic<br>
acid.<br><br>
10.	The compound according to any one of claims 1 to 9, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein k is 0.<br>
11.	The compound according to any one of claims 1 to 9, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein k is 1.<br>
12.	The compound according to claim 1, or a pharmaceutically acceptable salt,<br>
esler, hydrate or prodrug thereof, wherein X' is a lysine mimetic.<br><br>
13.       The compound according to claim 12, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein the lysine mimetic is selected from:<br><br>
wherein:<br>
2' is selected from H, (CH2)m-C6.20 aryl, (CH2)m-5-20 membered heteroaryl,<br>
C(O)(CH2)m-C6-20 aryl, C(O)(CH2)m-5-20 membered heteroaryl, (CH2)mC(O)-C6-20<br>
aryl, (CH2)mC(O)-5-20 membered heteroaryl. S(O)2(CH2)m-C6-20 aryl, and<br>
S(O)2(CH2)m-5-20 membered heteroaryl, wherein each of the C6-20 aryl and 5-20<br>
membered heteroaryl is optionally substituted with 1-5 Q groups;<br>
R5 is HI or an optionally substituted C1-10 alkyl;<br>
m is 0, 1, or 2;<br>
E is selected from C(O)OR6, C(O)NR6R7, and a carboxylic acid bioisostere;<br>
provided that the compound is not 1-(2-aminopropanoyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid or 1-(2-aminopropanoyl)-4-<br>
benzamidopiperidine-2-carboxylic acid.<br><br>
14.	The compound according to claim 12 or 13, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein Y is OR2 or NR2R3.<br>
15.	The compound according to any one of claims 12 to 14, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein Y is<br>
OH or NH2.<br>
16.	The compound according to claim 12 or 13, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein Y is NR2R3, R2 is H, and<br>
R3 is C(O)R6.<br>
17.	The compound according to any one of claims 13 to 16, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein E is<br>
C(O)OR6.<br><br>
18.	The compound according to claim 17, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein E is C(O)OH.<br>
19.	The compound according to any one of claims 13 to 16, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein E is<br>
C(O)NR6R7.<br>
20.	The compound according to claim 19, or a pharmaceutically acceptable salt,<br>
ester, hydrate; or prodrug thereof, wherein E is C(O)NHR7.<br>
21.	The compound according to claim 19 or 20, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein R7 is selected from H, an<br>
optionally substituted C1-10alkyl optionally substituted C3-20 cycloalkyl, an<br>
optionally substituted C6-20 aryl and an optionally substituted 3-20 membered<br>
cycloheteroalkyl.<br><br>
22.	The compound according to any one of claims 13 to 21, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein:<br>
Z' is C(O)(CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups; and<br>
m is 0.<br>
23.	The compound according to any one of claims; 13 to 22, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein 71 is<br>
benzoyl.<br>
24.	The compound according to any one of claims 12 to 23, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein R1 is H.<br>
25.	The compound according to any one of claims 12 to 23, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein R1 is<br>
an amino acid side chain, wherein the amino acid is selected from valine, norvaline,<br>
leucine, norleucine, isoleucine, methionine, alanine, phenylalanine, tyrosine,<br>
tryptophan, serine, threonine, cysteine, lysine, argenine, histidine, aspartlc acid,<br>
glutamic acid, asparagine, glutamine, omithine, 2,4-diaminobutyric acid, and 2,6-<br>
diaminopimelic acid,<br>
provided that the compound is not 1-(2-aminopropanoyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid or 1-(2-aminopropanoyl)-4-<br>
benzamidopi peridine-2-carboxylic acid.<br>
26.	The compound according to any one of claims 12 to 25, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein k is 0.<br>
27.	The compound according to any one of claims 12 to 25, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein k is 1.<br><br><br>
28.       A compound having the Formula II:<br>
or a pharmaceutically acceptable salt, ester, hydrate or prodrug thereof,<br>
wherein:<br>
A is (CH2)k-Y';<br>
k is 0, 1, or 2;<br>
Y1 is OR2 or NR2R3;<br>
R1 is selected from H, an optionally substituted C1-10 alkyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, and an amino acid side<br>
chain;<br>
alternatively, A and R1 together with the carbon atom to which they are<br>
bound form a 5-20 membered heteroaryl containing 1-4 ring heteroatoms<br>
independently selected from N, O, or S and optionally substituted with 1-5 Q<br>
groups;<br>
B is selected from NR5, NR6(CH2)nC(O), NR5(CH2)nSO2, and an amide<br>
bioisostere;<br>
n is 0, 1, or 2;<br>
Z is selected from H, (CH2)m-C6-20 aryl optionally substituted with 1-5 Q<br>
groups, and (CH2)m-5-20 membered heteroaryl optionally substituted with 1-5 Q<br>
groups;<br>
m is 0, 1, or 2;<br>
E is selected from C(O)OR6, C(O)NR6R7, a carboxylic acid bioisostere and<br>
an amide bioisostere;<br>
Q, at each occurrence, independently is selected from an optionally<br>
substituted C1-10 alkyl, an optionally substituted C2-10 alkenyl,,an optionally<br>
substituted C2-10 alkynyl, an optionally substituted C3-20 cycloalkyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, an optionally substituted<br>
3-20 membered cycloheteroalkyl, an optionally substituted 5-20 membered<br>
heteroaryl, F, Cl, Br, I, CN, CF3, OCF3, NO2, OR8, SR8, S+R82, S(O)R8, S(O)2R8,<br><br>
S(O)2OH, S(O)2NR8R9, NR8S(O)2R9, C(O)R8, C(O)OR8, C(O)NR8R9, OC(O)R8,<br>
NR8R9, NR8C(O)R9, NR8C(O)OR9, NR8C(O)NR8R9, and N+R83;<br>
R2 and R3 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C7-20<br>
aralkyl, an optionally substituted C6-20 aryl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R6,<br>
C(O)OR6, C(O)NR6R7, S(O)2R6, and S(O)2NR6R7;<br>
alternatively, R2 and R3 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N or S and optionally substituted with<br>
1-5 Q groups;<br>
R5 is H or an optionally substituted C1-10 alkyl;<br>
R6 and R7 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R8,<br>
C(O)OR8, and C(O)NR8R9;<br>
alternatively, R8 and R7 together with the nitrocjen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N or S and optionally substituted with<br>
1-5 Q groups; and<br>
R8 and R9 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, and an optionally substituted 5-20 membered heteroaryl,<br>
provided that the compound is not 1-(2-aminopropanoyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid.<br>
29.       The compound according to claim 28, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein A is (CH2)k-Y' and Y' is NR2R3.<br><br>
30.	The compound according to claim 29, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein<br>
R2 is H; and<br>
R3 is selected from H, an optionally substituted C1-10 alkyl, C(O)R6, and<br>
C(O)OR6.<br>
31.	The compound according to claim 30, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein R3 is H.<br>
32.	The compound according to claim 30, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein R3 is C(O)R6 and R6 is H or an optionally<br>
substituted C-.10 alkyl.<br>
33.	The compound according to claim 28, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein A is (CH2)k-Y', Y' is OR2 and R2 is H.or<br>
C1-10 alkyl.<br><br>
34.	The compound according to any one of claims 28 to 33, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein k is 0.<br>
35.	The compound according to any one of claims 28 to 33, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein k is 1.<br>
36.	The compound according to any one of claims 28 to 35, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein R1 is H.<br><br>
37.	The compound according to any one of claims 28 to 35, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein:<br>
R1 is an amino acid side chain; and<br>
the amino acid is selected from valine, norvaline, leucine, norleucine,<br>
isoleucine, methionine, alanine, phenylalanine, tyrosine, tryptophan, serine,<br>
threonine, cysteine, lysine, argenine, histidine, aspartic acid, glutamic acid,<br>
asparagine, glutamine, ornithine, 2,4-diaminobutyric acid, and 2,6-diaminopimelic<br>
acid,<br>
provided that the compound is not 1-(2-aminopropanoyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid.<br>
38.	The compound according to claim 28, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein A and R1 together with the carbon atom<br>
to which they are bound form a 5-20 membered heterocycie containing 1-4 ring<br>
heteroatoms independently selected from N, O, or S and optionally substituted with<br>
1-5 Q groups.<br>
39.	The compound according to claim 38, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein the 5-20 membered heterocycie is<br>
selected from piperidine, piperazine, morpholine, thiomorpholine, pyrrolidine,<br>
oxazolidine, thiazolidine, imidazolidine, pyrrole, imidazole, pyrazole, triazole, .<br>
tetrazole, furan, thiofuran, oxazole, isoxazole, thiazoles, isothiazole, oxadiazole,<br>
thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, indole, benzofuran, and<br>
benzothiophene, each of which optionally is substituted with 1-5 Q groups.<br><br>
40.	The coimpound according to any one of claims 28 to 39, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein B is<br>
NR5(CH2)nC(O) and Z is (CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups or<br>
(CH2)m-5-20 membered heteroaryl optionally substituted with 1-5 Q groups.<br>
41.	The compound according to claim 40, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein n is 0.<br>
42.	The compound according to claim 40 or 41, or a pharmaceutically<br>
acceptable salt, ester, hydrate or prodrug thereof, wherein R5 is H.<br><br>
43.	The compound according to any one of claims 40 to 42, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein m is 0.<br>
44.	The compound according to any one of claims 40 to 43, or a<br>
pharmaceutically acceptable salt, ester; hydrate or prodrug thereof, wherein Z is<br>
optionally substituted phenyl.<br>
45.	The compound according to any one of claims 40 to 42, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein m is 1<br>
or 2.<br>
46.	The compound according to any one of claims. 28 to 40, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein B is<br>
NHC(O) and Z is optionally substituted phenyl.<br>
47.	The compound according to any one of claims 28 to 39, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein B is<br>
NR5, R5 is H, Z is (CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups or <br>
(CH2)m-5-20 membered heteroaryl optionally substituted with 1-5 Q groups, and m<br>
is 0 or 1.<br><br>
48.	The compound according to any one of claims; 28 to 39, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein B is<br>
NR6(CH2)nSO2 and Z is (CH2)m-C6-20 aryl optionally substituted with 1-5 Q groups or<br>
(CH2)m-5-20 membered heteroaryl optionally substituted with 1-5 Q groups.<br>
49.	The compound according to any one of claims; 28 to 39, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein B is an<br>
amide bioisostere.<br>
50.	The compound according to claim 49, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein Z is phenyl optionally substituted with 1-5<br>
Q groups.<br><br>
51.	The compound according to any one of claims 28 to 50, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein E is<br>
C(O)OR6.<br>
52.	The compound according to claim 51, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein E is C(O)OH.<br>
53.	The compound according to any one of claims 28 to 50, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein E is<br>
C(O)NR6R7.<br>
54.	The compound according to claim 53, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein E is C(O)NH2.<br><br>
55.	The compound according to claim 53, or a pharmaceutically acceptable, salt,<br>
ester, hydrate or prodrug thereof, wherein R6 is H and R7 is selected from an<br>
optionally substituted C1-10alkyl, an optionally substituted C3-20 cycloalkyl, an<br>
optionally substituted 3-20 membered cycloheteroalkyl and an optionally substituted<br>
C6-20 aryl.<br>
56.	The compound according to any one of claims 28 to 50, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein E is a<br>
carboxylic acid bioisostere.<br><br>
57.       A compound having the Formula III:<br><br>
or a pharmaceutically acceptable salt, ester, hydrate or prodrug thereof,<br>
wherein:<br>
Y1 is OR2, or NR2R3;<br>
k is 0, 1, or 2;<br>
Z' is selected from H, (CH2)m-C6-20 aryl, (CH2)m-5:20 membered heteroaryl,<br>
C(0)(CH2)m-C6-20 aryl, C(O)(CH2)m-5-20 membered heteroaryl, (CH2)mC(O)-C6-20<br>
aryl, (CH2)mC(O)-5-20 membered heteroaryl, S(O)2(CH2)m-C6-20 aryl, and<br>
S(O)2(CH2)m-5-20 membered heteroaryl, wherein each of the C6-20 aryl and 5-20<br>
membered heteroaryl is optionally substituted with 1-5 Q groups;<br>
m is 0, 1, or 2;<br>
Q,- at each occurrence, independently is selected from an optionally<br>
substituted C1-10 alkyl, an optionally substituted C2-10 alkenyl, an optionally<br>
substituted C2-10 alkynyl, an optionally substituted C3-20 cycloalkyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, an optionally substituted<br>
3-20 membered cycloheteroalkyl, an optionally substituted 5-20 membered<br>
heteroaryl, F. Cl. Br, I, CN, CF3, OCF3, NO2, OR8, SR8, S+R82, S(O)R8, S(O)2R8.<br>
S(O)2OH, S(O)2NR8R9, NR8S(O)zR9, C(O)R8, C(O)OR8, C(O)NR8R9, OC(O)R8,<br>
NR8R9. NR8C(O)R9, NR8C(O)OR9, NR8C(O)NR8R9, and N+R83;<br>
R1 is selected from H, an optionally substituted C1-10 alkyl, an optionally<br>
substituted C6-20 aryl, an optionally substituted C7-20 aralkyl, and an amino acid side<br>
chain;<br>
R2 and R3 each independently is selected from H, an optionally substituted<br>
C1-10 alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C7-20<br>
aralkyl, an optionally substituted C6-20 aryl, an optionally substituted 3-20 membered<br><br>
cycloheteroalkyl, an optionally substituted 5-20 mernbered heteroaryl, C(O)R6,<br>
C(O)OR6, C(O)NR6R7, SO2R6, and SO2NR6R7;<br>
alternatively, R2 and R3 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N or S and optionally substituted with<br>
1-5 Q groups;<br>
R4 is OR6 or NR6R7;<br>
R5 is H or optionally substituted C1-10alkyl;<br>
R6 and R7 each independently is selected from H, an optionally substituted<br>
C1-10alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, an optionally substituted 5-20 membered heteroaryl, C(O)R8, <br>
C(O)OR8, and C(O)NR8R9;<br>
alternatively, R6 and R7 together with the nitrogen atom to which they are<br>
bound form a 3-20 membered heterocycle optionally containing 1-4 ring<br>
heteroatoms independently selected from O, N or S and optionally substituted with<br>
1-5 Q groups; and<br>
R8 and R9 each independently is selected from H, an optionally substituted<br>
C1-10alkyl, an optionally substituted C3-20 cycloalkyl, an optionally substituted C2-10<br>
alkenyl, an optionally substituted C2-10alkynyl, an optionally substituted C6-20 aryl, an<br>
optionally substituted C7-20 aralkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl, and an optionally substituted 5-20 membered heteroaryl,<br>
provided that the compound is not 1-(2-aminopropanoyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid.<br>
58.	The compound according to claim 57, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein k is 0.<br>
59.	The compound according to claim 57, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein k is 1.<br><br>
60.	The compound according to any one of claims 57 to 59, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein:<br>
Y1 is NR2R3;<br>
R2 is H; and<br>
R3 is selected from H, an optionally substituted C1-10alkyl, C(O)R6, and<br>
C(O)OR6.<br>
61.	The compound according to claim 60, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein R3 is H.<br>
62.	The compound according to claim 60, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein R3 is C(O)R6 and R6 is H or an optionally<br>
substituted C1-10alkyl.<br>
63.	The compound according to any one of claims 57 to 59, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein Y' is<br>
OR2.<br><br>
64.	The compound according to claim 63, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein R2 is H.<br>
65.	The compound according to claim 63, or a pharmaceutically acceptable salt,<br>
ester, hydrate: or prodrug thereof, wherein R2 is an optionally substituted C1-10alkyl.<br>
66.	The compound according to any one of claims 57 to 65, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein R1 is H.<br><br>
67.	The compound according to any one of claims 57 to 65, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein:<br>
R1 is an amino acid side chain; and<br>
the amino acid is selected from valine, norvaline, leucine, norleucine,<br>
isoleucine, methionine, alanine, phenylalanine, tyrosine, tryptophan, serine,<br>
threonine, cysteine, lysine, argenine, histidine, aspartic acid, glutamic acid,<br>
asparagine, glutamine, ornithine, 2,4-diaminobutyric acid, and 2,6-diaminopimelic<br>
acid,<br>
provided that the compound is not 1~(2-aminopropanoyl)-4-<br>
benzamidopyrrolidine-2-carboxylic acid.<br>
68.	The compound according to any one of claims 57 to 67, or a<br>
pharmaceuticially acceptable salt, ester, hydrate or prodrug thereof, wherein R4 is<br>
OR6.<br>
69.	The compound according to claim 68, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein R4 is OH.<br><br>
70.	The compound according to any one of claims 57 to 67, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein R4 is<br>
NR6R7.<br>
71.	The compound according to claim 70, or a pharmaceutically acceptable salt,<br>
ester, hydrate; or prodrug thereof, wherein R4 is NH2.<br>
72.	The compound according to claim 70, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein<br>
R6 is H; and<br>
R7 is selected from an optionally substituted C1-10alkyl, an optionally<br>
substituted C3-20 cycloalkyl, an optionally substituted 3-20 membered<br>
cycloheteroalkyl and an optionally substituted C6-20 aryl.<br><br>
73.	The compound according to claim 70, or a pharmaceutically acceptable salt,<br>
ester, hydrate or prodrug thereof, wherein<br>
R6 and R7 together with the nitrogen atom to which they are bound form a 3-<br>
20 membered heterocycle optionally containing 1-4 ring heteroatoms independently<br>
selected from O, N or S and optionally substituted with 1-5 Q groups; and<br>
the 3-20 membered heterocycle is selected from piperidine, piperazine,<br>
morpholine, thiomorpholine, pyrrolidine, oxazolidine, thiazolidine, and imidazolidine.<br>
74.	The compound according to any one of claims 57 to 73, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein:<br>
Z' is C(O)(CH2)rn-C6-20 aryl optionally substituted with 1-5 Q groups; and<br>
m is 0.<br>
75.	 The compound according to any one of claims 57 to 74, or a<br>
pharmaceutically acceptable salt, ester, hydrate or prodrug thereof, wherein 71 is<br>
benzoyl.<br>
76.	The compound according to any one of claims 57 to 75 having the following<br>
structure:<br><br>
or a pharmaceutically acceptable salt, ester, hydrate or prodrug thereof.<br><br>
77.       The compound according to any one of claims 57 to 75 having the following<br>
structure:<br><br>
or a pharmaceutically acceptable salt, ester, hydrate or prodrug thereof.<br>
78.        The compound according to any one of claims 57 to 75 having the following<br>
structure:<br><br>
or a pharmaceutically acceptable salt, ester, hydrate or prodrug thereof.<br><br>
or a pharmaceutically acceptable salt, ester, hydrate or prodrug thereof.<br>
79.        The compound according to any one of claims 57 to 75 having the following<br>
structure:<br><br>
80.	The compound according to claim 1, claim 28 or claim 57, selected from:<br>
1-(2-Aniino-acetyl)-4-(4-nitro-benzoylamino)-pyrrolidine-2-carboxylic acid;<br>
1-(2-Arnino-acetyl)-4-benzoylarnino-pyrrolidine-2-carboxylic acid;<br>
1-(2-Aniino-acetyl)-4-(4-methyl-benzoylamino)-pyrrolidine-2-carboxylic acid;<br>
1-(2-Amiino-acetyl)-4-(4-methoxy-benzoylamino)-pyrrolidine-2-carboxylic<br>
acid;<br>
1-(2-Amiino-acetyl)-4-(4-hydroxy-benzoylamino)-pyrrolidine-2-carboxylic<br>
acid;<br>
1 -(3-Amino-propionyl)-4-benzoylamino-pyrrolidine-2-carboxylic acid; and<br>
4-Benzoylamino-1 -(2-hydroxy-acetyl)-pyrrolidine-2-carboxylic acid,<br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br>
81.	The compound according to claim 80 selected from:<br>
(2S, 4R) 1-(2-Arnino-acetyl)-4-(4-nitro-benzoylamino)-pyrrolidine-2-<br>
carboxylic acid;<br>
(2S, 4R) 1-(2-Amino-acetyl)-4-benzoylamino-pyrrolidine-2-carboxylic acid;<br>
(2S, 4R) 1-(2-Amino-acetyl)-4-(4-methyl-benzoylamino)-pyrrolidine-2-<br>
car boxylic acid;<br>
(2S, 4R) 1-(2-Amino-acetyl)-4-(4-methoxy-benzoylamino)-pyrrolidine-2-<br>
carboxylic acid;<br>
(2S, 4R) 1-(3-Amino-propionyl)-4-benzoyiamino-pyrrolidine-2-carboxylic<br>
acid;<br>
(2S, 4R) 1-(2-Amino-acetyl)-4-(4-hydroxy-benzoylamino)-pyrrolidine-2-<br>
cairboxylic acid;<br>
(2S, 4S) 1-(2-Amino-acetyl)-4-(4-methoxy-benzoylamino)-pyrrolidine-2-<br>
carboxylic acid;<br>
(2S, 4S) 1-(2-Amino-acetyl)-4-(4-methyl-benzoylamino)-pyrrolidine-2-<br>
carboxylic acid;<br>
(2S, 4S) 1-(2-Amino-acetyl)-4-(4-nitro-benzoylamino)-pyrrolidine-2-<br>
carboxylic acid;<br>
(2S, 4S) 1-(2-Amino-acetyl)-4-benzoylamino-pyrrolidine-2-carboxylic acid;<br>
and<br>
(2S, 4R) 4-Benzoylamino-1-(2-hydroxy-acetyl)-pyrrolidine-2-carboxylic acid,<br>
and pharmaceutically acceptable salts, esters, hydraies, and prodrugs thereof.<br><br>
82.	The compound according to claim 1, claim 28 or claim 57, selected from:<br>
1-(2-Amino-4-carboxy-butyryl)-4-benzoylamino-pyrrolidine-2-carboxylic acid;<br>
1-[2-Amino-3-(1H-indol-3-yl)-propionyl]-4-benzoylamino-pyrrolidine-2-<br>
carboxylic acid;<br>
1-(2-Amino-4-methyl-pentanoyl)-4-benzoylamino-pyrrolidine-2-carboxylic<br>
acid; and<br>
1-(2-Amino-3-phenyl-propionyl)-4-benzoylamino-pyrrolidine-2-carboxylic<br>
acid;<br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br>
83.	The compound according to claim 82 selected from:<br>
(2S, 4R) 1-(2-Amino-4-carboxy-butyryl)-4-benzoylamino-pyrrolidine-2-<br>
carboxylic acid;<br>
(2S, 4R) 1-t2-Ai-nino-3-(1H-indol-3-yl)-propionyl]-4-benzoylamino-pyrrolidine-<br>
2-carboxylic acid;<br>
(2S, 4R) 1-(2-Amino-4-methyl-pentanoyl)-4-benzoyIarnino-pyrrolidine-2-<br>
cafboxylic acid; and<br>
(2S, 4R) 1-(2-Amino-3-phenyl-propionyl)-4-benzoylarnino-pyrrolidine-2-.<br>
carboxylic acid,<br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br><br>
84.       The compound according to claim 1, claim 28 or claim.57, selected from:<br>
1-(2-arninoacetyl)-4-benzamidopyrrolidine-2-carboxamide;<br>
1-(2-aminoacetyl)-4-benzamido-N-methylpyrro!idine-2-carboxamide;<br>
1-(2-anniinoacety!)-4-benzamido-N-ethylpyrrolidine-2-carboxamide;<br>
1-(2-arninoacetyl)-4-benzamido-N-isopropylpyrrolidine-2-carboxamide;<br>
1-(2-arrunoacetyl)-4-benzamido-N-cyclopropylpyrrolidine-2-carboxamide;<br>
4-benzamido-1-(2-(tert-butoxycarbonylamino)acetyl)pyrro!idine-2-<br>
carboxamide;<br>
1-(2-aminoacetyl)-4-benzamido-N-(pentan-3-yl)pyrrolidine-2-carboxamide;<br>
1-(2-arninoacet/l)-4-benzamido-N-cyclopentylpyrrolidine-2-carboxamide;<br>
1-(2-aminoacetyl)-4-benzamido-N-isobutylpyrrolidine-2-carboxamide;<br>
1-(2-aminoacetyl)-4-benzamido-N-cyclobutylpyrrolidine-2-carboxamide;<br>
1-(2-arninoacetyl)-4-benzamido-N-tert-butylpyrrolidine-2-carboxamide;<br>
1-(2-aminoacetyl)-4-benzamido-N-(tetrahydro-2H-pyran-4-yl)pyrrolidine'-2-<br>
carboxamide;<br>
1-(2-arninoacetyl)-4-benzamido-N-(3-methylbutan-2-yl)pyrrolidine-2-<br>
carboxamide;<br>
1-(2-aminoacetyl)-4-benzamido-N-(3,3-dimethylbutan-2-yl)pyrrolidine-2-<br>
carboxamide;<br>
1-(2-aminoacetyl)-4-benzamido-N-phenylpyrrolidine-2-carboxamide; and<br>
1-(2-aminoacefyl)-4-benzamido-N-(tetrahydrofuran-3-yl)pyrrolidine-2-<br>
carboxamide,<br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br><br>
85.       The compound according to claim 84 selected from:<br>
(2S, 4R) 1-(2-aminoacetyl)-4-benzamidopyrroUdine-2-carboxamide;<br>
(2S, 4R) 1-(2-aminoacetyl)-4-benzarnido-N-methylpyrroIidine-2-<br>
carboxamide;<br>
(2S, 4R) 1-(2-aminoacetyl)-4-benzamido-N-ethylpyrrolidine-2-carboxamide;<br>
(2S, 4R) 1-(2-aminoacetyl)-4-benzamido-N-isopropylpyrrolidine-2-<br>
carboxamide;<br>
(2S, 4R) 1-(2-arninoacetyl)-4-benzamido-N-cyclopropylpyrrolidine-2-<br>
carboxamide;<br>
(2S, 4R) 4-benzamido-1-(2-(tert-butoxycarbonylamino)acetyl)pyrrolidine-2-<br>
carboxamide;<br>
(2S, 4R) 1 -(2-aminoacetyl)-4-benzamido-N-(pentan-3-yl)pyrrolidine-2-<br>
carboxamide;<br>
(2S, 4R) 1 -(2-aminoacetyl)-4-benzamido-N-cyclopentylpyrrolidine-2-<br>
catboxamide;<br>
(2S, 4R) 1-(2-aminoacetyl)-4-benzamido-N-isobutylpyrrolidine-2-<br>
carboxamide;<br>
(2S, 4R) 1-(2-aminoacetyl)-4-benzamido-N-cyclobutylpyrrolidine-2-<br>
cairboxamide;<br>
(2S, 4R) 1 -(2-aminoacetyl)-4-benzamido-N-tert-butylpyrrolidine-2-<br>
carboxamide;<br>
(2S, 4R) 1 -(2-aminoacetyl)-4-benzamido-N-(tetrahydro-2H-pyran-4-<br>
yl)pyrrolidine-2-carboxamide;<br>
(2S, 4R) 1-(2-Bminoacetyl)-4-benzamido-N-((R)-3-methylbutan~2-<br>
yl)pyrrolidine-2-carboxamide;<br>
(2S, 4R) 1 -(2-aminoacetyl)-4-benzamido-N-((R)-3,3-dimethylbutan-2-<br>
yl)pyrrolidine-2-carboxamide;<br>
(2S, 4R) 1-(2-aminoacetyl)-4-benzamido-N-phenylpyrrolidine-2-<br>
carboxamide; and<br>
(2S, 4R) 1 -(2-aminoacetyl)-4-benzamido-N-((R)-tetrahydrofuran-3-<br>
yl)pyrrolidine-2-carboxamide,<br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br><br>
86.	The compound according to claim 1, claim 28 or claim 57, selected from:<br>
1-(2-acetamidoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid;<br>
4-benzamido-1-(2-(methylamino)acetyl)-pyrrolidine-2-carbaxylic acid;<br>
4-benzamido-1-(2-(2,2,2-trifluoroacetamido)acetyl)pyrrolidine-2-carboxylic<br>
acid;<br>
4-benzamido-1-(2-(tert-butoxycarbonylamino)acetyl)pyrrolidine-2-carboxyl&gt;c<br>
acid;<br>
4-benzamido-1-(2-(dimethylamino)acetyl)pyrrolidine-2-carboxylic acid; and<br>
4-benzamido-1-(2-formamidoacetyl)pyrrolidine-2-carboxylic acid,<br>
and pharmaceutically acceptable salts, esters, hydrates, and prodrugs thereof.<br>
87.	The compound according to claim 86 selected from:<br>
(2S, 4R) 1-(2-acetamidoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid;<br>
(2S, 4R) 4-benzamido-1-(2-(methylamino)acetyl)-pyrrolidine-2-carboxylic<br>
acid;<br>
(2S, 4R) 4-benzamido-1-(2-(2,2,2-trifluoroacetamido)acetyl)pyrrolidine-2-<br>
carboxylic acid;<br>
(2S, 4R) 4-benzamido-1-(2-(tert-butoxycarbonylamino)acetyl)pyrrolidine-2-<br>
carboxylic acid;<br>
(2S, 4R) 4-benzamido-1-(2-(dimethylamino)acetyl)pyrrolidine-2-carboxylic<br>
acid; and<br>
(2S, 4R) 4-benzamido-1-(2-formamidoacetyl)pyrrolidine-2-carboxylic acid,<br>
and pharmacEsutically acceptable salts, esters, hydrates, and prodrugs thereof.<br>
88.	A prodrug of a compound according to any one of claims 1 to 87, wherein<br>
the prodrug is an oxazolidinone or imidazolidinone prodrug.<br>
89.	A pharmaceutical composition comprising a compound according to any one<br>
of claims 1 to 88 or a pharmaceutically acceptable salt, ester, hydrate or prodrug<br>
thereof, and a pharmaceutically acceptable carrier.<br>
90.	A method of treating or preventing a pathological condition comprising<br>
administering to a subject in need thereof a therapeutically effective amount of a<br>
compound or a pharmaceutical composition according to any one of claims 1 to 89.<br><br>
91.	The method according to claim 90, wherein the subject is a human being.<br>
92.	The method according to claim 90, wherein the pathological condition is<br>
selected from cardiovascular disease; osteoporosis; inflammation of airway<br>
epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing;<br>
endothelial lesions; Type I or Type II diabetes; diabetic retiriopathy; diabetic<br>
neuropathy; atherosclerosis; CNS related conditions; seizures; ischemia; dental<br>
tissue disorders; kidney diseases; anaemia; leukopenia; thrombocytopenia;<br>
pancytopenia; superficial wounds; deep wounds resulting from trauma; bone<br>
fractures; erectile dysfunction; urinary bladder incontinence; neuropathic pain; .<br>
subchronic and chronic inflammation; cancer; failure of bone marrow; stem cell<br>
transplantation; conditions arising during transplantation of cells and tissues;<br>
conditions arising during medical procedures; conditions caused by an excess of<br>
reactive oxygen species, free radicals or nitric oxide; diseases or disorders of<br>
pregnancy; female infertility; and stroke.<br>
93.	The method according to claim 90 or 91, wherein the pathological condition<br>
is cardiovascular disease.<br><br>
94.	The method according to claim 93, wherein the cardiovascular disease is<br>
selected from atrial fibrillation, atrial flutter, ventricular tachycardia and ventricular<br>
fibrillation.<br>
95.	The use of a compound according to any one of claims 1 to 88 for the<br>
manufacture of a medicament for the prevention or treatment of a pathological<br>
condition that responds to administration of the compound.<br>
96.	The method or use according to any one of claims 90 to 95, wherein the<br>
compound is formulated for parenteral or oral administration.<br><br>
Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable<br>
bioavailability properties are disclosed.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1kcmF3aW5ncy5wZGY=" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-drawings.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1ncGEucGRm" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1wY3QgcHJpb3JpdHkgZG9jdW1lbnQgbm90aWZpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-pct priority document notification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI2OTkta29sbnAtMjAwOC1wY3QgcmVxdWVzdCBmb3JtLnBkZg==" target="_blank" style="word-wrap:break-word;">02699-kolnp-2008-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgxNi0xMi0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(16-12-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgxNi0xMi0yMDEzKS1QQS5wZGY=" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(16-12-2013)-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNC0wNC0yMDE0KS1BTUFOREVEIFBBR0VTLnBkZg==" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(24-04-2014)-AMANDED PAGES.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNC0wNC0yMDE0KS1BTk5FWFVSRSBUTyBGT1JNLTMucGRm" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(24-04-2014)-ANNEXURE TO FORM-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNC0wNC0yMDE0KS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(24-04-2014)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNC0wNC0yMDE0KS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(24-04-2014)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNi0xMi0yMDEzKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(26-12-2013)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNi0xMi0yMDEzKS1BTk5FWFVSRSBUTyBGT1JNIDMucGRm" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(26-12-2013)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNi0xMi0yMDEzKS1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(26-12-2013)-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNi0xMi0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(26-12-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNi0xMi0yMDEzKS1EUkFXSU5HUy5wZGY=" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(26-12-2013)-DRAWINGS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNi0xMi0yMDEzKS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(26-12-2013)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNi0xMi0yMDEzKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(26-12-2013)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LSgyNi0xMi0yMDEzKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-(26-12-2013)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LUFORVhVUkUgVE8gRk9STSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-ANEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1rb2xucC0yMDA4LUNPUlJFU1BPTkRFTkNFIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">2699-kolnp-2008-CORRESPONDENCE 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LUZPUk0gMTgucGRm" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-FORM 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1rb2xucC0yMDA4LUZPUk0gMyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">2699-kolnp-2008-FORM 3 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY5OS1LT0xOUC0yMDA4LVBBLnBkZg==" target="_blank" style="word-wrap:break-word;">2699-KOLNP-2008-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDI2OTkta29sbnAtMjAwOC5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-02699-kolnp-2008.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="260873-method-for-producing-polymers-incorporating-living-material.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="260875-a-combination-latch-meant-to-make-the-fastening-system-pertaining-to-doors-much-safer-and-stronger.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>260874</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>2699/KOLNP/2008</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>22/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>30-May-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>27-May-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>03-Jul-2008</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>WYETH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>FIVE GIRALDA FARMS MADISON, NJ</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>LARSEN, BJARNE, DUE</td>
											<td>RORHOLM 12, HIMMELEV, DK 4000 ROSKILDE</td>
										</tr>
										<tr>
											<td>2</td>
											<td>HAUGAN, KETIL, JORGEN</td>
											<td>KAERVEJ 5, DK-3550 SLANGERUP</td>
										</tr>
										<tr>
											<td>3</td>
											<td>BUTERA, JOHN, A.</td>
											<td>6 LAWRENCE SPRING DRIVE, CLARKSBURG, NJ 08510</td>
										</tr>
										<tr>
											<td>4</td>
											<td>HENNAN, JAMES K.</td>
											<td>285 STORMFIELD DRIVE, HARLEYSVILLE, PA 19438</td>
										</tr>
										<tr>
											<td>5</td>
											<td>KERNS, EDWARD, H.</td>
											<td>20 HAMPTON COURT, SKILLMAN, NJ 08558</td>
										</tr>
										<tr>
											<td>6</td>
											<td>PIATNITSKI, EVGUENI, LVOVICH</td>
											<td>1300 FAYETTE STREET, #246, CONSHOHOCKEN, PA 19428</td>
										</tr>
										<tr>
											<td>7</td>
											<td>PETERSEN, JORGEN, SOBERG</td>
											<td>HELLEBAKKEN 1, DK-3150 HELLEBAEK</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07C 233/81</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2006/048790</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2006-12-21</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/753628</td>
									<td>2005-12-23</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/260874-modified-lysine-mimetic-compounds by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:13:12 GMT -->
</html>
